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“Du sollst Dich nicht nach einer vollkommenen Lehre sehnen, sondern nach einer 
Vervollkommung Deiner selbst” [Hermann Hesse]
“Space and time are the framework within which the mind is constrained to construct its
experience of reality” [Immanuel Kant]
“Every truth passes through three stages before it is recognized. First, it is ridiculed. 
Second, it is opposed. Third, it is regarded as self-evident.” [Arthur Schopenhauer]
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Abstract
Alzheimer’s disease (AD) is the most common form of dementia affecting around 70% of dementia cases.
The global prevalence of dementia is estimated to be 44.4 million people. The pathological hallmarks of
AD are  amyloid  plaques  and  neurofibrillary tangles.  AD impairs  many cognitive  functions  including
memory,  language,  abstract  thinking,  and  spatial  orientation  and  alters  mood  and  behaviour.  These
symptoms become gradually more severe, affecting common daily activities until eventually full time care
is required. There is currently no cure. A large number of promising drugs are being tested in clinical
trials, but their effect on disease progression is difficult to assess using existing psychometric measures.
New biomarkers, including cognitive-, MRI-, and blood-based measures could be combined to accurately
predict disease progression. 
First,  potential  associations of  1-year  cognitive  decline  with baseline  volumes  of  MRI White  Matter
Hyperintensities (WMH) from the whole brain, were evaluated. Higher baseline WMH volumes were
found  to  be  significantly associated  with  greater  AD-cognitive  decline  (number  of  subjects  (n)  =84,
P<0.05), with a median, yearly, cognitive change of -1.2 points in the Minimal-Mental-State-Exam, 1.5
points in ADAS-cog, and 1.3 points in Clinical-Dementia-Rating. 
Second, WMH volume was associated with an identified panel of mRNAs (trainingset: n=53,  P<0.001,
R2=0.75;  validationset:  n=21,  R2=0.11),  and  with  proteins  (trainingset:  n=59,  P<0.001,  R2=0.76;
validationset: n=30,  R2=0.03), in individuals with AD. Disease progression, measured by AD-cognitive
decline in CDR-SOB points, was associated with an identified panel of mRNA transcripts (trainingset:
n=46,  P<0.001, R2=0.86; validationset: n=16, R2=0.13). 
It  can be suggested that WMH and cognitive disease progression affect mRNA expression and protein
concentration in blood. A limitation was that there were only small independent validationsets. Future
work could investigate the identified molecular candidates in larger subject groups, and if confirmed, they
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Organisation of the thesis
PART I – State of the art: provides essential background knowledge of AD, and the 
subsequent analysis.
PART II – Data and experiments: there are two main studies.
PART III – A wider horizon for future disease related scenarios is drawn.
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PART I: STATE OF THE ART
Chapter 1. Alzheimer's disease and its manifestations
1 Epidemiological facts and figures
Alzheimer’s disease (AD), the most common form of dementia, is an enormous global
challenge  for  societies  and  their  health  care  systems which  have  to  be  adapted  by
improving the quality of care while containing costs. The implementation of appropriate
policies is a matter of current worldwide endeavour. To date, over 44 million people
globally are affected by dementias and new cases are expected to double by 2030 and
more than triple by 2050 to 115 million  (Prince et al. 2013).  In the European Union,
population-based studies indicate that the age-standardized prevalence in people older
than 65 is 4.4 % for AD and 6.4 % including other forms of dementia; the prevalence of
dementia increases with age rising up to 28.5% at age 90 years and older  (Lobo et al.
2000). In the United Kingdom alone, 800 000 people are currently affected by dementia,
a figure which might increase by 160 000 per year (Alzheimer’s Research UK 2013).
Disturbingly, the numbers in low- and middle- income countries are vastly increasing,




Alzheimer’s  disease  (Alzheimer  1907;  Glenner  1981) is  an  irreversible,  progressive
neurodegenerative disorder characterised by a variety of cognitive deficits. AD usually
begins  with  memory  decline,  affects  behaviour  and  personality  (Bonate  &  Howard
2011), and eventually full time care is required. In the past, AD patients have often been
diagnosed only when showing behaviour symptoms such as aggression, dis-inhibition,
and  agitation  and  have  been  institutionalised  only  when  they  presented  a  risk  for
themselves and other people  (Eastley & Wilcock 1997). In recent decades, established
criteria have been described to facilitate and standardise the diagnosis of Alzheimer’s
disease in clinical and research context. The diagnosis persists under the paradigm of
diagnosing  “Probable  Alzheimer's  disease”  referring  to  the  fact  that  only  after
histopathological  examination  the  presence  of  AD  is  100%  confirmed.  For  clinical
diagnosis, the National Institute of Neurological and Communicative Disease and Stroke
and  Alzheimer’s  disease  and  Related  Disorders  Association  (NINCDS-ADRDA)
(McKhann et al. 1984; McKhann et al. 2011) and the Diagnostic and Statistical Manual
of  Mental  Disorders  5th edition  (DSM-V)  (Arlington  2013) specify  eight  cognitive
domains that may be impaired in AD: memory, language, perceptual skills, attention,
constructive abilities, orientation, problem solving and functional abilities. The minimal
criteria for assessing cognitive or behavioural impairment involve at least two of the
three  domains:  (i)  acquisition  and  retention  of  new  information;  (ii)  reasoning  and
handling  of  complex  tasks;  (iii)  visuo-spatial  abilities  and  language.  Additionally,
insidious onset, known history of worsening cognition, learning and recall of recently
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learned information, word-finding, face recognition, impaired reasoning, judgement, and
problem solving, are also taken into account. For accurate diagnosis of AD various co-
morbidities should be excluded such as other types of dementia, diabetes, depression,
severe  infections,  schizophrenia,  or  vitamin  B  deficiency.  Other  types  of  dementia
include Dementia with Lewy bodies (DLB), Vascular Dementia (VD), Fronto-Temporal
Dementia (FTD), and other less common forms. While most of dementias overlap with
AD certain symptoms make them sufficiently distinct:
(1)  DLB is usually accompanied by a progressive decline in mental abilities and the
formation of lewy bodies (proteins) in the brain (Fujishiro et al. 2013). In DLB and AD
tau  proteins  contribute  to  neurodegeneration  (Huang  &  Halliday  2013).  On  the
molecular  level  LBD  is  further  characterised  by  α-synuclein  proteins  in  neurons,
synaptic degeneration, as well as dopamine deprivation (Spillantini et al. 1998; Overk &
Masliah  2014;  H-J.  Lee  et  al.  2014). In  addition,  symptoms such as  hallucinations,
behavioural  abnormalities,  rigid  muscles  and  tremors,  olfactory  dysfunction,
dysautonomia, depression, rapid eye movement, and disturbed sleep behaviour can be
observed (Molano 2013).
(2) VD has been associated with focal, multi-focal or diffuse cortical and/or sub-cortical
micro-infarcts,  lacunas (in thalamus, frontobasal and/or limbic systems), hemispherical
White Matter Hyperintensities (WMH), and in a few cases brain infarcts resulting from
systemic, cardiac or small vessel disease affecting cognition, memory, and behaviour
(Jellinger 2008). VD is usually difficult to distinguish from AD, for instance there is  a
similar distribution of WMH (Gootjes et al. 2004). 
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(3) FTD is an overarching term used for a range of clinically, neuropathologically and
genetically heterogeneous disorders, and in total accounts for ca. 20 % of all dementia
cases (Brun 1987; The Lund and Manchester Groups 1994; Goedert et al. 2012) (Pan &
Chen  2013).  FTD symptoms  include:  focal  atrophy of  the  orbitomesial  frontal  and
anterior temporal lobes, and can be accompanied by changes in social and emotional
behaviour, already at ages 45-60 (Siri et al. 2001). In 1892, Arnold Pick firstly described
a patient with these core symptoms (Rossor 2001).
(4)  Other  less  common forms of  dementia  include  Binswanger’s  disease  (Caplan  &
Gomes  2010),  Parkinson's  disease  (Goetz  & Pal  2014),  Huntington’s  disease  (Roos
2010),  Creutzfeldt-Jakob Disease  (Creutzfeldt 1920;  Panegyres et  al.  2013),  Multiple
Systems Atrophy  (Ahmed et  al.  2012),  Corticobasal  degeneration  (Grijalvo-Perez  &
Litvan 2014), and HIV-related cognitive impairment (Zhao et al. 2014).
A  further  distinction  between  cortical  (mostly  affecting  the  cerebral  cortex)  and
subcortical  (affecting  areas  beneath  the  cortex)  dementia  is  usually  made:  AD,
Creutzfeldt-Jakob, Parkinson’s  disease and Frontotemporal dementia  are  classified as
forms of cortical dementia whereas cerebral palsy disorders  (R. W. Lee et  al.  2014),
Huntington’s,  Wilson’s  (Li  et  al.  2014),  White  matter  diseases  (Weller  et  al.  2015),
AIDS,  and  other  rare  encephalopathies  are  considered  subcortical  with  dementia
symptoms (Huber et al. 1986).
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2.1 Clinical definitions
2.1.1 Clinical definition of AD
Probable AD is diagnosed when the patient fulfils the core clinical criteria for dementia 
and in addition, the following characteristics (McKhann et al., 2011):
1. Insidious onset: gradual onset of symptoms over a longer period of time (years)
2. Worsening of cognition
3. Amnesic symptoms including learning impairment and recall of learned information
4. Nonamnesic characteristics: language, visuospatial, executive dysfunction
Probable AD should not be diagnosed in cases of cerebrovascular disease, Lewy body 
dementia, frontotemporal dementia, aphasia, other neurological disease or medical 
comorbidity. 
Memory loss is one of the first and most prominent symptoms of Alzheimer's disease.
First memory problems start with subtle forgetfulness. Later, the capability of recall,
recognition,  registration  and  retention  of  information  becomes  more  impaired;  this
includes  difficulties  with  recognizing  people  and  naming  objects  leading  to
disorientation and confusion: for instance, an individual with severe AD can get lost in
his/her own home. As symptoms worsen all activities of daily living become affected
and  eventually  full  time  care  is  required  (Velayudhan  2011).  Memory  loss  is
hypothesised to be associated with the main pathological features of AD: accumulation
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of amyloid-β plaques  (Kam et al. 2013), and with the spread of neurofibrillary tangles
from the  entorhinal  cortex  to  the  hippocampus  in  the  brain  (Kerchner  et  al.  2012).
Additionally, structural and functional brain changes (Jahn 2013), for instance atrophy in
specific regions such as the posterior and medial temporal lobes (Smits et al. 2013), and
in the hippocampus, affect memory severely (Kerchner et al. 2012). 
Language becomes affected in AD with regard to oral, written expression, and selection
of words, and also pronunciation in later stages (Abou-Saleh et al. 2010), and has been
related to structural changes in the frontal lobe (Mega 2000). 
Higher visual functions become gradually impaired: the primary visual cortex is initially
less  affected  than  the  brain  regions  in  which  visual  association  tasks  are  performed
(Prvulovic  et  al.  2002).  The  lower  performance  on  visual  tasks  is  associated  with
different areas in the brain: in early onset AD posterior atrophy has been observed and in
late onset medial temporal lobe atrophy (Smits et al. 2013). 
Executive  functions  are  hampered  by  the  disease:  usually,  AD  patients  encounter
problems with executing planned movements, especially sequential execution of several
steps, (re-)organising, and abstraction capabilities; all of these tasks depend on proper
function of frontal lobe brain activity (Swanberg et al. 2004).
Disruptions  of  memory,  language,  spatial  awareness,  praxis  and the  associated  brain
activities can lead to severe mood swings and the behavioural symptoms associated with
AD: including delusions, hallucinations, depression, aggression, dis-inhibition, agitation,
and sleep disturbances. Sleep patterns have been found to be more fragmented, causing
people to wake up more often during the night, and also rapid eye movement sleep is
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disturbed  (Petit et al.  2005). Some changes in eating behaviour have been observed;
however,  they  do  not  occur  as  frequently  as  in  other  dementias  (Ikeda  2002).
Hallucinations or delusional thinking occur later in the disease course and have been
associated with cognitive decline  (Wilson 2000). Cognitive and behavioural problems
dominate the patient's life and he/she requires eventually full time care. On MRI scans
whole brain atrophy,  hippocampal  atrophy are prominent  features and on PET scans
increased amyloid burden can be observed. In the late stages, Aβ1-42 has accumulated in
the brain alongside with tau-pathology, leading to dementia.
2.1.2 Clinical definition of MCI
 
Exact boundaries between normal cognition and MCI and between MCI and dementia 
are difficult, and clinical judgement is required for such distinctions (Albert et al., 2011).
1. There is evidence of a change in cognition
2. Increasing impairment in one or more cognitive domains including memory, executive
function, attention, language, and visuospatial skills, and episodic memory (the ability to
learn and retain new information). 
3. Persons with MCI are usually still performing in day-to-day tasks but less efficiently. 
4. MCI requires evidence of intra-individual change.
There are known limitations in the search for accurate biomarkers. The diagnosis of AD 
and MCI can take place on a biomarker spectrum and in some cases can be inaccurate 
even when using standardised tests. The challenge is avoiding misclassification, thus a 
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combination of biomarkers such as imaging, clinical cognitive test, gene expression, and
protein data could be more accurate for diagnosis. In the current study, individuals with 
MCI reported problems with memory but performed normal in activities of daily living 
as specified in the Petersen’s criteria for amnestic MCI (Peterson et al. 1999; Peterson et 
al 2001).
2.1.3 Definition of Preclinical AD
Preclinical  AD describes  a  newly defined stage of  the  disease reflecting measurable
biomarker  changes  that  could  occur  a  number  of  years  before  symptoms  affecting
memory,  thinking  or  behaviour.  However,  such  changes  are  not  used  as  diagnostic
criteria  yet.  They  are  regarded  as  complementary  indicators  (biomarkers)  under
investigation  to  better  define  AD  in  future  and  move  the  efforts  toward  earlier
intervention, and finally, toward the prevention of AD dementia (Sperling et al., 2011).
The preclinical phase starts usually more than a decade before first symptoms occur
(Jack  et  al.  2013),  sometimes  already  15  years  before.  During  this  period  several
structural, functional,  and biochemical events are occurring along with neuro-cellular
instabilities. Markers of these changes were detected in plasma and cerebrospinal fluid
(Gold et al. 2012; Lunnon et al. 2013), fibrillar amyloid deposition (Morris et al. 2010),
cognitive event-related potentials (Olichney & Hillert 2004), mitochondrial dysfunction
(Maruszak & Żekanowski 2011), and immune activation (Lunnon et al. 2012).
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2.1.4 Definition of Prodromal AD
Prodromal AD is referred to as the pre-dementia stage of AD in which clinical amnestic 
symptoms and biomarker evidence of AD progression are detectable (Chertkow et al., 
2013) (Figure 1).  At the minimum one abnormal AD progression biomarker has to be 
found for reclassification of a patient from MCI (a risk state) to prodromal AD (a stage 
of AD). 
In the prodomal phase, subtle cognitive and behavioural problems can occur, often in
executive functions, motivation, or affective behaviour. The patient remains independent
but often shows a set of symptoms referred to as MCI. About 3 to 19 percent of those
aged 65 and older  meet  MCI criteria (Gauthier  et  al.  2006),  and 50%-70% of  them
develop dementia (Drago et al. 2011). Nevertheless, not all patients with MCI develop
AD, some stabilize or even improve their mental abilities.  
                
       Figure 1: Stages of AD related to molecular events The course the disease is characterised by three phases: (1)
preclinical, (2) prodomal, (3) symptomatic, phase with dementia present(Adapted from Forlenza et al., 2010)
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2.2 Neuropsychiatric scales
Neuropsychological tests remain the most prevalent tool for AD diagnosis (Jahn 2013).
Since 1984 cognitive standardized assessments and global measurements of dementia
are  used:  the  Alzheimer's  Disease  Assessment  Scale-cognitive  subscale  (ADAS-cog)
(Pea-Casanova 1997), the Clinical Dementia Rating (CDR) (Hughes et al. 1982), and the
Mini-Mental State Exam (MMSE) (Folstein et al. 1975), and many other others. These
tests measure many aspects of memory, language and spatial orientation skills. 
2.2.1 ADAS-cog
The ADAS tests have been developed to measure the severity of the most important
symptoms of Alzheimer's disease. A subscale of the ADAS-cog is frequently employed
for  cognitive  assessments  in  clinical  trials  comprising  11  tasks  covering:  memory,
language,  praxis,  attention.  Its  scoring system ranges from 0-70 points where higher
scores means worse cognitive performance.
2.2.2 Clinical Dementia Rating
The CDR-Global is a combined functional scale ranging from 0-18 points, and the CDR-
Sum Of Boxes (CDR-SOB) comprises six different assessment categories ranging from
0-3 points. Higher scores are associated with greater cognitive impairment. The ADAS-
cog and the CDR-SOB provide more detailed information than the global CDR score
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(Lynch et al. 2006). CDR is important to differentiate MCI from AD, it has been found
suitable  for  identifying  subgroups  of  individuals  with  MCI who  have  more  widespread
neurodegeneration and are more likely to progress to probable AD (Chang et al., 2011).
2.2.3 Mini-Mental State Exam
The MMSE is the most commonly used assessment in early AD stages, and is also often
used for measuring AD progression and severity. The questions are focused on memory
and  orientation  ranging  from 0-30  points.  Lower  scores  are  associated  with  greater
cognitive impairment. Patients with AD often lose up to four points yearly (on average)
measured  by  MMSE.  Doctors  usually  consider  the  MMSE  performance  when
administering drugs. The MMSE boundary for AD is described with a score of 20 to 24
suggesting mild dementia, 13 to 20 moderate dementia, and less than 12 indicates severe
dementia. On average, the MMSE score of a person with Alzheimer's declines about two
to four points each year. A score of 24 yielded a sensitivity of 0.58 and a specificity of
0.98 in detecting probable and possible Alzheimer's disease across ethnicities (Spering et
al., 2012). The MMSE boundary for MCI is 25-30 = Normal / 19-24 = Borderline / <19
= Impaired (Folstein MF, Folstein SE, and McHugh PR, 1975)
General considerations regarding cognitive testing
A bad performance in a cognitive test does not necessarily indicate persistent dementia,
it  remains  the  possible  that  the  patient  suffers  from other  conditions  which  impact
his/her  cognitive  performance  temporarily.  The  daily  mental  fitness  could  vary
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depending on mood, pain, or health problems. 
Additionally, a  disadvantage of cognitive tests is that education, cultural background,
and (speech)  disabilities can severely influence the test  results.  A person with lower
education might be misclassified of having dementia.
4 Pathology
4.1 Molecular pathology
There are two major pathological features that characterize AD: (i) the presence of large
extracellular  ‘neuritic  plaques’  composed  of  aggregated  amyloid  β peptide  42
(Alzheimer  1907;  Glenner  & Wong 1984;  Findeis  2007),  surrounded by  abnormally
formed  neuronal  processes  or  neurites  (Perl  2010),  and  (ii)  the  accumulation  of
intracellular ‘neurofibrillary tangles’ which are cytosolic inclusions mainly consisting of
hyperphosphorylated and presumably abnormally cleaved tau protein,  a  microtubule-
associated protein (Grundke-Iqbal et al. 1986; Huang et al. 2001) (Figure 2). 
Figure 2: Senile plaque (left) and neurofibrillary tangle (right). (Adapted from (Ingolia 2014)
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 Aβ is produced in the brain from the Amyloid Precursor Protein (APP). APP is a single-
pass transmembrane protein with a large extracellular domain containing two heparin-
binding sites (Mok et al. 1997) (O’Brien & Wong 2011); the gene which expresses the
APP protein is located on chromosome 21. Multiple alternative splicing isoforms of APP
have  been  identified  in  humans  with  from 365  to  770  amino  acids  length.  Certain
isoforms are preferentially expressed in neurons and changes in their ratio have been
related to Alzheimer's disease (Matsui et al. 2007). The exact physiological role of APP
is still not known but it has been shown that APP is capable of modulating cell growth
and survival, motility, neurite outgrowth (Pung et al. 2013), intracellular trafficking, and
proteolytic processing (Thinakaran & Koo 2008). APP is the precursor to the amyloid β
protein, a 38-43-amino acid residue peptide which is the core of the “amyloid cascade
hypothesis”. 
4.1.1 The Amyloid Cascade Hypothesis
Although  the  current  prevailing  explanation  for  AD (the  so-called  ‘amyloid  cascade
hypothesis’) is based on the strong correlation between the development of the disease
and the appearance of Aβ deposition in the brain of patients, the views on the exact role
of Aβ still remain obscure and somehow controversial. The amyloid cascade hypothesis
initially proposed by Hardy & Higgins (1992) postulates two different pathways of APP
processing in the cell. Interestingly, only one of these pathways is associated with the
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generation of toxic amyloidogenic Aβ deposits (Figure 3).
Figure 3: The amyloid cascade hypothesis: the mechanism of A- β 42 mediated neurotoxicity; the pictures
correspond to crystal structures of protein subunits deposited in 'The Worldwide Protein Data Bank'
[http://www.wwpdb.org/]
APP can  be  involved  in  a  non-amyloidogenic  (i.e.,  non-pathological)  pathway  that
involves the sequential action of  α- and  γ-secretases on the cell surface. This pathway
generates a harmless version of Aβ. However, in the amyloidogenic (i.e., pathological)
pathway, APP is proteolytically processed and reinternalized through clathrin-coated pits
into  endosomal  (or  lysosomal)  compartments  that  contain  the  proteases  BACE1  (β-
secretase) and γ-secretase  (Vassar et al. 1999;  O’Brien & Wong 2011;  Nakayama et al.
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2013). First, BACE1 (the neuronal β-secretase), a transmembrane aspartic protease, cuts
APP at the positions +1 and +11 sites of Aβ (Cai et al. 2001). Second,  the remaining
APP C-terminal fragment is cut by  γ-secretase complex at one of several varying sites
from positions +40 to +44, generating the APP intracellular domain and Aβ peptides
(such  as  Aβ1-40 or  Aβ1-42)  which  eventually  will  reach  the  extracellular  milieu.  It
remains unknown what signals decide which proteolytic processing (α+γ versus β+γ)
APP will undergo in the cell. Of note, the Aβ1-42 peptide has been found to be the most
abundant  proteolytic  fragment  and also  the  most  toxic.  Aβ1-42 accumulation  (or  the
excessive accumulation of Aβ1-42 versus Aβ1-40) is therefore the most deleterious event
in the current molecular hypothesis underlying the etiology of AD. 
In  the  amyloidogenic  pathway  γ-secretase,  is  a  multiprotein  complex  composed  of
presenilin  1  (PSEN1),  presenilin  2  (PSEN2),  nicastrin,   APH-1,  and  PEN-2.  This
complex mediates the cleavage of transmembrane protein such as APP and NOTCH (De
Strooper et al. 1999). The exact role of the different subunits of the γ-secretase complex
is still not fully understood but it is hypothesized that changes in NOTCH-proteolysis
mediated by γ-secretase may be involved in the pathogenesis of AD (Woo et al. 2009).
An increase in BACE1 activity has been reported in brain tissue samples of patients with
sporadic  AD  (Hampel  &  Shen  2009).  Up-regulated  BACE1  activity  could  be  a
consequence  of  the  activation  of  the  transcription  factor  HIF-1α or  a  general
augmentation of oxidative stress in the brain (Chami & Checler 2012). It is still unclear
whether monomeric, oligomeric, or fibril forms of toxic Aβ peptides are the most toxic
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to neurons. Also, it has been shown that Aβ can be toxic extracellularly and not only
when accumulates in the lumen, it binds strongly to tau in solution which could be a
precursor event to later self-aggregation of both molecules (Guo et al. 2006). 
Neurofibrillary tangles, formed by aberrantly paired helical filamentous aggregates of
the microtubule-associated protein tau, are hypothesized to cause neural cell death and
lead  to  the  symptoms  associated  with  AD  (Chesser  et  al.  2013).  They  stabilize
microtubules during axonal transport  and also enhance neuronal processes outgrowth
(Kowall & Kosik 1987). Hyperphosphorylated Tau aggregates in filaments and loses its
microtubule-binding  and  -stabilizing  functions  leading  to  neuronal  death.  Tau
hyperphosphorylation  has  been  reported  to  be  mediated  by  several  protein  kinases
including GSK3 (F. Hernández et al. 2010), CDK5 (Hernández & Avila 2008), p38 (Zhu
et al.  2000), JNK  (Ploia et al.  2011), PKA (Tanaka et al.  2000), PKC  (Tanaka et al.
2000), CAMKII  (Wang et al. 2007), CKII  (G. Yu et al. 2013), and MARK  (Gu et al.
2013). In total, up to 79 serines/threonines have been reported to be phosphorylated in
the longest tau mammalian isoform of 441 amino acids (Figure 4).
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Figure 4: Disintegrating microtubule and tau protein tangles (Adapted from ADEAR: “Alzheimer's Disease Education
and Referral Center of the National Institute of Ageing.”)
4.1.2 Pathways implicated in the initiation and progression of AD
Recent novel insights in key-pathways lead to a deeper understanding of AD: (1) the
innate immune system, (2) cholesterol metabolism, (3) endosomal vesicle recycling, (4)
autophagy, and most recently (5) protein ubiquitination provide a more holistic view of
AD pathogenesis involving a number of different cell-types and mechanisms.
(1) The innate immune system
In the central nervous system microglia, a type of glial cell with macrophagic function,
are capable of  responding to injury and infection.  On their surface Toll-like receptors
(TLR)  are expressed  which  are critical  for  eliciting  an innate  immune response and
triggering  the  adaptive  immune  system,  recognising  pathogen-associated  molecular
patterns, and also Aβ (Boutajangout & Wisniewski 2013). TLR respond to fibrillar  Aβ
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by  accumulating  toxins  and  increasing  cytokine  production  leading  to  neuro-
inflammation, and -degeneration. Other stimuli that lead to elevated microglia activity
include:  oxidative  stress,  proinflammatory  cytokines  (a  vicious  cycle),  glutamate
receptor  antagonists,  cell  necrosis  factors,  lipopolysaccharide,  and  changes  in
extracellular  potassium.  It  is  hypothesized  that  also  environmental  toxins  and
endogenous proteins induce microglial overactivity (detectable with imaging methods)
leading  to  neuroinflammtion.  Drugs,  acting  upon  inflammatory  processes  and  thus
microglia could potentially influence the AD progression  (Block et al. 2007;  Schott &
Revesz 2013). There could be other feedback loops, yet to be identified, between Aβ and
microglia involved in the process of inflammation in AD (Meyer-Luehmann et al. 2008).
One practical implication of the effect of inflammation has been shown in late-onset AD
where anti-inflammatory drugs, taken long before disease onset, have been shown to be
beneficial in decreasing the disease risk (Etminan et al. 2003).  Another innate immune
receptor on microglia is TREM2. Defects in this gene lead to chronic neuroinflammation
and  microglial  activation  by  increase  of  cytokine  production  and  secretion
(Boutajangout & Wisniewski 2013). Other genes that are associated with microglia and
increased risk of late-onset AD are CR1, CD33, and MS4A4A/MS4A6A (Hollingworth
et  al.  2011;  Gandy  et  al.  2013;  Proitsi  et  al.  2014).  These  studies  suggest  that
modification of microglial function in AD is a potential therapeutic target.
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(2) Cholesterol metabolism
High levels of cholesterol in the blood (hypercholesterolemia) and abnormal cholesterol
processing  are  strongly  related  to  toxic  amyloid  plaque  formation  and  tau
hyperphosphorylation;  possibly  cholesterol  oxidation  products  “oxysterols”  are
contributing to toxic deposits (Gamba et al. 2012). 
(3) Endosomal vesicle recycling
Neurotransmitters are transported in vesicles (Figure  5); the supply of vesicles comes
from  the  cell-body.  Remarkably,  the  neurons  can  sustain  high  rates  of  synaptic
transmission without  using up their  supply of synaptic vesicles relying on endocytic
recycling of synaptic vesicle membranes  (Saheki & De Camilli 2012). However, this
local recycling at nerve terminals requires them to be structurally and chemically intact
which is probably not the case in AD leading to failure of synaptic transmission (Overk
& Masliah 2014).  There is evidence that defective vesicle recycling or exo-endocytic
coupling  can  be  related  to  deficits  in  short-term  synaptic  plasticity,  memory,  and
cognitive performance (Murthy & De Camilli 2003; Lambert et al. 2013). 
Additionally,  other  important  AD molecules  are  trafficked in  vesicles,  as  previously
mentioned:  “APP is  reinternalized  through  clathrin-coated  pits  into  endosomal  (or
lysosomal)  compartments  that  contain  the  proteases  BACE1  (β-secretase)  and  γ-
secretase.  This  process  results  in  the  production  of  Aβ (Aβ1-40  or  Aβ1-42)  which
eventually will reach the extracellular milieu. Endocytic mechanisms can be also found
in other cell  types but in neurons there are some specific adaptations  (Saheki & De
Camilli 2012), especially in AD implicated cells. 
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(4) Autophagy
Autophagy  is  usually  a  protective,  highly  conserved  eukaryotic  cellular  recycling
process  (Parzych  &  Klionsky  2014),  disruption  of  which  can  lead  to  various
neurodegenerative diseases, inclusive AD. Autophagy functions by degrading toxic and
damaged organelles,  macromolecules  such as  protein aggregates,  and eventually this
cytoplasmic  cell  waste  is  destroyed  in  lysosomes;  defective  lysosomal  acidification
contributes to proteolytic failure and loss of other important cell functions (Wolfe et al.
2013).   Recent  research  suggests  that  defects  in  the  autophagosomal  fusion  with
lysosomes lead to insufficient protective autophagy in AD (Barnett & Brewer 2011).  
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Figure 5: Endosomal vesicle recycling (Adapted from Jahn & Fasshauer 2012)
(5) Protein ubiquitylation
Ubiquitin  and  Ub-like  modifiers  are  small  proteins  that  upon  covalent  attachment
regulate  protein  functions  in  eukaryotic  organisms;  they can  be  determined  in  most
cellular pathways and are a key-players in disease onset.  Ub requires three types of
enzymes:  ubiquitin-activating enzymes,  ubiquitin-conjugating enzymes and ubiquitin
ligases.  Ubiquitylation  might  play  an  important  role  in  AD  by regulating  the
development of the immune system and immune responses: initiation, propagation and
termination  (Bhoj & Chen 2009). A number of ubiquitin ligases prevent auto-immune
attacks. Their dysfunction is implicated in disease but the exact role in AD remains to be
elucidated. 
4.2 Structural and functional brain changes
The most  remarkable  visible  feature,  on MRI scans  or  post-mortem,  is  whole  brain
atrophy,  including many important structures:  hippocampus,  cerebral-,  and entorhinal
cortex (Figure  6).  Atrophic changes in the brain are associated with worse cognitive
performance  (Rayaprolu et al. 2013), and cognitive decline  (L. Smits et al. 2013). At
early  stages  of  AD,  atrophy  and  metabolic  changes  emerge  especially  in  posterior
cortical regions and also in medial temporal regions (Velayudhan et al. 2013).
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Figure 6: Healthy brain versus AD brain (Adapted from the National Institute of Ageing, 2002) 
Other pathological structure-related features include granulovacuolar degeneration and
eosinophilic rodlike bodies (Hirano bodies), and the loss of synaptic connectivity which
clearly has a huge impact on cognitive function (Buckner et al. 2005). 
5 Genetics 
Around 95 % of the AD cases occur sporadic (late-onset AD). However, among the 30%
proportion of unknown cases, new common variants have been recently detected; most
of these genes are associated with very small relative risk of AD (Figure 7 & 8). 
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  Figure 7: Distribution of AD forms and of their related genetic susceptibility factors
Mutations in the APP, PSEN1, PSEN2, TREM2 (Triggering Receptor Expressed on 
Myeloid cells 2) and CSF1R (Stimulating Factor 1 Receptor) genes occur in less then 
5% of AD cases (Figure 8). 
Figure 8: Rare and common genetic loci with their associated risk in AD (Adapted from
Manolio et al., 2009, and updated with recently discovered variants)
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The onset in these rare genetic cases is much earlier, affecting people already in their 40s
in contrast to the cases with increased risk due to common susceptibility genes with
onset above 65. Rare mutations have usually a large disease effect (Table 1). Individuals
with rare mutations deteriorate very fast, whereas late-onset cases develop the disease
over years, probably even decades.  
Genetic disease Genetic susceptibility
Onset early late
Genetic component mutation disease related mutation risk related 
Mutation frequency rare common
Inheritance mendelian complex
Effect on individual large weak
Effect on population weak large
Epigenetic influence small large 
Table 1: Genetic disease versus susceptibility (Manolio et al. 2009)
5.1 Early Onset Familial AD
Rare genetic variants which are associated with early onset AD include:  APP, PSEN1,
PSEN2, TREM2, and CSFR1. Their functions are associated with APP- processing (APP,
PSEN1, PSEN2) and immune responses (TREM2, CSFR1). Mutations in  APP, PSEN1
and PSEN2 have been mainly associated with early onset AD (<60 years) in familial AD
cases (Richard & Amouyel 2001). However, new evidence has been found which relates
also late onset familial AD to these rare variants (Goate et al. 1991; Cruts et al. 1998).
Early onset  familial  cases  are  due  to  a  strong genetic  element:  autosomal  dominant
missense  mutations  (a  single  nucleotide  change  results  in  a  codon  that  codes  for  a
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different amino acid), in individuals younger than 60 years, in the  Amyloid Precursor
Protein (APP) and Presenilins 1 and 2 (PSEN 1 and 2) genes (O’Brien & Wong 2011)
(De  Strooper  et  al.  1999) (Cruchaga  et  al.  2012),  and  a  rare  autosomal  recessive
missense mutation in the TREM2 gene. 
Clinically and neuropathologically there are some differences between early onset and
late onset AD, such as increased levels of C-reactive protein, creatine, and blood urea
nitrogen. C-reactive protein is produced by the liver as a response to injury, infection,
and inflammation which could have an impact on cognitive decline in AD (Panegyres &
Chen 2013). 
However, some neuropsychological ﬁndings suggest that there are similarities between
early onset and sporadic AD such as amnesic and dys-executive syndrome which can be
observed in both  (Greene et al., 1995).  
5.1.1 APP- mutations
There are  at  least  36 APP gene missense mutations  usually clustering around the  γ-
secretase cleavage site, but also around the BACE1 cleavage site in primary cultures of
human neurons  (Guerreiro et  al.  2013),  resulting in early-onset,  autosomal dominant
AD; these mutations account for 10% to 15% of early-onset familial AD (De Jonghe et
al.  2001). Of note, it  is hypothesized that APP plays also a role in sporadic AD and
trisomy 21 (Down's syndrome). People with Down's syndrome produce increased levels
of APP (and therefore Aβ 1-42) as a consequence of a gene duplication  on chromosome
21, leading to early AD. These patients can develop dementia and AD pathology already
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in their 20s (Abou-Saleh et al. 2010; Cruts et al. 2012). Interestingly, there are also more
common  AD  variants  within  genes  such  as  APOE,  SORL1,  RUNX1,  BACE1,
ALDH18A1, which are also associated with Down's syndrome (Sparks et al. 2013). 
5.1.2 PSEN-mutations
In the past rare PSEN mutations have been associated with early onset familial  AD:
these mutations have been found in two genes, PSEN1 on chromosome 14 and PSEN2
on chromosome 1. The incidence of PSEN 1 is very low with 3%, and for PSEN2 even
lower with 0.1% of all reported AD cases worldwide (Patel et al. 2011).  According to
the “Alzheimer Disease & Frontotemporal Dementia Mutation Database”  (Richard &
Amouyel 2001), at least 185 mutations in PSEN1 have been mapped while 14 mutations
have been found for PSEN2. Mutations in the presinilin genes facilitate proteolysis of
APP by  γ-secretase  to  form toxic  Aβ in  transgenic  mice  with  APP mutations  who
develop  plaques  as  they  age;  genetically-modified  mice  (Tg2576  crossed  with
PS1M146L)  with  both  the  human  APP and  PSEN  genes  show  plaques  at  a  much
younger  age  (Holcomb  at  al.  1998).  These  mice  had  enhanced  amyloid  deposition,
behavioural symptoms, less performance in the water maze, and reflect largely disease
pathogenesis.  Such  remarkable  findings  have  led  to  the  hypothesis  that  the  loss  of




Recently,  rare mutations in the  TREM2 gene (affecting around 1-3% of AD patients)
have been found to be associated with AD (Jonsson et al. 2013;  Guerreiro et al. 2013;
Ruiz et al. 2013).  TREM2 is found in the membrane of cell types linked with immune
function, including macrophages, dendritic cells, osteoclasts, and microglia.  TREM2 is
expressed at high levels in white matter but also in the hippocampus, medulla, putamen,
neocortex and at lower levels in the cerebellum (Forabosco et al. 2013). 
The  rs75932628 variant
The variant rs75932628, predicted to cause a R47H substitution in TREM2, increases the
AD risk with an odds ratio similar to that of the APOE ε4 allele, ranging from 2.9-5.1
(Guerreiro et al.  2013;  Jiang et al. 2013;  Forabosco et al. 2013;  Jonsson et al. 2013;
Gonzalez Murcia  et  al.  2013).  AD  onset  occurs  ~3.5 years  earlier  in  carriers of  the
rs75932628  variant  than  in  non-carriers  and  the  carriers  exhibit  mature  and  diffuse
amyloid plaques already in an early disease stage (Jonsson et al. 2013). Interestingly, the
variant is associated with lower cognitive functioning in AD but also in non-demented
subjects, above age 80 (Guerreiro et al. 2013; Jonsson et al. 2013; Benitez et al. 2013). 
There was also evidence for an association of R47H with FDT and Parkinson's disease 
(Fenoglio et al. 2007; Guerreiro et al. 2013; Jiang et al. 2013; Ruiz et al. 2013). Another 
study confirms the strong association of R47H with AD but did not find an association 
with FTD (Forabosco et al. 2013). 
In the Icelandic population  R47H has been associated with a lack of containment of
neuroinflammation. Further verification is needed in other racial and ethnic groups to
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verify if the harmful mutation has the same effect (Guerreiro et al. 2013). 
Other AD-specific variants in the TREM2 gene
In  addition,  six  TREM2 variants  were  observed  in  AD subjects  but  not  in  controls:
H157Y,  R98W,  D87N,  T66M,  Y38C,  and  Q33X.  These  could  contribute  to  AD
pathogenesis  (Rayaprolu et al. 2013).  More large-scale genetic screenings to discover
other functional variants in TREM2 remain to be performed. 
TREM2 and Nasu-Hakola disease
Of interest,  mutations  in  TREM2 appear  to  play  a  role  in  Nasu-Hakola  disease  by
triggering  the  production  of  constitutive  inflammatory  cytokines  (Cella  et  al.  2003;
Paloneva  et  al.  2003;  Bianchin  et  al.  2010;  Bock  et  al.  2013). Nasu-Hakola,  a
progressive  presenile  inflammatory  neurodegeneration,  disease  is  a  rare  mendelian
disease  characterized  by  bone  reabsorption  dysfunction  and  chronic  inflammatory
neurodegeneration, leading to death at ages in the 40s or 50s. The exact pathomechanism
underlying  Nasu-Hakola  disease  remains  unclear  but  microglial  clearance  failure
appears  to  be  implicated  (which  seems  to  be  also  related  to  late-onset  AD  and  to
malfunction of TREM2 gene expression).
TREM2 and TYROB
Early  studies  have  found  that  TREM2 together  with  TYROBP (former  DAP12)
expression  deficiency  is  associated  with  impaired  osteoclast  differentiation  and
osteoporosis  (Paloneva et al. 2003). The  TREM2  and TYROB  receptor complex plays
also  an important  role  in  immune cells  such as  microglial  cells  which  protect  from
foreign pathogens and remove dead cells and other debris in the brain (Ito & Hamerman
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2012; Jiang et al. 2013). However, the exact function of the TREM2 - TYROB complex
remains to be elucidated.
TREM2 and phagocytosis
TREM2 is  associated with Alzheimer's  disease,  multiple  sclerosis,  and motor  neuron
disease,  supporting  the  hypothesis  that  these  diseases  have  common  underlying
pathways  implicating  microglia  (Forabosco  et  al.  2013).  Experimental  evidence  has
shown that an increase of TREM2 expression enhances microglial clearance of amyloid
plaques in mice via a process known as phagocytosis (Melchior et al. 2010; Forabosco et
al.  2013;  Rayaprolu  et  al.  2013;  Sierra  et  al.  2013).  These  results  have  led  to  the
hypothesis that TREM2 has a protective role in AD by suppressing inflammatory cell
responses as well as promoting phagocytosis of Aβ in damaged neurons. TREM2 could
be  potentially  used  in  vaccine-based  autoimmune  (anti-amyloid)  treatments  by
decreasing the severity of auto-immune responses (Melchior et al. 2010). 
5.1.4 CSFR1-mutations
CSFR1 a human cell-surface  protein of the  CSF1R gene,  is a  receptor  for a  cytokine
called colony stimulating factor 1 (CSF1) and IL34 (Guerreiro et al. 2013),  located on
chromosome  5.  CSF1  controls  the  production,  differentiation,  and  functioning  of
macrophages. 
CSF1R  missense  mutations  are  rare  and  associated  with  Hereditary  Diffuse
Leukoencephalopathy with Spheroids (HDLS) and sometimes diagnosed together with
AD. HDLS is characterized by huge axonal swellings (spheroids) within the CNS white
matter, executive dysfunction, memory decline, personality changes, motor impairment,
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and seizures (Wang et al. 2012; Rademakers, et al. 2012); the age of onset is below 60
years. 
Elevated levels of CSF1R1 are found in hyperactive  microglia in  Alzheimer's disease
and after brain injuries (Sundal et al. 2012). CSF1R and CSF1 may be involved in breast
cancer (Mitrasinovic et al. 2005). 
CSF1is  a  key regulator  of  the  monocyte/macrophage  lineage.  The  administration  of
human  recombinant  CSF1  improves  memory  in  a  transgenic  mouse  model  of
Alzheimer’s disease (Tamimi et al. 2008).
Most cases of Alzheimer's disease are not hereditary but sporadic. It is still unclear how
sporadic  cases  of  AD  arise.  To  date,  research  efforts  have  somehow  focused  on
hereditary cases even if they represent a small subset of the total cases of AD. Rare
variants contributing to early-onset AD have a larger effect size on the individual in
comparison  to  common  variants  which  usually  have  smaller  effect  sizes.  Loci  of
common variants  can  be identified  by means  of  DNA sequencing methodology and
computationally processed in a GWAS (Genome-Wide Association Study). More work
has to be done on sporadic early onset which includes screening of larger patient pools
for rare mutations.
Consistent  with the amyloid cascade hypothesis,  it  can be concluded that  mendelian
genes are involved in Aβ production, which is controlled and can even be reduced by
certain protective variants. Some of these genes play a role in major biological responses
such as neuronal survival, plasticity, innate and adaptive immune responses, and glucose
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metabolism  (Saura et al. 2004;  Lanier 2009;  Fowler et al. 2011;  Mosconi 2013). It is
thought  that  increasing understanding of their  roles in  both normal  and pathological
conditions would eventually lead to the development of drugs able to manage, control,
or cure Alzheimer's disease.
5.2 Late Onset Sporadic AD
In the past most of the studies focused on APOE, however, recently many more common
risk variants have been identified. In this section, the APOE isoforms and their functions
are described in detail and afterwards an overview of the recently discovered variants is
provided.
5.2.1 APOE-variants
There are three variants of the human APOE gene, which is located on chromosome 19:
the polymorphic alleles (isoforms) ε2, ε3, and ε4 with a population frequency of 8.4%,
77.9%, and 13.7%, respectively. At least one APOEε4 allele is found in ca. 37% of AD
patients; a very common genetic variant (APOE genotype  ε3,  ε4) can be found in ca.
65% of the cases  (Luo et al. 2013).  There are there isoforms representing variants at
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5.1    Intermediate
18     risk
APOEε4 Arg Arg 13.7 36.7 ε4/ε4 2 65     High risk
Table 2: APOE isoforms, differences, allele & genotype frequencies, and functions (Richard & Amouyel 
2001)
Carriers of the  APOE ε4 allele  have lower  Cerebro-Spinal Fluid (CSF) Aβ1-42 levels,
elevated tau levels, and more brain or hippocampal atrophy than non-carriers (Raber et
al. 2004; Hostage et al. 2013). These factors increase the risk for developing late onset
AD (Vemuri et al. 2010). 
APOEε4, synthesized by astrocytes, supports transport of cholesterol into cells, immune
response, and controls repair after brain injury.  APOEε4 binds to cell-surface receptors
delivering  lipids,  and  to  Aβ,  leading  to  synaptic  malfunction  and  neurodegenerative
cascades underlying AD (Liu et al. 2013); this allele is further associated with increased
risk of cerebral amyloid angiopathy and age-related cognitive decline in normal ageing. 
5.2.2 Recent common risk variants
Recently, 21 common risk variants have been discovered (Table 3). 
1. ABCA7 (Hollingworth et al. 2011) (Reitz et. Al 2013)
2. BIN1 (Miyashita et al. 2013) (Thambisetty et al. 2013)
3. CASS4 (Mayeux et al. 2013)
4. CELF1 (Hinney et al. 2014)
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5. CD2AP (Karch & Goate 2014) (Hollingworth et al. 2011)
6. CD33 (Naj et al. 2011) (Hollingworth et al. 2011) (Lambert et al. 2013) 
7. CR1  (Aso & Ferrer 2013) (Lambert et al. 2013) 
8. CLU (Lambert et al. 2009)  (Harold et al. 2009) (Lambert et al. 2009) (Lambert et al. 2013) (Thambisetty et al. 
2013) (Chapuis et al. 2013)
9. DSG2 (Lambert et al. 2013)  (Karch & Goate 2014)
10. EPHA1 (Naj et al. 2011) (Hollingworth et al. 2011) (Lambert et al. 2013) 
11. FERMT2 (Karch & Goate 2014)
12. HLA-DRB5/DRB1 (Lambert et al. 2013) (Naj et al. 2011) (Killick et al. 2014)
13. INPP5D  (Lambert et al. 2013)
14. MEF2C (Karch & Goate 2014)
15. MS4A6A (Harold et al. 2009) (Hollingworth et al. 2011) (Naj et al. 2011) (Lambert et al. 2013) (Gandy et al. 
2013) (Gandy et al. 2013) 
16. NME8 (Karch & Goate 2014)
17. PICALM (Harold et al. 2009) 
18. PTK2B (Karch & Goate 2014)
19. SLC24H4-RIN3 (Karch & Goate 2014)
20. SORL1 (Reitz et al. 2013) (Lambert et al. 2013) (Aso & Ferrer 2013)
21. ZCWPW (Karch & Goate 2014)
Table 3: Recent common risk variants
The discovery of these new risk variants has implicated several biological pathways,
including the immune system,  processing  of  cholesterol  and lipids  in  the brain,  and
endocytosis, a process which removes toxic amyloid-β protein from the brain. According
to their involvement in cellular functions and pathways, the different common variants
genetic risk factors can be classified (Table 4).
1. Lipid/ cholesterol processing (Carter 2011): 
APOEε4 (Malpass 2013), ABCA7 (Crehan et al. 2012), CLU (Poirier 2000), SORL1
2. Immune response/microglial activation/inflammation: 
APOEε4, ABCA7, CD33 (Jones et al. 2010), CR1 (Harold et al. 2009) (Rosenthal & Kamboh 2014), 
INPP5D (Lambert et al. 2013),  MEF2C (Lambert et al. 2013), HLA-DRB5/DRB1 (Lambert et al. 2013) 
3.  Endocytosis/endosomal vesicle recycling: 
APOEε4 (Meurs et al. 2012), BIN1 (Rhinn et al. 2013) (Reitz et al. 2013), CD2AP (Carter 2011), CLU 
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(Carter 2011), EPHAI1 (Hollingworth 2011), MS4A6A, PICALM (Carter 2011), SORL1 (Karch & 
Goate 2014)
4.  Amyloid processing:
SORL1 (Lambert et al. 2013), CASS4 (Lambert et al. 2013),
5.  Tau processing: 
CASS4  (Lambert et al. 2013), FERMT2 (Lambert et al. 2013)
6.  Hippocampal synaptic function/cell migration:
PTK2B (Lambert et al. 2013), MEF2C  (Lambert et al. 2013)
7.  Cytoskeletal and axonal transport:
CASS4 (Lambert et al. 2013), CELF1 (Lambert et al. 2013), NME8 (Lambert et al. 2013)
8.  Iris /neuronal development/sodium/patassium/calcium signalling: 
SLC24A4/RIN3 (Kingwell 2013)
Table 4:  Recent common risk variants and their cellular functions and pathways 
6 Treatments
6.1 Pre-Symptomatic treatment & clinical trials
A multi-target therapeutic approach applied in the pre-symptomatic phase of AD might
be most effective.  of the main targets currently being explored. However, none of the
main targets have been validated in phase III trials yet (Figure 9). 
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Figure 9: Overview of main cellular AD targets (Adapted from Aso & Ferrer 2013)  
The main targets include: (1) Aβ production, (2) tau inhibition, (3) limiting the effects of
oxidative stress, (4) controlling neuroinflammation, (5) targeting impaired function of 
energy metabolism, (6) neurotransmitter dysfunction, (7) synaptic dysfunction, (9) 
neurotrophic factors, and degradation pathways such as (10) autophagy, and (11) the 
ubiquitin-proteasome system (Aso & Ferrer 2013). 
(1) Aβ production
Aβ production could be regulated by (a) α-secretase activators, however, not enough is
known about  the  effect  of  activating  α-secretase  on  other  substrates;  (b)  β-secretase
inhibitors, nevertheless, adverse effects from BACE1 inhibition can be expected; (c) γ-
secretase  inhibitors,  a  recent  drawback:  two  large  phase  III  clinical  trials  of
Semagacestat failed because of detrimental cognitive and functional effects of the drug;
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(d) Aβ degrading enzymes, there are potential therapeutic properties in insulin-degrading
enzymes;  (e)  decreasing  Aβ aggregation,  there  has  been  shown  indeed  significant
cognitive improvement in AD patients in a recent phase IIa clinical trial. (f) facilitating
Aβ clearance,  it  has  been demonstrated  that  immunotherapy against  Aβ reduced the
number of Aβ plaques and the number of dystrophic neurites (Aso & Ferrer 2013).
(2) Tau inhibition
There are four possible scenarios for tau inhibition: (a) preventing tau aggregation; (b)
reduction of tau hyperphosphorylation: the neuronal microtubule-associated Tau protein
is highly phosphorylated by glycogen synthase kinase 3 (GSK3) which regulates tau
binding to microtubules, tau degradation and tau aggregation (Hernández & Avila 2008).
In AD, it  has been suggested that the peptide  β amyloid promotes GSK3 activation,
resulting in tau phosphorylation. Thus, targeting GSK3 dysregulation and reduction of
tau hyperphosphorylation could be beneficial: for instance, the kinase GSK-3β acts on
multiple metabolic pathways, learning and memory, and oxidative stress in mice (Wang
et al. 2007;  Farr et al. 2014); (c) reduction of tau levels via passive immunization: a
study has shown reduced behavioural impairment and tau pathology in two transgenic
models  (Chai et al. 2011); (d) stabilization of microtubules: A synthetic peptide called
'NAP'  has  stabilized  microtubules  in  a  phase  II  clinical  trial  (Aso  & Ferrer  2013).
However, the treatment effects have not been sufficiently tested.
(3) Limiting the effects of oxidative stress
Oxidative stress can lead to  unfolded protein in  the endoplasmic reticulum, and cell
death  through activation  of  CHOP,  caspase-4,  and caspase-12  (Aso & Ferrer  2013).
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There  is  a  potential  beneficial  treatment  effect  with  antioxidant  compounds:  (a)
naturally-occurring  anti-oxidants,  for  instance  phytochemicals  such  as,  catechins,
resveratrols have anti-inflammatory, anti-carcinogenic and anti-infectious properties; (b)
mitochondrial  antioxidants:  free  radical  damage  to  mitochondria  can  occur  under
exposure to  polluted air,  radiation or  can be induced by chemicals.  Nutritional  anti-
oxidants relieving oxidative stress, inflammation, Aβ levels have shown benefits (Lee et
al. 2010).
(4) Neuroinflammation
(Neuro-)inflammation,  due  to  a  pathogenic  insult,  is  usually  a  part  of  healing  but
maintained chronically  the  effects  are  malicious,  and  can  be  observed in  AD.  Anti-
inflammatory drugs have shown positive effects in mouse models, it has been speculated
that also naturally occurring anti-inflammatory agents found in nutrition could influence
the level of inflammation (Aso & Ferrer 2013).
(5) Energy metabolism
Energy metabolism is altered in the AD brain. Targeting energetic failure by facilitating
energy  metabolism  and  availability  by  regulating  the  lack  of  glucose  (metabolic
deficiency)  and  oxygen  (mitochondrial  impairment)  could  have  potential  therapeutic
effects (Aso & Ferrer 2013).
(6) Neurotransmitter dysfunction
Cognitive and neuropsychiatric symptoms in AD can ameliorate when stabilising the (a)




Stabilising  imbalances  in  lipid  function  early  enough  in  the  disease  could  reverse
cognitive deterioration due to its regulatory effect on synapses (Aso & Ferrer 2013). 
(8) Neurotrophic factors and hormones
Many different growth factors and other signalling molecules have been linked to AD
(Gold  et  al.  2010).  In  particular,  the  levels  of  Brain-Derived  Neurotrophic  Factor
(BDNF) are low in AD patients  (Lee et al. 2005;  Sudduth et al. 2013) and infusion of
BDNF improves cognitive functions in ageing primates (Peng et al. 2005). On the other
hand, levels of Nerve Growth Factor prohormone (proNGF) are increased in AD, which
is accompanied by a downregulation of TrkA (one of the NGF receptors)  (Peng et al.
2004; Nagahara et al. 2009). A recent disease model for AD is a mouse line expressing
anti-NGF  antibodies  that  presumably  impair  NGF  signalling.  Finally,  studies  have
showed that lower plasma levels of the hormone leptin correlate with an increased risk
of developing AD  (Counts et al. 2004). Although in this latter case, it is still unclear
whether  leptin  levels  drop  is  a  cause  or  a  consequence  in  the  etiology  of  AD.
Neurotrophic factors such as BDNF responsible for neuronal survival, differentiation,
modulation of dendritic branching and dendritic spine morphology as well as synaptic
plasticity,  synaptogenesis,  and  apoptosis  should  be  maintented  at  certain  levels  to
guarantee their function (Aso & Ferrer 2013).  Understanding the impact of the BDNF
Val66Met polymorphism in Alzheimer's disease on episodic memory and hippocampal
volume could lead to new 'synaptic repair' therapies (Aso & Ferrer 2013). 
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Neuroprotective hormones, such as estrogen have shown to play an important role in
mitochondrial  function,  neuroinflammation  and  cognition  in  AD.  Estrogen  mediated
processes  in  the  IGF1  (insulin-like  growth  factor  1)  pathway  and  prevented  Aβ
formation in mice (Aso & Ferrer 2013). 
(9) Autophagy
Failure in autophagic processes, due to defective lysosomal acidification  (Wolfe et al.
2013),  can  result  in  the  accumulation  of  aggregate-prone  proteins  leading  to
neurodegenerative processes (Son et al. 2012; Lu et al. 2013). 
(10) Ubiquitin-Proteasome System (UPS)
The ubiquitin-proteasome system is a crucial regulatory mechanism in cellular processes
such as cell division  (Gutierrez & Ronai 2006). The UPS could play a role in early
stages of AD, in synaptic dysfunction, and in later stages where neurodegeneration is
significant (Upadhya & Hegde 2007). UPS-dysfunction could lead to the accumulation
of insoluble protein aggregates. Usually proteins which should be degraded receive a
ubiquitin-tag, however if structural changes in the protein substrates (e.g Aβ 1-42) occur,
the UPS does not recognize and degrade them. Inhibition of proteasomes thus could
contribute to neuropathogenesis  (Lam et al. 2000), and targeting UPS components has




Cognitive  rehabilitation  could  relieve  AD  symptoms  associated  with  cognitive
functioning and improve the performance of  the patient  in  activities  of  daily living.
However, the effect of cognitive training has not yet been clearly defined but it has been
noticed that it can improve patients' quality of life (Aso & Ferrer 2013). 
(2) Non-cognitive
AD is  also accompanied  by aberrant  levels  of  several  neurotransmitters  in  neuronal
populations  such  as  acetylcholine,  glutamate,  norepinephrine,  serotonin,  and
somatostatin. In particular, if there are brain lesions in regions associated to cholinergic
pathways, AD patients are more severely affected with regard to cognitive and physical
performance (Kurz et al. 2011). Glutamate is the main excitatory neurotransmitter in the
nervous system, and disruptions in glutamate metabolism have also severe behavioural
effects in AD patients (Francis et al. 1999; Butterfield 2004). Several currently applied
AD drugs (such as statins) act on somatostatin levels by inhibiting the enzyme HMG-
CoA (3-Hydroxy-3-Methyl-Glutaryl-Acetyl-Coenzym  A)  reductase,  which  is  a  rate-
limiting enzyme in the metabolic pathway producing cholesterol and other isoprenoids.
These drugs indeed belong to the family of cholesterol-lowering medicines which are
often used in patients with heart conditions.
In  addition,  there  are  possibly  common  neuropathological  mechanisms  behind
depression and AD related to neurotransmitters such as serotonine and acetylcholine,
hypothalamic-pituitary-adrenal glands and the brain derived neurotrophic factor. Thus,
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patients show lower stress resistance, anxiety, and irritability which are a major factors
contributing to depression  (Francis 2003). Targeting these neurotransmitter imbalances
could also relieve the AD symptoms of depression.
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Chapter 2. White Matter Hyperintensities (WMH)
White  Matter  Hyperintensities  (WMH)  are  commonly  observed  on  T2-weighted
Magnetic Resonance Images (MRI). Variants of the term WMH include leukoaraiosis,
white matter lesions, leukoencephalopathy, ischeamic white matter disease, and white
matter  changes  (Hachinski  et  al.  1987;  Fisher  1991;  Hoppe  et  al.  2013).  The exact
aetiology of WMH is unknown but they are associated with vascular diseases, stroke,
and white matter rarefraction (Hernandez et al. 2013; Wardlaw et al. 2013). Vascular risk
factors  for  elevated  WMH  burden  include  hypertension,  diabetes  mellitus,  obesity,
hyperlipidemia, and stroke  (Schneider et al. 2007;  Smith 2010;  Wardlaw et al. 2013);
the  same risk  factors  are  associated  with  AD  (Fazekas  et  al.  1987;  Kivipelto  2001)
(O’Sullivan 2008;  Ben-Assayag et al. 2012;  Provenzano et al. 2013;  Makedonov et al.
2013),  lower  cognitive  performance  (Dichgans  &  Zietemann  2012), more  rapid
cognitive decline and dementia (Fazekas et al. 1993; Burton et al. 2004) (Brayne et al.
2009;  Matthews et al.  2009;  Moon et al. 2011), and contribute to the severity of the
disease  (Pantoni 2008).  In vascular or post-stroke dementia the presence of WMH is
much higher compared to individuals with Alzheimer's disease  (Jokinen et al.  2005).
There  are  various  levels  of  severity  of  WMH depending  on the  type  of  stroke:  (a)
lacunar -  a  type of stroke resulting from occlusion of main arteries;  (b) non-lacunar
stroke - large-artery atherosclerosis, cardioembolism, stroke of other or of undetermined
aetiology (Fein et al. 2000; Wardlaw 2005; Debette & Markus 2010).
WMH indicate hypertensive damage  (Nyenhuis & Gorelick 1998), possibly caused by
arteriosclerotic changes involving penetration of small arteries and arterioles in the brain
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(Toyoda 2008).  Hypertension  has  been linked to  high  mean diffusivity (detected  by
diffusion  tensor  imaging),  suggesting  altered  water  content  (best  visible  on  FLAIR
images) associated with WMH development  (Smith et  al.  2009;  Fazekas & Wardlaw
2013).  High  diffusivity  is  linked  to  increased  arterial  stiffness,  a  factor  possibly
contributing to the pathogenesis of WMH, in particular periventricular WMH (de Groot
et al. 2013).  
WMH are more prevalent in ageing individuals (Ohmine et al. 2008; Valdés Hernández
et al.  2013) while younger people usually do not have severe WMH  (Enzinger et al.
2007).  Individuals with greater extent of WMH had more severe depression and lower
cognitive scores (Scheltens et al. 1992). Elevated levels of WMH have also been found
in subjects with multiple sclerosis, Parkinson's disease, bipolar disorder, Binswanger’s
disease,  and a number of demyelinating and bone metabolism diseases (Sundal et  al
2012). 
1 Imaging methods for WMH detection
WMH  can  be  detected  in  (1)  Structural  Magnetic  Resonance  Imaging  (sMRI);  (2)
Diffusion Tensor Imaging (DTI), and (3) Computer Tomography (CT)  brain scans: 
(1)  sMRI: WMH are best detected by T2-weighted MRI or Fluid Attenuated Inversion
Recovery (FLAIR) images in which they can be seen as hyper intensive signals resulting
from a more than usual amount of water molecules in particular regions (Heiden et al.
2005). The term 'hyperintensity' is used in T2-weighted MRI images and 'hypointensity'
in T1-weighted images.
(2)  DTI:  The  change  in  apparent  diffusion  coefficients  and  fractional  anisotropy  is
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measured to identify WMH (Scheltens & Korf 2000).
(3) CT: WMH changes can also be detected by CT scans in which the high water content
is indicated by a low-density (dark-gray) signal  (Fazekas et al. 1987). However, CT is
usually less accurate than MRI in showing WMH. 
2 Regional distribution of WMH in the brain
Previous studies defined WMH as diffuse patchy areas in the white matter, adjacent to
basal ganglia or the brain stem, and hyperintense compared to normal white and grey
matter on T2-weighted and FLAIR images  (Fazekas et al. 2002;  Holland et al. 2008).
WMH are usually located in periventricular regions but are also found in subcortical
areas of the deep white matter extending up to 13 mm beyond the ventricles (Yoshita et




Figure 10: Confluent (left), periventricular lines and caps (middle), and punctate (right) WMH
Several studies have focused on analysing the regional WMH in AD  versus vascular
dementia (Capizzano 2004), and in comparison to normal ageing  (Barber et al. 1999;
Gootjes et al.  2004).  WMH probability maps have shown typical WMH distributions
from aged individuals featuring WMH clusters around the anterior and posterior horns
of the lateral ventricles and in the centrum semiovale (Valdés Hernández et al. 2013). In
Alzheimer's disease, increased WMH have been found particularly in the frontal lobes
(Valdés Hernández et al. 2010). Confluent deep white matter changes are more likely to
be related to cerebrovascular pathology and cognitive decline (Fellgiebel et al. 2008). It
is  likely  that  the  regional  distribution  of  WMH  is  associated  with  certain
pathophysiological conditions. 
3 Software for WMH extraction and quantification 
There  are  various  methods  for  the  assessment  of  WMH from MRI images  such  as
automatic segmentation (computer analysis), semi-automatic extraction (computer based
with manual removal of false positives) or visual rating scales (Fazekas et al. 2002; de
Leeuw  et  al.  2005;  Hernández  et  al.  2010).  The  benefit  of  automatic  MRI  image
processing is that large amounts of data can be analysed in minimal time. Visual rating
scales  rely  on  the  judgement  of  the  human  observer  but  are  necessary  for  random
inspection.  Fully quantitative  methods  often  detect  higher  WMH volume than  other
methods but the measures are  more rudimentary (less sensitive,  more false  positives
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such as CSF artefacts are included) (Wahlund et al. 2001). One problem with automatic
processing is  that  usually all  signals  across the brain,  above a certain threshold,  are
interpreted in contrast to visual inspection where the radiologist confines his search to
very specific  regions.  Semi-automatic  WMH quantification  software  offer  a  solution
enabling easy masking of brain areas for extraction of WMH in relevant regions (Tanabe
et al. 1997). 
4 Reasons for heterogeneity of WMH measurements
There are several possible reasons for the wide range of WMH measurements: (a) the
choice of imaging methods (CT is less reliable than MRI to detect WMH); (b) a reliable
automated/semi-quantitative  segmentation  method is  a  precondition;  (c)  subject  pool
size; (d) different image protocols; (e) non-optimal selection criteria;  (f) inclusion or
exclusion of confounding variates such as age, total brain volume and risk factors. For
instance,  studies  including  AD  patients  with  high  cardio-vascular  risk,  stroke,  and
vascular dementia lead to measurements of a larger range of WMH.
5 Radiological correlates
The radiological manifestations of WMH can be observed in a number of diseases such
as,  multiple  sclerosis,  dementia,  large,  and  small  vascular  diseases,  hypertensive
vasculopathy, and cerebral amyloid angiopathy  (Tsai et al. 2014). The examination of
the brain regions underlying WMH in deceased subjects does not show abnormalities in
white matter tissue on pure visual inspection. However, histo-pathological differences
with normal brain tissues have been found, possibly indicating a vascular origin (Kelley
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2008; Young et al. 2008).  Thus, the clinical and cognitive consequences of WMH have
been drawn from pathological  correlates  and observations  in  epidemiological  studies
(Matsusue  et  al.  2006). For  instance,  evidence  for  ischemic/arteriosclerotic  changes
comes  from post-mortem tissues  (Fazekas  et  al.  1993;  Pantoni  2010).   It  has  been
hypothesised  that  WMH  areas  derive  blood  supply  primarily  from  ventriculofugal
vessels  originating from the subependymal arteries and are particularly vulnerable to
injury due to hypoperfusion (Thomas et al. 2002). 
6 Clinico-pathological correlates
Various  clinico-pathological  correlates  have  been  associated  with  WMH  such  as
ischemic  small  vessel  disease  and  leukoaraiosis  (Rowbotham  &  Little  1965).
Leukoaraiosis  is  characterised  by  demyelinisation,  thinner  axons,  or  loss  of  axons,
ependymitis  granularis  (periventricular,  symmetric,  patchy loss  of  ependymal  lining,
anterior and lateral  to the frontal  horns),  proliferation of glial  cells  (i.e.,  astrocytes),
thickening of blood vessels with age, cavitation (formation of cavities by high pressure)
and  small  vessel  infarcts  (Brun  &  Englund  1981;  Wardlaw  et  al.  2013).  WMH
neuropathology intersects also with vascular dementia, manifesting in multifocal, diffuse
lesions, lacunes and microinfarcts, hippocampal sclerosis, multi-infarct encephalopathy,
and diffuse post-ischemic lesions. WMH are often found sub-cortically and disrupt brain
connectivity affecting the thalamus, frontobasal or limbic systems (Pantoni 2008).
7 Neuro-psychiatric & neuro-psychological correlates
In AD patients, increased WMH have been related to anxiety, aberrant motor behaviour,
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night  time  disturbance,  and  apathy  (Jellinger  2008).  WMH  have  been  found  to  be
correlated  with  an  overall  decrease  in  global  cognitive  functioning,  in  particular  in
processing speed,  memory,   attention,  visuo-spatial  ability,  motor function,  executive
functions, daily living activities (Bowen et al. 1990; De Groot et al. 2002; Burton et al.
2004; Capizzano 2004; Murray et al. 2005; DeCarli et al. 2005; van der Flier et al. 2005;
Nordahl  et  al.  2006;  Berlow et  al.  2010;  Moon et  al.  2011). In  addition,  WMH are
associated with higher dementia risk (Prins et al. 2004; Smith et al. 2008; Stavitsky et al.
2010). Increased WMH burden is linked to cognitive dysfunction also in non-demented
aged individuals (Au et al. 2006; Kim et al. 2008; Debette & Markus 2010). WMH are
significantly related to cognitive impairment in AD, however there has been debate on
whether cortical, medial temporal lobe or hippocampal atrophy might be a more striking
cause for cognitive dysfunction (Son et al. 2012).
8 Molecular correlates & genetic contribution to WMH
The combined analysis of WMH and the level of amyloid deposition could give clues to
the underlying mechanisms of the disease  (Hirono et al. 2000;  Chao et al. 2013). The
association of WMH with the AD risk genotype  APOE has been a matter of debate.
WMH are highly heritable and have been linked to small artery ischemic stroke, and
therefore could shed more light on the genetics of Small Vessel Disease (Paternoster et
al.  2009;  Smith  et  al.  2009).  Previous  studies  have  attempted  to  find  associations
between polymorphisms in several candidate genes and WMH. Genes involved in lipid
metabolism, vascular factors, or blood pressure regulation have been identified but no
polymorphisms have shown sufficiently strong associations with WMH (Paternoster et
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al. 2009). A recent GWAS has identified two Single Nucleotide Polymorphisms (SNPs)
associated  with  a  variation  in  FBF1  expression  in  the  brain  and  TRIM47  in
lymphoblastoid cell  lines;  in addition,  the functional polymorphisms in TRIM65 and
WBP2 have also been linked to WMH in small artery ischemic stroke (Fornage et al.
2011). However, to date, few genetic loci have been identified; it is clear that larger
studies need to confirm these associations and ideally find new ones. 
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Chapter 3. Biomarkers
A biomarker is an objective, quantifiable measurement of the physical or mental state of
a patient, or a test subject in a drug development trial, that can be used to diagnose or
predict  a  physiological  or  pathological  condition  (Humpel  2011).  Biomarkers  are
classified by usage: antecedent (risk), screening (detection), diagnostic (identification),
prognostic (course of disease), stratification (likelihood of drug response). A biomarker
should be chosen to reflect fundamental disease features and be specific compared with
other  disorders.  In  addition,  the  measurements  have  to  be  reproducible,  repeatable,
reliable and not harmful. Finally, a method which is non-invasive and easy to perform is
preferable  -  for  obvious  reasons,  non-invasive  biomarkers  are  preferred  by patients,
especially if  the  exam has  to  be repeated.  In  the case  of  AD  a  biomarker  for  early
diagnosis  or  disease progression  is  particularly important  to  enable  adequate  patient
stratification  helping  to  determine  drug  efficacy  in  clinical  trials  (Lovestone  2006;
Lovestone et al. 2007; Barber 2010). 
Biomarkers can be used in at least five different ways (Lovestone et al. 2009): 
(1) In research for new drugs to gain understanding of AD pathogenesis, identifying and
validating new drug targets in preclinical and early clinical research.
(2) For diagnosis in clinical trials assisting in the identification of the presence of AD in
order to enrol those subjects. Currently,  the  APOE genotype is one of the most used
biomarkers for AD patient stratification.
(3) For screening, prevention and early treatment: blood-based and cognitive function
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markers.
(4) For monitoring disease progression and drug response in clinical trials and adjusting
interventions. 
(5) For risk prediction and prevention: identifying subjects who most likely respond to a
certain treatment. 
Since abnormal changes associated with AD occur before there are easily detectable
symptoms,  such  as  memory  impairment,  biomarkers  linked  to  such  changes  could
provide early warning of possible AD. 
Biomarkers such as phenotypic measurements (cognitive decline scores, etc.) are often
not  very accurate  because  cognitive  tests  yield  inaccurate  results  based  on how the
patient is feeling on a certain date, time, season or other biocyclic/hormonal influences.
The inclusion of factors contributing to disease such as white matter hyperintensities,
age,  sex,  education,  and  APOE status could improve biomarkers'  accuracy.  Here,  we
focus on a biomarker capable of predicting disease progression. 
1 Neuroimaging
Advances in imaging technology and biomarkers have allowed earlier detection of brain
changes  related  to  AD.  Remarkably,  these  changes  appear  years  before  the  first
traditional symptoms, opening up the possibility of pre-symptomatic trials. Information
from brain images of patients and high-risk individuals can potentially become surrogate
markers in clinical trials. One advantage of imaging biomarkers is that they are non-
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invasive. Alzheimer's disease's changes regarding WMH, atrophy, hippocampal atrophy,
large  ventricles,  can  be  investigated.  The  estimated  accuracy  depends  on  the
measurement  target  and  the  imaging  method:  Single-Photon  Emission  Computed
Tomography  (SPECT)  has  lower  accuracy  (50-55%)  than  MRI  (80%).  Metabolic
changes in the brain can be detected with Positron Emission Tomography (PET), blood
flow with Functional Magnetic Resonance Imaging (fMRI), and the diffusion process of
molecules with DTI- Diffusion Tensor Imaging. 
(1) Magnetic Resonance Imaging: In general Magnetic Resonance Imaging (MRI) can
create images of many parts of the body providing structural images. An MRI sequence
is an ordered combination of radio frequency signals and gradient pulses designed to
acquire  the  image  information.  The  pulse  sequences  are  Fluid  Attenuated  Inversion
Recovery (FLAIR),  Spoiled Gradient Echo (SPGR), T2-weighted and T1-weighted or
Proton Density  (PD). Scanners  can  have  different  field  strengths,  with  later  models
having field strengths up to 3 Tesla.  The acquisition parameters are depicted by matrix
size, field of view, slice thickness and 2D or 3D acquisition: frequency/phase encoding.
Image contrasts can be T1 weighted or T2 weighted with tissue parameters T1, T2 and
acquisition parameters  Repetition Time (TR),  Echo Time (TE).  In MRI the spinning
nuclei align with the direction of the magnetic field. For example, water nuclei resonate
at 64MHz in a 1.5 Tesla field. The advantage of MRI imaging is that the reliability and
reproducibility of these scans is high (Lovestone et al. 2013). Common AD related MRI
measures are: whole brain atrophy, white matter hyperintensities (Hampel et al. 2010),
hippocampal atrophy (Brickman et al. 2008), and enlargement of ventricles (Henneman
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et al. 2009).
(2) Functional Magnetic Resonance Imaging  (fMRI) is a commonly utilized research
tool  to  detect  functional  differences  (blood  flow)  in  the  brain  compared  to  healthy
controls and may be a promising biomarker for AD (Damoiseaux 2012). fMRI studies
have  detected  increased  brain  activation  in  patients  treated  with  acetylcholinesterase
inhibitors in MCI and AD (Nestor et al. 2008) (Saykin et al. 2004).
(3)  In Positron Emission Tomography (PET) imaging a  radioactive tracer  shows the
amyloid plaques in the living human with up to 75% accuracy. Using specific tracers
such as N-methyl-[11C]2-(4′-methylaminophenyl)-6-hydroxybenzothiazole, also known
as  Pittsburgh  Compound-B  (PiB),  amyloidosis  can  be  quantified.  PiB-PET  studies




Cerebrospinal fluid (CSF) biomarkers are currently the most efficient for diagnosis of
probable  AD,  for  predicting  conversion  from  MCI  to  AD  in  the  prodomal  phase
(Mattsson et al. 2009), and for predicting the rate of cognitive decline in AD (Snider et
al. 2009).  Several core biomarkers have been established Aβ40, Aβ42, total tau (t-tau),
and phosphorylated tau (p-tau) which indicate the amyloid levels in the brain and neuro-
fibrillary pathology (Hansson et al. 2010). In AD patients, there is a significant drop in
the concentration of Aβ(1-42) peptides in the cerebrospinal fluid that likely reflects the
accumulation (deposition) of the toxic protein fragment in the brain, whereas total tau is
elevated in CSF (Wu et al. 2012).
Aβ(1-42), t-tau, and p-tau demonstrated a much higher accuracy (95%) in the diagnosis
of AD than the combined groups of MCI and healthy controls (Hampel et al. 2010).  The
CSF is extracted from the spine of the patient via lumbar puncture.  The accuracy is
usually relative good with 80-90% sensitivity and specificity. The disadvantage of the
method is that the procedure for obtaining CSF is invasive; therefore, less preferred by
patients  for  repeated  measurements,  and  in  addition,  in  some  countries,  it  is  not
approved for routine use. The basic CSF biomarkers reflect pathological processes such
as  inflammation,  Brain  Blood  Barrier  function,  or  intrathecal  immunoglobulin
production (Hampel et al. 2010) (Blennow et al. 2010).
3 Blood
On the one hand, the use of blood as a biomarker for Alzheimer’s disease is challenging.
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On the other hand, measurements of blood are easy to obtain, even at the patient's home,
inexpensive, and repeatable. This offers also a good possibility for already frail, elderly
people. The assumption is that if AD can be diagnosed earlier in the disease stage it can
be  treated  better,  however  at  the  moment  this  is  not  proven  in  real  life  and  more
importantly not with medications. There is communication between the blood and the
brain but they are not directly connected (blood-brain-barrier). Thus, if changes were
found in blood careful validation of the new potential biomarker is necessary.  Blood
plasma  proteins  are  potential  candidates  for  identifying  aged  individuals  at  risk  for
Alzheimer's disease, diagnosis of AD, and could possibly support in the prediction of
decline in Alzheimer's disease. Evidence has suggested that there are protein signatures
of pathological processes in blood before disease onset; this evidence has been drawn
from candidate protein studies or inflammatory markers (Leung et al. 2013; Kiddle et al.
2014). 
Different signatures such as (1) proteins, (2) RNA, (3) antibodies, and (4) lipids can be
found in blood and serve as biomarkers in the future:
(1)  Proteins can be detected in plasma, serum, or other cellular compartments. They
have  a  number  of  advantages:  (a)  respond  to  changes  in  health  status  and  drug
administration;  (b)  are  readily  accessible  via  the  blood  circulation;  (c)  measuring
multiple  proteins  simultaneously  can  capture  the  contribution  of  various  –  and
sometimes  unforeseen  –  biological  processes;  (d)  new high-throughput  technologies
enable rapid progress in the search for protein biomarkers  (Thambisetty & Lovestone
2010). However, a disadvantage can be that proteins reflect not only the internal but also
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external environment. For instance, a certain degree of disease could be associated with
life-style  and  protein  signatures  reflecting  this  life-style  could  be  found  rather  than
reflecting the disease itself.  
(2) RNA can potentially contain information useful as a biomarker for AD diagnosis in
early stages (Lunnon et al. 2013; Kumar et al. 2013).  
(3) Reddy et al. have recently identified diagnostically useful antibodies (IgGs) by using
natural or synthetic molecules that retained significantly more IgGs in patient samples
than in controls. In this  way,  they have found two potential  IgG biomarkers for AD
(Reddy et al. 2011).
(4) A very recent study has determined lipids in blood from cognitively normal older
individuals which predicted conversion to MCI or Alzheimer's disease within a 2–3 year
period with over 90% accuracy (Mapstone et al. 2014).
4 Cognitive Assessments
For assessing the disease severity usually a battery of cognitive assessments is available.
The advantage of using cognitive measures as biomarkers is that these methods are not
invasive and provide good accuracy ranging between 60 – 70%. Frequently, methods
such as  the  Minimal  Mental  State  Exam (Folstein et  al.  1975),  DRS  (Mattis  1976),
ADAS  (Rosen et al.  1984), CAMCOG  (Huppert et al. 1995), and Hodkinson Mental
(Hodkinson 1972) are utilized to assess cognitive performance. The presence of AD can
be detected with analysis of the pattern and evolution of cognitive deficits, delineation of
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the particular cognitive strengths and weaknesses of individual patients, and monitoring
disease progression and the effects of treatment. Moreover, the method is relatively cost-
effective.  Apart  from  adequately  trained  medical  staff  and  a  recent  version  of  the
assessment questionnaire, no major accessories or equipment are needed.
Chapter 4. Aims & Objectives of the Thesis
This work aims to contribute to a better understanding of disease progression in AD.
Molecular, cognitive and structural brain changes linked to the disease will be identified
and  related  to  AD  progression.  Finding  molecular  signatures  in  blood  can  reveal
important  relationships  within  the  implicated  panels  of  mRNAs and  proteins.  Once
validated, the signatures can be incorporated in the development of a blood test for AD
and ideally qualify as an endpoint in clinical trials.
Many promising  drugs  are  currently  being  tested  in  clinical  trials  for  AD but  their
efficacy is difficult to assess using existing outcome measurements such as psychometric
scores (L. Zhou et al. 2012; Yu et al. 2013). Biomarkers capable of accurately predicting
rates of disease progression are urgently needed: they can provide important information
on the current pathological state of a potential participant in a clinical trial  (Lovestone
2006). Novel biomarkers that enable better patient stratification models, with optimized
numbers of participants, could significantly reduce the length of trials, and could help to
provide a time-frame for preventive measures.  Accordingly, the main objectives of the
study (1 and 2 below) are focused on investigating factors which could influence disease
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progression. 
The 1st objective is to evaluate the association between WMH and the rate of cognitive
decline in  AD. For  this  purpose,  several  statistical  models  of cognitive decline with
different covariates are tested. WMH are hypothesized to contribute significantly to AD
cognitive decline and to explain a proportion of the variability in the rate of disease
progression.  Here,  the  focus  was  on  WMH  across  the  whole  brain  and  disease
progression  indicated  by  cognitive  decline  across  the  specific  cognitive  domains
measured by MMSE, ADAS-cog, and CDR-SOB. 
The 2nd objective is to apply statistical classifiers in order to define a panel of mRNA
transcripts and proteins correlated with WMH and cognitive decline in AD. 
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Part II. DATA AND EXPERIMENTS
Chapter 1. Association of White Matter Hyperintensities with 
cognitive decline in AD
1 Introduction
1.1 WMH and cognitive decline
A number  of  studies  have  established  a  relationship  between  WMH  and  cognitive
decline (Yoshita et al. 2006) (Kelley 2008) (Kearney-Schwartz et al. 2009) (Weinstein et
al. 2013) (Jacobs et al. 2012) (Wardlaw et al. 2013). In the past there were inconclusive
results regarding the clinical significance of WMH, specifically in AD  (DeCarli et al.
2004) (Smith et al. 2008). However, later studies increasingly recognised WMH to be
associated with AD-cognitive decline (Carmichael et al. 2010) (Moon et al. 2011) (Gold
et  al.  2012).  Patients  who  have  co-existing  AD and  WMH experience  more  severe
longitudinal cognitive decline than those having either alone (Yoshita et al. 2006). Thus,
there is a clear need for investigating the effects of WMH on cognitive decline in AD. 
WMH  are  signal  abnormalities  commonly  detected  on  MRI  brain  scans  in  ageing
individuals and patients with cerebrovascular disease,  and have been associated with
cognitive  loss  and AD  (Kelley 2008;  Valdés  Hernández  et  al.  2012;  Wardlaw et  al.
2013). The prevailing view of WMH is that they represent perfusion abnormalities, in
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particular in the posterior cortex, implicating them in the presentation and pathogenesis
of AD with amyloidogenic pathology (Kelley 2008). 
WMH could be linked to increased rate of cognitive decline, possibly in combination
with other variables such as, advanced age, gender, APOE ε4 genotype, and especially
atrophy (van der Flier et al. 2004). For defining an AD disease progression biomarker
the best combination of variables still remains to be elucidated. Whole brain atrophy is
clearly a major factor influencing cognitive decline (Provenzano et al. 2013; Matthews
et  al.  2009;  Carmichael  et  al.  2010).  Hippocampal  atrophy is  a  strong predictor  for
cognitive decline  (Schmidt et al. 2005; Brickman et al. 2008; Mok et al. 2011). Age,
APOE ɛ4 genotype, and gender can also influence the rate of disease progression (Ito et
al.  2011).  Many age-related  changes  occur  in  small  arteries,  arterioles,  venules,  and
capillaries  having  malicious  effects  on  the  brain  leading  to  hypertension,  increased
WMH and lower cognitive performance  (Murray et al. 2005; Kearney-Schwartz et al.
2009;  Wardlaw et al.  2013).  Carriers of the APOE  ε4 allele  are at  increased risk of
developing AD (Schiepers et al. 2012). The effect of APOE on WMH has been debated
and remains unclear. Some studies did not find a relationship between  APOE  ε4 and
WMH volume (Kim, 2013).  However,  APOE has been shown to be correlated with
WMH and cognitive decline in other studies  (Pantoni 2010;  Salmon et al. 2013). An
association of APOE ε4 with the rate of cognitive decline in healthy, aged individuals
has been found: non-demented carriers of the APOE ε4 allele are more likely to develop
AD and have increased rate of cognitive decline (Schiepers et al. 2012). 
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In the past, there has been mixed evidence regarding the importance of gender regarding
the risk of AD  (Hebert  2001;  Barnes et  al.  2003;  Wen & Sachdev 2004).  However,
recent studies have identified gender as an important covariate in disease progression
models of AD (Ito, 2011). Higher education has been associated with a higher cognitive
reserve, lower CDR sum of boxes scores and significantly modified the association of
WMH with cognitive abilities (Scarmeas et al. 2006). 
Short-term measurements of WMH-associated AD-cognitive decline might be important
in clinical trials to determine the efficacy of a drug or in a situation in which the care
situation of a patient has to be decided, such as admission to a nursing home. WMH
might be included as a covariate in statistical prediction models to better define clinical
endpoints. 
Clearly, future work should focus on investigating the cause-effect relationships between
WMH and cognitive decline, in order to better predict AD progression. Currently, it is
hypothesized that WMH are important radiological correlates of cognitive functioning,
however studies remain inconsistent in reporting the actual effect size  (Kelley 2008).
Heterogeneous AD pathology is complicating these efforts. 
1.2 Aims
The hypothesis  under investigation was: “WMH associate with more rapid cognitive
decline in AD, and their inclusion in a prognostic biomarker of AD progression might
increase its prediction accuracy”.
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To test this hypothesis, linear mixed models were used, including individuals with AD
who  were  assessed  over  the  course  of  approximately  1  year,  with  three  different
neuropsychological  assessments,  CDR-SOB,  MMSE,  and  ADAS-cog.  The  cognitive
change in assessment scores, under consideration of MRI measures of WMH volumes




The subjects were drawn from the AddNeuroMed study which had 781 participants.
Blood samples were collected from each subject for DNA (APOE genotyping) and RNA
analyses (gene expression). Subjects who met MRI inclusion criteria (no claustrophobia,
no  trauma  or  surgery  which  may  have  left  ferromagnetic  material  in  the  body,
ferromagnetic implants or pace- makers, and the ability to lie still for at least one hour)
were invited to undertake an MRI scan until a total of ~20 subjects per diagnostic group
(AD, MCI, CTL) per centre were scanned (Lunnon et al. 2013). There were 6 centres
(Kupio,  Lodz,  London,  Perugia,  Thessaloniki,  and Toulouse).  In total  there were ca.
20x3x6= 360 samples. However, during the sample quality control process a number of
samples  had to  be removed (Lunnon et  al.  2014)  (Sattlecker  et  al.  2014).  The total
number of subjects of blood samples matched with mRNA measures was 331. The total
number of subjects matched with proteins measures was 337 of which 104 AD patients
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had  baseline MRI scans (Simmons et al. 2011). Four subjects were excluded because
they had a glioma or a stroke. WMH from the remaining 100 brain scans were extracted
using BRIC1936 software  (Valdés Hernández et al. 2012). The longitudinal cognitive
assessments  were  available  for  AD  patients  with  all  five  visits:  CDR-SOB (n=90),
MMSE and ADAS-cog (n=90). The 5th visit took place between 323 days and 1 year 117
days after the 1st visit, thus, we describe the time period with ca. 1 year. The visits took
place in approximately 3 months intervals. After matching with WMH with CDR-SOB,
MMSE, and ADAS-cog fewer subjects remained: 84 subjects were included in the linear
mixed models for the rate of cognitive decline with the covariates WMH, atrophy, and
gender (Table 5 & 6). 





a.  MRI scans for AD     
b.  Excluded                   
c.  WMH extracted         
104       
4       
100       
     
100      
    
100     
    
100     
     
100     100       100     
d.  CDR-SOB 
     MMSE
     ADAS-cog
    (min 5 visits)
90      
90      
90      
85       
85       
85       
87     
87     
87     
85     
85     
85     
88      
88      
88      
88       
88       
88       
88     
88     
88     
e.  WMH+CDR-SOB
     WMH+MMSE
     WMH+ADAS-cog
    
84      
 84      
84      
84       
87       
84       
86     
86     
86     
84     
83     
  86     
87      
87      
87      
87       
87       
87       
 87     
 87     
87     
Table 5: Number of participants in the AddNeuroMed study, (a) number of AD patients with brain scans, (b) excluded 
subjects, (c) quantified WMH from AD patients, (d) cognitive measures obtained from 5 visits, (e) number of subjects 
remaining when cognitive measures matched quantified WMH, used in linear mixed models.
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Characteristics of AD subjects with quantified WMH at visit 1 
(baseline)
N=100
Age at baseline (years)a 74.7 ± 6.4 
Age of disease onset (years)a 76.5 ± 6.5 
Gender female/male 64/36
Education (years) (n=97a; 3 unknown) 6 ± 4.3  
Disease duration since first diagnosis (months)a 48 ± 28.6




  6.4 ± 3.0 
20.0 ± 4.7 
28.0 ± 9.7 





  1.5 ± 1.6 
-1.4  ± 1.8 
  1.9 ± 0.5 
WMH median [IQR] (mm)3 3310 [7777]
Atrophya    ( normalized by the subject’s intracranial volume ) 0.82 ± 0.02
APOE e33; e34; e44; unknown 36; 41; 15; 8
Table 6: Subject characteristics of the AddNeuroMed study: aData are represented as mean ± standard deviation.
All available details of the patient cohorts were integrated. Information about vascular 
risk factors was not collected. It seems that the group who had only 6 years of education 
was growing up during the Second World War and had indeed had only 6 years of school
attendance. They were on average 75 years old this would be during the 1940s. 
The AD patients of the AddNeuroMed cohorts receive Donepizil, Rivastigimine, and 
Galantamine which could explain that their average decline is not as steep as in 
untreated individuals with AD. The fact that the age of MRI scan was lower on average 
than the average age at AD diagnosis is possible because samples from subjects who had
undergone an MRI scan and had subsequently changed their diagnosis from MCI to AD 
within 2 years of the sample being analysed were included in the studies (Lunnon et al. 
2014).
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The Dementia Case Register cohort
For the King’s Health Partners Dementia Case Register (Kiddle et al. 2013) cohort 47
baseline scans were available of which 3 had to be excluded, WMH was extracted from
44 MRI volumes (Table 7).
Dementia Case Register (DCR) Number of subjects
Available AD baseline scans 47
Excluded: 3 had a stroke 3
WMH quantification 44
Table 7: Number of AD subjects with MRI and WMH quantification in the DCR cohort 
After  matching  the  44 WMH  volumes  only  12 subjects  remained  who  had  also
longitudinal cognitive measures (Table 8). Therefore, the cohort could not be used in the
linear mixed model for cognitive decline. However, in the second study of the current
work in which WMH was analysed together with proteins, the 44 WMH volumes could
be included (Table 19). Below a summary of the DCR subject characteristics (Table 9). 
     Cognitive assessment
     (min 3 visits)
Total APOE Gender Education Age of
onset
WMH
     WMH
     MMSE
     ADAS-cog
  44      
30      
30      
       
29       
30       
    
29     
30     
     
28     
30     
     
29       
30       
      
12      
12      
Table 8: Number of participants from the Dementia Case Register study
Characteristics of DCR subjects with quantified WMH 
at baseline
N=44
Age at baseline (years)a 73.5 ± 14.9
Gender female, male 18, 26
WMH (median [IQR]) in mm3 4871 [10954]
Table 9: Subject characteristics of the DCR study: aData are represented as mean ± standard deviation.
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2.2 Cognitive assessments and calculation of the rate of cognitive decline
The rate of cognitive decline in AD patients was calculated using MMSE, ADAS-cog,
and CDR-SOB, for subjects of which longitudinal assessments were available from 5
visits within a one year period. The rate of decline was estimated by fitting  separate
mixed models for each assessment scale. The cognitive performance of AD patients was
assessed at five visits in a three month interval over the course of 1 year. The package
'nlme' in R was used to generate the statistical models. The average baseline cognitive
outcome and average change in cognitive outcome over follow-up time was calculated
for  all  patients  as  a  group (random effects)  and subject-specific  intercept  and slope
which  reflected  the  deviation  from  the  group  average  (fixed  effects)  including  the
adjustment  for  covariates  such  as,  WMH,  atrophy,  age  a  baseline,  disease  duration,
gender, education, and  APOE genotype, were calculated (advanced model). Follow-up
time was defined as the number of days passed since the baseline visit, and 5 timepoints,
3-months  apart  were  recorded  for  each  patient.  Covariates  which  were  significant
(P<0.1) in the advanced models of CDR-SOB, MMSE, and ADAS-cog, and remained
significant  in  the  simple  model,  were  kept  in  the  final  model  (WMH, atrophy,  and
gender).  The coefficients (β-value) for the follow-up variable (days) denoted the slope
(per day) and the coefficients (β-value) for each variable indicated their association with
overall cognitive levels.  Power and sample size were calculated using a R-script (see
appendix) provided by Donohue and colleagues (Donohue et al. 2013).
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2.3 Structural magnetic resonance imaging
MR Image parameters
MRI images were available from a subset of the AddNeuroMed subjects (Simmons et al.
2011). The image data were acquired using six different 1.5 T MR systems (four General
Electric,  one  Siemens  and  one  Picker)  and  a  quadrature  birdcage  coil  for  RF
transmission and reception. The acquisition process was designed to be compatible with
the Alzheimer disease neuroimaging initiative (ADNI). A high resolution saggital 3D
MP-RAGE  dataset,  using  a  three-plane  localizer,  and  an  axial  proton  density/T2-
weighted  dual  echo  fast  spin  echo  dataset  was  acquired.  London  cohort  for
AddNeuroMed were acquired at King’s College London with the following parameters:
DESPOT1 pulse sequence for T1 mapping with TR¼8.45 ms, TE¼2.92 ms, one data
average  and  voxel  size  1.2*1.02*1.02  mm,  and  DESPOT2  pulse  sequence  for  T2
mapping with TR¼3.6 ms, TE¼1.8 ms, one data average and voxel size 1.2 x  1.02 x
1.02 mm. The Quality Control (QC) took place immediately after acquisition at each site
and an on-site radiologist excluded any subjects with non-AD related brain pathologies
(Simmons et al. 2011). Firstly, regular phantom scans were performed at each site using
the ADNI phantom (manufactured from urethane which consists of an array of spheres
arranged in a precise geometric pattern). Quantitative measures of signal to noise ratio,
uniformity and geometric distortion were recorded and assessed using the ImageOwl
web-based automated  QC system (www.imageowl.com).  Secondly,  in  vivo measures
were validated using two young adult volunteers (to ensure no age-related changes) who
were periodically scanned after any hardware or software upgrade. Human phantom data
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were processed using an automated image analysis pipeline (Jack et al. 2008). The in-
vivo measures QC included: onsite visual image control according to the QC protocol,
image data transfer, data upload and automated QC, manual QC at the Data Control
Centre, feedback and real time statistics. Trained experts performed the on-site visual
image control and manual QC to assess technical aspects such as full brain coverage,
wrap-around  artefacts,  motion  artefacts,  intensity  inhomogeneity.  Preprocessing,  co-
registration  and  optimization  has  been  previously  performed  within  the  group:  The
AddNeuroMed images were transformed from DICOM to a sagittal T1 and an axial, co-
registered pair of PD/T2 images.  For the DCR images three modalities were received as
a co-registered axial set T1/T2/FLAIR. The spatial orientations, voxel size, and number
of slices were compatible across the six study sites, with some exceptions: some images
were received with different properties (inverted orientation, weak contrast) from which
some but not all could be co-registered and normalised using spm8 and ImageJ.
MRI Subject criteria
Inclusion criteria for Alzheimer’s Disease subjects
(1) AD subjects were diagnosed using the NINCDS-ADRDA (McKhann et al. 1984),
and  Diagnostic  and  Statistical  Manual  of  Mental  Disorders  (DSM-IV)  criteria  for
possible  or probable AD (DSM–IV–TR (2000) 4th ed.,  text  rev.),  following a semi-
structured interview with the patient and an informant and detailed case history;
(2) subjects aged 65 years or above.
Exclusion criteria for Alzheimer’s Disease subjects
(1) significant neurological or psychiatric illness other than AD; (2) significant 
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systematic illness or organ failure.
Structural MRI plays a role in defining entry criteria for AD clinical trials and as an 
outcome measure of AD disease progression (Kennedy, 2009). For each study, the most 
appropriate protocols should be chosen. In the AddNeuromed, the range of protocols 
included a high-quality high-resolution T1-weighted 3D sequence guaranteeing accurate 
morphometric information as well as dual contrast T2-weighted/proton density 
information to a certain AD brain pathology. 
T2-weighted MR sequences are much more sensitive than CT for the detection of WMH 
(Gauthier, 2006). T2-W1 has high sensitivity for thalamic lesions. It is recommendable 
to include several T2-weighted sequences such as T2 and FLAIR, for instance FLAIR 
has the advantage of detecting cystic lesions. In addition, a combination of T1-W1 and 
FLAIR could identify more severe lesions. It is to be noted that very severe lesions are 
associated with cognitive impairment and cognitive decline (Gauthier, 2006). FLAIR 
images have not been acquired in the AddNeuroMed study but could have given 
additional information on WMH load and morphometry, and AD brain pathology.
2.4 WMH extraction methodology
The first approach explored was based on an automated procedure for the assessment of
WMH by multispectral (T1, T2, PD) MRI (Maillard et al. 2008). This procedure could
not successfully be applied because the T1 image data of most subjects were not suited
to  this  approach  without  implementing  time-consuming  extensions.  The  second
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approach involved a semi-automatic software: BRIC 1936 -  Brain Research Imaging
Centre of The University of Edinburgh (Valdés Hernández et al. 2012). Currently, there
is no fully-automated WMH extraction method because removing misclassified WMH
regions  remains  an  issue.  BRIC forms  part  of  MCMxxxVI  (Multispectral  Colour
Modulation and Variance  Identification),  a  suite  of  image manipulation  and analysis
tools written in MATLAB by Dr. Maria Hernandez, ported to C++ by the The Software
Sustainability  Institute.  Using the  BRIC software  suite,  quantification  of  WMH was
successfully performed. Image fusion (of different image modalities), WMH extraction
(based on RGB-values), and removal of false positives is performed with the in BRIC
integrated tools. The output consists of descriptive statistics and image data with the file-
type ANALYZE (.img/.hdr).  Blinded to clinical information,  WMH were defined, as
described in previous studies: diffuse patchy areas in the white matter, basal ganglia or
brain  stem,  and  hyper-intense  compared  to  normal  white  and  grey  matter  on  T2-
weighted and FLAIR images. WMH probability maps shown in previous studies were
visually  assessed  to  prepare  for  the  WMH extraction  (Enzinger  et  al.  2006).  Tissue
segmentation in BRIC relies on defining a set of Red-Green-Blue (R-G-B) values (Table
10). To determine the best and most cohort specific thresholds, the first image of the
cohort  was  used  as  a  reference  and  the  best  WMH  threshold  chosen  on  visual
assessment. Once the best combination for differentiating WMH from other brain tissue
was  found,  the  colour  parameters  were  applied  to  the  whole  cohort.  
In total we had 6 specific combinations of R-G-B parameters from the AddNeuroMed
study of which the images were extracted from T2 alone (Figure 11).  For the DCR
cohort WMH have been extracted from T1/ T2 and FLAIR (Figure 12). 
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Figure 11: Example of WMH extraction from T2-MRI for the AddNeuroMed cohorts: slice from an AddNeuroMed
subject with extensive caps of WMH and punctuate lesions extracted with BRIC: (1a) T2 MRI volume; (1b)
brainmask; (1c) WMH in blue overlay on a T2 volume; and (1d) segmented WMH.
Figure 12: Example of WMH extraction from the Dementia Case Register cohort: slice from a DCR subject with
extensive periventricular WMH extracted with BRIC: (1a) multi-spectral Colour Fusion of T1/T2/Flair MRI
volumes; (1b) brain tissue mask created with ImageJ; (1c) segmentation of WMH volume in yellow showing on
the overlay on a R-G-B colour-fused image; and (1d) segmented WMH.
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MRI image acquisition and preprocessing was compatible (same parameters) with the
AddNeuroMed study (Simmons et al. 2011). The WMH extraction was different to the
AddNeuroMed study,  WMH was  quantified  using  co-registered  sets  of  T1,  T2,  and
FLAIR  images  (Table  10).  Areas  in  which  WMH  was  incorrectly  detected  (false
positives) were removed manually with the BRIC software by masking and deleting
relevant foci and regions, and their WMH extracted. 
WMH extraction from T2 MRI Red / green / blue parameters (% range of the full scale [0-265])
1. AddNeuroMed/ Kupio 58%-86%  –  58%-86%  –  58%-86% 
2. AddNeuroMed/ Lodz 51%-70%  –  51%-70%  –  51%-70% 
3. AddNeuroMed/ London 70%-86%  –  70%-86% –  70%-86% 
4. AddNeuroMed/ Perugia 64%–90% –  64%–90% –  64%-90%
5. AddNeuroMed/ Thessaloniki 59%-86%  –  59%-86%  – 59%-86%
6. AddNeuroMed/ Toulouse 58%-90% –   58%-90% –  58%-90%
WMH extraction from T1, T2, and 
FLAIR
Dementia Case Register 8%-74%  – 74%-84%  – 7%-12%
Table 10: WMH extraction parameters for the six AddNeuroMed cohorts and the Dementia Case Register
The degree of agreement among WMH lesion extraction with BRIC and Fazekas 
validation on visual inspection of the T2 images is high (n=89, R2= 0.66, p<0.001).
2.5 Atrophy measures 
Whole brain volumes were obtained using FreeSurfer 5.1.0 from 274 AddNeuroMed
subjects  who  had  undergone  structural  magnetic  resonance  imaging  (sMRI).  The
extraction of atrophy measures was not in the scope of this thesis; detailed information
about  data  acquisition,  pre-processing,  and  quality  control  assessment  have  been
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described in detail elsewhere (Simmons et al. 2009) (Simmons et al. 2011) (Westman et
al. 2011). 
2.6 Validation of WMH 
The validation was performed by the author of this thesis and an independent observer
according to  Fazekas  scale  (Fazekas  et  al.  2002).  Different  WMH appearances  were
classified as: absent (0); punctuate, thin periventricular lines, small lesion caps (1); early
confluent  and thicker  periventricular  lines,  large  lesion  caps  (2);  and confluent  with
punctuate, lesion caps and lines (3). In particular, attention was paid to false positives
(Fazekas et al. 2002). Some hyper-intense regions have been shown to represent normal
anatomical variants such as symmetrical hyper intense “caps” around the frontal horns,
regular  periventricular  lines,  signal  alterations  in  the  basal  ganglia,  pons,  and  in
particular Virchow-Robin spaces or lacunas (Enzinger et al. 2007). The WMH volumes
were significantly correlated with the Fazekas scale (n=100, P<0.05).
3 Results 
3.1 Baseline WMH as a predictor of cognitive decline in AD 
The  main  objective  was  to  evaluate  relationships  between  MRI  measures  of  WMH
volumes from the whole brain,  measured at  the first  visit,  and the rate  of cognitive
disease progression, calculated from repeated visits over a period of ca. 1 year, after the
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MRI scan.  Mixed-effects  models  evaluated relationships  between WMH volume and
changes in outcome measures including MMSE, ADAS-cog, and CDR-SOB. 
Higher baseline WMH volumes were found to be significantly associated with greater
cognitive  decline  in  AD (P<0.05)  with  three  assessments  (CDR-SOB,  MMSE,  and
ADAS-cog).  Specifically,  each 1-Standard Deviation(SD) increase in  baseline WMH
was associated with an additional  0.0001-SD increase  per  day (x 365.24 = 0.04-SD
increase per  year)  in  CDR-SOB, with an additional  -0.0002-SD decrease per day (x
365.24 = 0.07-SD decrease per  year)  in  MMSE,  and with an additional  0.0003-SD
increase per day (x 365.24 = 0.11-SD increase per year) in the ADAS-cog (Table 11).
Significant Association of Baseline WMH with Change in Cognition in the CDR-SOB, MMSE and ADAS-cog model
Variable
CDR-SOB n=84 MMSE n=84 ADAS-cog n=84
β Std. Error P Value β Std. Error P Value β Std. Error P Value
Baseline WMH 0.0001 0.00004 <0.05* -0.0002 0.00007 0.02*  0.0003 0.00015 0.04*
Atrophy -39..47 8.9184 <0.001* 30.99 14.613 0.04* -45.7 31.3787 0.1^
Gender (Male) -2.11 0.71 <0.05* 2.43 1.163  0.04* -4.85 2.4984 0.06*
Table 11: Summary of the CDR-SOB, MMSE, and ADAS-cog mixed-effects models of cognitive change using baseline
WMH volume and the predictors atrophy, education, and gender as fixed effects. The regression coefficient is shown
for the fixed effect followed by the associated P value (“*” denotes that the P-value is significant at the 0.05 level, ^
denotes that the P-value is significant at the 0.1 level), and standard errors of coefficients are reported. Regression
coefficients represent the number of standard deviations' difference in the cognitive baseline that are associated with a
1-unit change in a predictor measured at baseline. The corresponding protocol of the R output can be found in Table
47-51.
The relationships between WMH and cognition were marginally modified when APOE
genotype, age, education, and disease duration were added to the models. In particular
baseline WMH volume, in the ADAS-cog model, was then only significant at  P=0.1
level (Table 12).
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Association of Baseline WMH with Change in Cognition including covariates education, APOE, gender, onset, disease duration, 
atrophy, and WMH
Variable
CDR-SOB n=84 MMSE n=84 ADAS-cog n=84
β Std. Error P Value β Std. Error P Value β Std. Error P Value
Baseline WMH 0.00011  0.00004 0.02* -0.0001  0.000074 0.05* 0.0003  0.0002 0.07 ^
Atrophy -42.61 9.7769 <0.001* 39.71  15.40746 0.01* -66.54  33.0176 0.05*
Education -0.1  0.0728 0.1 ^ 0.37  0.11487 <0.001* -0.76  0.2462 0.003*
Gender (Male) -1.93 0.7306 0.01* 2.05 1.15142 0.08^ -3.98  2.468 0.11 ^
APOE genotype -0.01  0.0692 0.89 0.027 0.10903 0.8 -0.13  0.2337 0.59
Age of onset -0.06  0.0543 0.28 0.04 0.08574 0.64 -0.16  0.1838 0.39
Disease duration 
since first visit
0.004 0.0107 0.7 0.01 0.01689 0.42 -0.02  0.0362 0.5
Table  12: Summary of the mixed-effects models of cognitive change using the predictors baseline WMH volume,
atrophy,  education,  gender,  APOE genotype,  age of  onset,  and disease duration as  fixed effects.  The regression
coefficient is shown for the fixed effect followed by the associated P value (“*” denotes that the P-value is significant
at the 0.05 level, ^ denotes that the P-value is significant at the 0.1 level), and standard errors of coefficients are
reported. Regression coefficients represent the number of standard deviations' difference in the cognitive baseline that
are associated with a 1-unit change in a predictor measured at baseline. The corresponding protocol of the R output
can be found in Table 47-51.
3.2 Model comparison using Akaike Information Criterion (AIC)
The models which performed better based on the AIC were chosen as the final models.
The CDR-SOB model of cognitive decline including WMH, atrophy, gender had an AIC
of 1575.67 which was better than the CDR-SOB model of cognitive decline including
WMH, atrophy, gender, education, age of onset, apoe, disease duration which had an
AIC of  1598.61.  The  MMSE model  of  cognitive  decline  including  WMH,  atrophy,
gender had an AIC of 1966.42 which was better than the MMSE model of cognitive
decline including WMH, atrophy, gender, education, age of onset, apoe, disease duration
which had an AIC of 1979.68. The ADAS-cog model of cognitive decline including
WMH, atrophy, gender had an AIC of 2483.89 which was worse than the ADAS-cog
model of cognitive decline including WMH, atrophy, gender, education, age of onset,
apoe,  disease  duration  which  had  an  AIC  of  2443.39.  A post-hoc  analysis  reveals
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weakness in the power of the CDR-SOB model. The smallest detectable effect size (d)
on  the  CDR-SOB scale  is  0.5  points.  The  random intercept  variance  was  3.24,  the
random slope variance 0.000015, and the residual variance 1.24. The variances were
calculated  from the  corresponding  standard  deviations  (1.79959,  0.00384,  1.114349)
which are reported in the linear mixed model output of the CDR-SOB rate of cognitive
decline model which included atrophy, WMH, and gender (see appendix).  The number
of subjects, required for a detectable minimal  effect in the CDR-SOB (d=0.5) and a
desired power of 80%, would be 89. Thus, the model is slightly underpowered because it
contains only 84 subjects. However, based on the comparison of AIC performance, the
CDR-SOB model of cognitive decline including WMH, atrophy, gender (AIC=1575.67)
performed  best  of  all  models  (Table  13).  Thus,  this  model  was  included  in  further
analysis in the next Chapter in which cognitive decline will be associated with mRNA
expression and proteins.
Model Comparison
















CDR-SOB model of cognitive decline
including WMH, atrophy, gender
299 1575.67 3.24 0.000015 1.24 0.78, d= 0.5 n= 89, d= 0.5
CDR-SOB model of cognitive decline
including WMH, atrophy, gender, education,
age of onset, apoe, disease duration
299 1598.61 3.27 0.000015 1.24 0.78, d= 0.5 n= 89, d= 0.5
MMSE model of cognitive decline
including WMH, atrophy, gender
300 1966.42 8.57 0.000021 3.9 0.87, d= 1 n= 69, d= 1
MMSE model of cognitive decline
including WMH, atrophy, gender, education,
age of onset, apoe, disease duration
300 1979.68. 7.84 0.000021 3.89 0.87, d= 1 n= 69, d= 1
ADAS-cog model of cognitive decline
including WMH, atrophy, gender, education,
age of onset, apoe, disease duration
299 2443.39 37.96 0.00012 11.56 0.43, d= 1 n= 207, d= 1
ADAS-cog model of cognitive decline
including WMH, atrophy, gender
299 2483.89 41.1 0.00012 11.57 0.43, d= 1 n=207, d= 1
Table 13: The Model Comparison table summarizes the fit statistics for each model. It is used it to compare several 
models fitted to the time series. Each row corresponds to a different model. The models are sorted by the AIC statistic.
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The random intercept variance, random slope variance, and residual variance were used to calculated the actual 
power of the models, and the required sample sizes for a desired power of 80%, p<0.05.The effect size (d) is the 
minimal detectable effect on a scale (here: 0.5 in CDR-SOB points, 1 point in MMSE, and 1 point in ADAS-cog). 
The median increase, and Interquartile Range [IQR], in points on the CDR-SOB scale,
was ~1.33 [IQR 2.05] per year1. An increase in CDR-SOB points means that there is a
decrease  in  cognitive  performance.  The  median  decrease,  and  IQR, in  cognitive
performance in points on the MMSE scale was 1.19 [IQR 2.47] per year2. The median
increase, and IQR, in cognitive performance in points on the ADAS-cog scale was 1.55
[IQR 5.62] per year3. An increase in ADAS-cog points means that there is a decrease in
cognitive performance (Table 14).  







Median [IQR] 1.33 [2.05] -1.19 [2.47] 1.55 [5.62]
Table 14: Cognitive decline rates over 1 year measured with three different assessments (CDR-SOB, MMSE, ADAS-
cog); median and IQR reported.
1 Calculated from  (0.0036 [IQR=0.0056]  per day * 365.24)  ~1.33 [IQR=2.05] per year.
2 Calculated from  (-0.00328 [IQR=0.0067]  per day * 365.24)  ~ 1.19 [IQR=2.47] per year.
3 Calculated from  (0.0042 [IQR=0.0154]  per day * 365.24)  ~ 1.55 [IQR=5.62] per year.
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Figure 13:  Histogram of cognitive decline slopes including covariates: WMH, atrophy and gender (left column)
and  including WMH, atrophy, gender, education, age of onset, and disease duration (right column); 1st row:
CDR-SOB slopes; 2nd row: MMSE slopes; 3rd row ADAS-cog slopes; plots of the corresponding baseline
cognitive decline slopes can be found in the appendix (Figure 19).
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Figure 14: Quantile-Quantile-plot for examining the distribution the of cognitive decline slopes including
covariates: WMH, atrophy and  gender (left column) and  including WMH, atrophy, gender, education, age of
onset, and disease duration (right); 1st row: CDR-SOB slopes; 2nd row: MMSE slopes; 3rd row ADAS-cog
slopes; the plots of the corresponding baseline cognitive decline slopes can be found in in the appendix (Figure
19).
4 Discussion
The  key  finding  of  this  study  is  that  WMH  volume  at  baseline  was  significantly
associated  with  greater  subsequent  deterioration  in  global  cognition  over  1  year,  as
measured by CDR-SOB, MMSE and ADAS-cog assessments, in a model controlled for
atrophy and gender. The finding is significant because it suggests that in a sample with
repeated cognitive evaluations  and short-term follow-up WMH may be an important
predictor of subsequent short-term global cognitive change. Especially, in clinical trials
WMH volumes might be an important covariate to consider when selecting patients or
evaluating treatment effects. 
Of note, there are known limitations of cognitive assessments with regard to measuring
short-term follow-up.  This  can  be  one  possible  explanation  of  why the  associations
between WMH volumes and cognitive assessment scores are relatively small. It can be
speculated that the true effect of WMH-related cognitive decline might be larger than it
is possible to show in this small sample containing only 84 subjects. 
Another limitation of the model is that its power is slightly under the usually desired
minimum power  of  80%  (Cohen,  1988).  Five  more  subjects  would  be  required  to
achieve this level of power. If the variable WMH would not be included in the model
then a larger number of cognitive decline slopes can be calculated (n= 89) which would
meet the required sample size.  The WMH variable has only a tiny effect on the rate of
cognitive decline (β=0.0001/day) in this particular model. Future studies should focus
on  subjects  with  severe  WMH volumes.  It  is  more  likely  to  find  a  large  effect  on
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cognitive decline and vice versa. A recent study claims that subjects  with aggressive
cognitive decline have more WMH (Tosto et al. 2014).
However,  overall  the  findings  agree  strongly  with  prior  studies.  Especially,  greater
WMH volumes at baseline were associated with decrease of global cognition in follow-
ups (Enzinger et al. 2007) (Fornage et al. 2008) (Silbert et al. 2009) (Carmichael et al.
2010). In the past there has been some controversy regarding the clinical significance of
WMH, with some clinicians even considering a high amount of WMH normal in old age
(Erkinjuntti  et  al.  1994).  In  the  recent  Carmichael  study,  baseline  WMH  were
significantly correlated with greater subsequent cognitive decline over 1 year measured
by MMSE (β= -0.096; P<0.001) and ADAS-cog (β=-0.034; P<0.05). Also in this study
the predictor values were relatively small indicating a small effect. 
A study by Brickman et al.  has shown that the degree of baseline WMH (β= -0.173;
P=0.03), atrophy (β= -0.316; P=0.04), and the interaction with atrophy predicted the rate
of cognitive decline measured by MMSE scores over 6 follow-up evaluations with 1-
year intervals. The MMSE scores decreased by an average of 3.5 points per year. 
In the current study, there was an average decrease of ~1.4 MMSE points per year in the
subjects of the AddNeuroMed cohort indicating that the general decline was less than
half as accelerated as in the cohort from the Massachusetts General Hospital (Erkinjuntti
et al. 1994). Atrophy was clearly the most influential variable in the cognitive decline
models calculated in the current study, as indicated by the large weight of the predictor
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atrophy,  with a  magnitude  from of  30  in  the  CDR-SOB and 39 MMSE model  and
significant  p-values  (P<0.05).  In comparison to  Brickman's  model,  here,  interactions
between WMH and atrophy were not significant.
WMH appear to be very prevalent in aged persons, including AD patients (Capizzano et
al. 2004; Van der Flier et al. 2005; Yoshita et al. 2006; Matsusue et al. 2006; Gouw et al.
2008;  Holland et  al.  2008;  Gold et  al.  2012).  Also in the current  study there was a
positive correlation between WMH volumes and age, R2=0.29, n=100, P<0.05.
Higher  education  can  influence  the  rate  of  cognitive  decline,  primarily  affecting
executive speed and memory (Scarmeas et al. 2006). Carmichael and colleagues found
that education was significant as a covariate in their CDR-SOB (β= -0.013;  P= 0.01),
but not in their ADAS-cog or MMSE models (Carmichael et al. 2010). In the current
study,  the  significant  of  effect  of  education  is  suggested  in  the  MMSE (β= 0.349;
P<0.05) and ADAS-cog model (β= -0.075; P<0.05).
The  prevailing  hypothesis  is  that  WMH  represent  small  ischemic  cerebrovascular
disease  and vascular  changes  affecting  perfusion  and blood flow  (Provenzano  et  al.
2013).
White  matter  contains  4-times  more  vascular  Aβ which  might  cause  micro-vascular
damage. It is possible that vascular Aβ increases the risk for the development of AD and
reflects the presence of WMH and the vascular problems associated with WMH (Roher
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et al. 2002). Also other studies confirm that high WMH burden and vascular problems
convey increased risk for the development of AD (De Leeuw et al. 2005; Gold et al.
2012; Weinstein et al. 2013). 
In the current study, patients had a mild cardiovascular profile because subjects with
stroke or severe vascular pathology were excluded from the study to analyse an overall
homogeneous AD group without the influence of comorbidities. 
Baseline WMH burden is a potentially important covariate in predicting an AD patient's
rate of disease progression. However, WMH progression is possibly another influential
variate.  Several  studies have  shown  that  white  matter  changes  progress  over  time
(Fazekas & Wardlaw 2013) (Silbert  et  al.  2009).  Carmichael  et  al. found significant
associations between progression of WMH and cognitive disease progression (β= -0.1;
P<0.001). In the current study, only baseline WMH volumes were available but future
work can include the continuation of this work with longitudinal WMH measures. 
Structural and functional imaging have the capabilities to detect AD related pathological
changes in brain regions which are particularly affected in AD  (Scheltens & Korf 2000)
(Scheltens & Korf 2000) (Gootjes et  al.  2004) (Henneman et al.,  2009)  (Prins et  al.
2004) (Zhang  et  al.  2009).  Earlier  studies  did  not  find  evidence  of  AD-specific
distribution of WMH  (Henneman et al. 2009) whereas recent studies suggest that the
extent and distribution of WMH in frontal and temporal brain regions is related to AD
severity and diminished cognition (Kim et al. 2011). WMH in AD have been found to be
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distributed in periventricular brain regions (DeCarli et al. 2005;  Holland et al. 2008), in
regions adjacent to the posterior corpus callosum (Scheltens et al. 2000; Ferrarini et al.
2008; Zhang et al. 2009; Silbert et al. 2009), in parahippocampal white matter and in
caudal portions of the cingulum (Gold et al. 2012). Brain regions with increased white
matter  dis-integrity  correlate  with  measures  of  decreased  cerebral  blood  flow/
metabolism in these areas (Chao et al. 2013) (Provenzano et al. 2013) (Kim et al. 2011).
More insights into the pathophysiology of WMH and their exact impact on cognitive
decline  are  clearly  needed  to  reduce  the  burden  of  disability  associated  with  this
common condition in neurodegenerative diseases.   
Although evidence from neuro-imaging studies using temporal models for short term
prediction of individual disease decline is available larger studies are required.  One
difficulty is that cognitive changes often occur in a non-linear, step-wise manner and are
highly variable. Jack  and colleagues propose a model for the temporal order in which
changes relating to the disease occur (Jack et al. 2013). Disease progression models can
contribute to understanding these changes over time and how and when the different
markers  correlate  with  each other.  Such models  provide  the  groundwork for  further
evaluation of study design and analysis  methodologies  for clinical  trials  in AD (and
MCI) (Ito et al. 2010).
WMH and AD share many of the same risk factors, both are hopefully preventable if
intervention takes place early enough. Initiatives guiding the future direction of research
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into Alzheimer's disease envisage a panel of preventative strategies such as recognising
vascular, lifestyle, psychological, and genetic risk factors of aged individuals (Ito et al.
2010).  Some  of  these  risks  can  be  possibly  targeted  with  new  drug  treatments,
psychological help, and lifestyle advice. 
In  the  current  work,  global  WMH have been correlated  with  measures  of  cognitive
change, and in addition, in the next Chapter, with mRNAs and proteins circulating in
blood. In future, cerebral structural and functional imaging combined with blood-based
markers could contribute to provide individual predictions for disease progression. 
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Chapter 2. Identification of a mRNA and protein panel 
associated with WMH and AD-cognitive decline
 1 Introduction
1.1 Transcriptomic markers
Transcriptomic  markers  are  based  on  measurements  of  RiboNucleic  Acid  (RNA)
obtained from blood samples. An RNA biomarker indicates the level of expression of a
gene, i.e., the amount of messenger RNA (mRNA) produced. RNA, together with DNA,
constitute the building blocks of life as we know it, and play various essential roles in
the coding, decoding, regulation, and expression of genes. We often refer to these RNA
molecules present in a cell at one point in time as the transcriptome, varying by cell type,
tissue, organ, environment, treatment, time of day and age. The fact that we can identify
the work of cell at a particular time point makes RNA interesting as a biomarker. 
Advantages  of  the  transcriptome  (all  RNA  expressed  in  a  cell)  are  that  current
techniques  allow multiplexing more  RNA at  once  than  proteome-related  techniques.
However, in this study, only mRNA is measured, not the other RNA types which are
present in a cell. Usually, only transcripts which are statistically significantly different,
under two or more conditions are taken into account for further analysis. 
The limitation  of  these transcripts  are  (a)  many genes  are  generally  turned off  in  a
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certain cell-type or tissue as a result of cellular differentiation; (b) some life sustaining
genes are always turned on and may produce confusing transcript/proteins signals; it is
necessary  to  discount  these  signals  in  the  analysis;  (c)  cells  can  control  protein
production  in  many  ways,  not  only  via altering  the  amount  of  mRNA,  thus  the
expression level might not correspond to the protein concentration. 
Previous  studies  identified  a  number  of  transcriptomic  markers  associated  with  AD:
these molecules were implicated in pathways such as immunity, long-term potentiation,
mitrochondrial function, phosphrylation, RAS-MAPK-ERK, and the ubiquitin protease
system (Altar et al. 2009; Grünblatt et al. 2009; Chen et al. 20011; Lunnon et al. 2013;
Kam  et  al.  2013).  For  instance,  RAS-MAPK-ERK  pathway  is  associated  with  the
development of many cancers by sending off/on signals to proteins (Imtiaz et al. 2014). 
Mitochondria,  the  energy production  facility  of  the  cell,  must  function  properly for
maintaining many bodily processes. Molecular signatures indicating their dysfunction
can be seen in blood of AD patients (Lunnon et al. 2013).  
The ubiquitin protease system is required for regulating immune responses. Dysfunction
of ubiquitination has been observed in AD (Upadhya & Hegde 2007). 
Memory is severely affected in AD, thus it is plausible that markers can be found in
blood  which  influence  long-term  potentiation  (the  underlying  synaptic  process  of
memory formation). It is also possible that post-translational modification play a role in
AD  (Grünblatt  et  al.  2009).  Below  an  overview  of  transcriptomic  markers,  their
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association with AD, and pathways they are implicated in (Table 15).





Gene and pathway targets 
replicated in expression 
profiling of human postmortem
brain, animal models, and cell 
culture studies
Ubiquitin-proteosome system,  
protein kinase C and RAS 
pathways
(Dhillon et al. 2007)
CB2 (Cannabinoid-receptor 2)
H3-histone






(Altar et al. 2009)
ABCB1 Positively correlated with 
MMSE
Immunity (Grünblatt et al. 2009)




(Chen et al. 2011)
FcyRIIb Mediates amyloid-β and 
memory impairment
Long-term potentiation (Lunnon et al. 2013)
Table 15: Summary of transcriptomic markers for Alzheimer’s disease from literature 
1.2 Proteomic markers
Proteomics has contributed enormously to a deeper understanding of the pathological
processes in AD and is playing an important role in identifying biomarkers for early
diagnosis,  monitoring  progression,  and  response  to  therapy  (Li  &  Wong  2001).
Proteomic markers are based on measurements of proteins, usually obtained from blood.
A protein biomarker indicates the amount of translated protein of each gene in a cell,
tissue, or organism. Proteins play vital roles in diseases. Certain protein levels in a cell
can be indicators of the presence of a disease. An advantage of proteins found in blood
plasma is  that changes in  blood can reflect  changes in  the brain to a certain degree
because the brain is not entirely segregated from the periphery; recent evidence suggests
there  is  vivid  communication  between  brain  and  peripheral  blood  (Lovestone  et  al.
2007) (Brunden et al. 2011) (Cortes-Canteli et al. 2012) (Banks 2012) (Wu et al. 2013).
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1.2.1 Blood-based protein markers
Ray et al. have measured eighteen signalling proteins that were found to be different in
early  stages  of  AD:  systemic  dysregulation,  hematopoiesis,  immune  responses,
apoptosis,  and  neuronal  support  in  pre-symptomatic  Alzheimer's  disease  (Ray et  al.
2007).  These  proteins  have  been used  for  identification  of  patients  with  AD,  or  for
predicting the onset of AD in presymptomatic patients, with up to 90% accuracy. Also
patients  with  mild  cognitive  impairment  were  analysed  and  it  has  been  found  that
progression to AD could be predicted with 81% accuracy in patients even 6 years before
their clinical diagnosis. 
However, in a reproduction study Björkqvist and colleagues quantified the same proteins
that have been already analysed by Ray et al. 2007 but did not find evidence of them
being useful as a good biomarker:  Only three proteins (EGF, PDG-BB and MIP-1δ)
were different in plasma between controls and AD (Björkqvist et al. 2012). 
Also Soares et al. tested the reproducibility of the original 18-analyte panel from Ray et
al. using a bead-based multiplex technology. Their results suggest diagnostic accuracy
using the subset  was 61%. Multivariate  analysis  of  an 89-analyte  multivariate  panel
yielded a diagnostic accuracy of 70% suggesting a plasma-based AD signature that may
be a useful screening tool in future but it still too weak for AD diagnosis based on this
set (Soares et al. 2009). 
O’Bryant  et  al. developed  an  algorithm  for  detecting  the  presence  of  AD  which
performed with 80% sensitivity and 91% specificity based on a panel of 30 proteins
(O’Bryant et al. 2010; O’Bryant et al. 2011). The panel included many proteins which
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are usually implicated in inflammation and vascular events. In addition, these proteins
correlated with neuropsychological scores. 
Laske  et  al.  applied  a  multivariate  approach  (based  on  a  support  vector  machine
algorithm) to  identify three most  discriminative parameters (cortisol,  von Willebrand
factor, oxidized low-density lipoprotein (LDL) antibodies). They could classify between
AD  and  cognitively  normal  subjects  with  an  accuracy  of  81.7%/  87.1%  in  the
training/independent test dataset. Later they found exaberrant levels of the soluble TNF
receptor 1 (sTNF-R1) in blood of AD patients versus controls (Laske et al. 2011) (Laske
2013).
Doecke  et al. found significantly altered concentrations of 18 proteins in AD subjects
compared to healthy controls  (Doecke et  al.  2012). The plasma samples were drawn
from 207 AD patients and 754 controls as part  of Australian Imaging, Biomarker &
Lifestyle  study  (AIBL).  A  complete  independent  validation  cohort  was  used:  the
Alzheimer's  disease  neuroimaging  initiative  (ADNI)  in  which  they  achieved  80%
accuracy, in 108 AD patients and 57 controls. However, in the ADNI cohort age, gender
and APOE ε4 genotype alone could predict the diagnosis of Alzheimer's disease with an
accuracy  of  77%.  Thus,  these  proteins  discovered  could  explain  only  3%  of  the
differences found in blood. 
Currently, quantitative mass-spectrometry assays are under development and in future
the investigation of post-translational modifications of proteins will be feasible (Snyder
et al. 2014). 
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1.2.2 Protein markers from brain tissue
Research  on  brains  from  AD  individuals  has  identified  not  only  the  two  hallmark
molecules,  amyloid  deposits  and  tau  pathology,  but  also  changes  in  astrocytes,
microglia,  immune  responses  implicating  cytokines  and  chemokines,  and  reactive
oxigen species  (Snyder  et  al.  2014) (Heneka et  al.  2010).  In  AD patients  and other
individuals with brain injury excessive load of pro-inflammatory cytokines such as TNF-
α  have been measured accelerating the rate of cognitive disease progression (Holmes
2009). 
Below an overview of blood and brain protein markers (Table 16). 
Biomarker Link with AD Pathways References
α-1-antitrypsin Enhances the formation of 
amyloid-fibrils




α-2-macroglobulin Inhibitor of coagulation (Hye et al. 
2006)
 Apolipoprotein E Cholesterol metabolism
Complement C3 Innate immunity
These four proteins above ... ... replicate in multiple studies  (Kiddle et al. 2014)
Serpin F1 (pigment epithelium-
derived factor) Complement 
C1 inhibitor
Down-regulated in AD blood (Maes et al. 2006)
18 proteins Different in AD versus controls Systemic deregulation, 
hematopoiesis, immune 
responses, apoptosis, and 
neuronal support
(Cutler et al. 2008)
Clusterin Amyloid chaperone protein Immune response (Ray et al. 2007)
Homocysteine Increased in blood from female
AD patients
(Obulesu & Jhansilakshmi 
2014)
Red cell folate decreased in AD blood
Fibrinogen Vascular dysfunction
Linked with brain atrophy
Altered hemostasis in AD
Coagulation
Binding of Aβ with fibrinogen 
leads to increased fibrinogen 
(Wood 2010)
(Thambisetty et al. 2011)
(Faux et al. 2011)
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aggregation, Aβ fibrillization, 




(Cortes-Canteli et al. 2012)
Cystatin C Inhibits Aβ oligomerization 
and amyloidogenesis, 
upregulated in response to 
injury
Apoptosis (Zellner et al. 2009)
Brain-derived neurotrophic 
factor 1
Role in neurodegeneration TrkB pathway (Kaur & Levy 2012)
Septin-3, septin-2, septin-5, 
dihydropteridine reductase, and
clathrin heavy chain 1
Altered levels in AD brain Energy metabolism, glycolysis,
oxidative stress, apoptosis, 
signal transduction, and 
synaptic functioning
(Honea et al. 2013)
Table 16: Summary of candidate protein markers for Alzheimer’s disease from literature 
1.3 Aims 
An ideal blood marker for AD should be easily obtainable and non-invasive. Therefore,
there is a clear need to search for biomarkers in blood. Blood markers for AD offer very
promising perspectives, however, do not yet provide sufficiently validated prognostic
information. In this work, the aims are to provide some transcriptomic and proteomic
candidates,  reflecting disease progression in AD, for further investigation in research
and maybe even in a clinical trial. 
One AD-related (but not AD-specific) condition is WMH burden which could impact the
prediction for the rate of cognitive decline. The study aims to find a panel of mRNA and
proteins associated with WMH.  The current study could reveal important clues to the
course of AD pathology. Our aims are formulated accordingly: 
(1) Applying statistical models for the identification of mRNA transcripts and proteins
from blood correlated with WMH, firstly in a mixed group of AD, MCI, and controls,
 110
regardless of disease status, and secondly in the subgroup of AD.
(2) Applying statistical models for the identification of mRNA transcripts and proteins
correlated  with  AD  disease  decline  using  the  cognitive  decline  slopes  previously
generated.
2 Methods
2.1 Cohorts & subjects
The detailed inclusion/exclusion criteria for AD have been described in the previous
chapter and by Simmons and colleagues (Simmons et al. 2011). 
The  inclusion criteria for MCI and control subjects were (Simmons et  al.  2011):  (1)
MMSE score range between 24 and 30; (2) geriatric depression scale score less than or
equal to 4/5; (3) subject aged 65 years or above; (4) subjects' medication; and (5) good
general health. 
The exclusion criteria for MCI and control subjects were (Simmons et al.  2011):  (1)
subjects  meet  the  DSM-IV  criteria  for  dementia;  (2)  significant  neurological  or
psychiatric illness, and (3) significant systematic illness or organ failure. The distinction
between MCI and controls was based on two criteria: (1) subject scores 0 on the CDR
scale  = control  and (2)  subject  scores  0.5 on CDR scale  = MCI.  Control  and MCI
subjects were further assessed using the CERAD (Consortium to Establish a Registry for
Alzheimer's Disease) battery (Fillenbaum et al. 2008). 
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Different versions of the cognitive assessments were used to avoid practice effects. If the
same cognitive tests would have been used 5 times a year it would have been likely that
the patients can remember some of the questions. 
2.2 Workflows and distribution characteristics
2.2.1 WMH versus mRNA transcripts in AD, MCI, and controls
74  AD,  65  MCI,  and  45  normal  controls,  matched  on  WMH  volumes  and  mRNA
measures, from the AddNeuromed study, were included (Table 17).
Workflow WMH versus mRNA transcripts in AD, MCI,
controls
Subjects with WMH measures (AddNeuroMed)
Total AD MCI CTL
245 100 87 58
Subjects with mRNA measures (AddNeuroMed)
Total AD MCI CTL
331 106 117 108
  1. Matching subjects
Total AD MCI CTL
184 74 65 45
2. Randomisation of subjects  [random.org/lists]
              3.  Dividing in training and validation set
         Training set
           138 subjects, 6282 mRNA transcripts
Validation set
                  46 subjects, 6282 mRNA transcripts
4. Feature selection on training 
set with WEKA automatic 
feature selection classifier Cfs 
subset eval, BestFirst, Crossval 
25-fold, seed 1
Training set with selected features
138 subjects, 18  mRNA transcripts
     Independent validation set
46 subjects, 18 mRNA transcripts
5. Nesting with WEKA 
CVParameterSelection:numFold
=10, seed=1; Linear Regression, 
M5 enabled
6.a Evaluation on training set 6.b Re-evaluation on 
validation set 
R2, Root mean squared error of 
evaluation on training set
R2, Root mean squared error of 
evaluation on validation se
Table 17:  Workflow  WMH volume as dependent variable versus mRNA transcripts in AD, MCI, and
controls
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There is only a marginally significant difference in WMH volumes by disease status
(Figure 15).
Figure 15: Boxplot of WMH volume by disease status used in the
analysis WMH versus mRNA, χ2 (2, N = 184) = 5.77, P = 0.05.
2.2.2 WMH versus mRNA transcripts in AD
74 AD, matched on WMH volumes and mRNA measures from the AddNeuromed study,
were included (Table 18). Of note, the training group and validation group are a subset
of the mixed group (section 2.2.1). 
Workflow WMH versus mRNA transcripts in AD
Subjects with WMH measures (AddNeuroMed)
Total AD
245 100
Subjects with mRNA measures (AddNeuroMed)
Total AD
331 106
  1. Matching subjects
Total AD
184 74
2. Randomisation of subjects  [random.org/lists]
        3.  Dividing in training and validation set
         Training set Validation set
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Workflow WMH versus mRNA transcripts in AD
           53 subjects, 6282 mRNA transcripts                  21 subjects, 6282 mRNA transcripts                   
4. Features were used from the 
previously analysed mixed AD, 
MCI, controls are used because
the AD group is a subset of the 
training of the AD|MCI|CTL 
group. 
Training set with selected features
53 subjects, 18  mRNA transcripts
     Independent validation set
21 subjects, 18 mRNA transcripts
5. Nesting with WEKA 
CVParameterSelection:numFold
=10, seed=1; Linear Regression, 
M5 enabled
6.a Evaluation on training set 6.b Re-evaluation on 
validation set 
R2, Root mean squared error of 
evaluation on training set
R2, Root mean squared error of 
evaluation on validation set
Table 18:  Workflow  WMH volume as dependent variable versus mRNA transcripts in AD
2.2.3 WMH versus proteins in AD, MCI, and controls
89  AD,  54  MCI,  and  39  normal  controls,  matched  on  WMH  volumes  and  protein
measures, from the AddNeuromed study and the Dementia Case Register were included
(Table 19). 
Workflow WMH versus proteins in AD, MCI, controls
Subjects with WMH measures 
(AddNeuroMed and Dementia Case Register)
Total AD MCI CTL
353  142  100  111
Subjects with protein measures 
(AddNeuroMed and Dementia Case Register)
Total AD MCI CTL
375  196  69 110
1.  Matching subjects
   Total AD MCI CTL
182  89  54  39
             2.  Randomisation of subjects  [random.org/lists]
3.  Dividing in training and validation set
         Training set
           136 subjects, 1016 proteins
Validation set
                46 subjects, 1016 proteins                   
4. Feature selection on training 
set with WEKA automatic feature
selection classifier Cfs subset 
eval, BestFirst, Crossval 25-fold, 
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Workflow WMH versus proteins in AD, MCI, controls
seed 1
Training set with selected features
136 subjects, 27 proteins
     Independent validation set with selected features
46 subjects, 27 proteins
5. Nesting with WEKA 
CVParameterSelection:numFold
=10, seed=1; Linear Regression, 
M5 enabled
6.a Evaluation on training set          6.b Re-evaluation on validation set
R2,, Root mean squared error of 
evaluation on training set
R2,, Root mean squared error of 
evaluation on validation set
Table 19: Workflow for WMH volume as dependent variable versus proteins in a mixed group of AD, MCI, 
and controls
There is only a marginally significant difference in WMH volumes by disease status
(Figure 16).
Figure 16: Boxplot of WMH volume by disease status used in workflow
WMH versus proteins, χ2 (1,N = 182) = 6.22, P = 0.04.
2.2.4 WMH versus proteins in AD
89 individuals with AD, matched on WMH volumes and protein concentrations from the
AddNeuroMed study and the Dementia Case Register,  were included (Table  20).  Of
note, the training group and validation group are a subset of the previous mixed group in
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order to test the previously identified proteins (section 2.2.3). 
Workflow WMH versus proteins in AD subjects
Subjects with WMH measures 
(AddNeuroMed and Dementia Case Register)
Total AD
353  142
Subjects with protein measures 
(AddNeuroMed and Dementia Case Register)
Total AD
375  196
1.  Matching subjects
   Total AD
   182  89
             2.  Randomisation of subjects  [random.org/lists]
3.  Dividing in training and validation set
         Training set
           59 subjects, 1016 proteins
Validation set
                30 subjects, 1016 proteins                   
4. Features were used from the 
previously analysed mixed AD, 
MCI, controls are used because
the AD group is a subset of the 
training of the AD|MCI|CTL 
group. 
Training set with selected features
59 subjects, 27 proteins
     Independent validation set with selected features
30 subjects, 27 proteins
5. Nesting with WEKA 
CVParameterSelection:numFold
=10, seed=1; Linear Regression, 
M5 enabled
 
6.a Evaluation on training set          6.b Re-evaluation on validation set
R2,, Root mean squared error of 
evaluation on training set
R2,, Root mean squared error of 
evaluation on validation set
Table 20:  Workflow for WMH volume as dependent variable versus proteins in AD subjects
2.2.5 Rate of cognitive decline versus mRNA in AD
62  individuals  with  AD,  matched  on  the  previously  calculated  CDR-SOB  rates  of
cognitive decline and mRNA expression from the AddNeuromed study, were included
(Table 21).
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 Workflow rate of cognitive decline
versus mRNA transcripts
AD subjects with WMH measures
(AddNeuroMed)
100
AD subjects with mRNA measures
(AddNeuroMed)
331
                  1. Matching subjects
62 AD
2. Randomisation of subjects
[random.org/lists]
   3. Dividing in training/validation
         Training 
           46 subjects, 6282 mRNAs
Validation 
16 subjects, 6282 mRNAs                
4. Feature selection on 
training set 
WEKA feature 
selection classifier Cfs 
subset eval, BestFirst, 
Crossval 25-fold, seed 1
Training set with selected features
46 subjects,  27 mRNAs
     Independent validation set
 16 subjects, 27  mRNAs







6.a Evaluation on 
training set                   
6.b Re-evaluation 
on validation set 
R2,, Root mean squared error of 
evaluation on training set
R2,, Root mean squared error of 
evaluation on validation set
Table 21: Workflow for rate-of-cognitive decline as dependent variable versus mRNA transcripts
2.2.6 Rate of cognitive decline versus proteins in AD
63  individuals  with  AD,  matched  on  the  CDR-SOB rates  of  cognitive  decline  and
protein measures from the AddNeuromed study, were included (Table 22). 
Workflow rate of cognitive decline
versus proteins
AD subjects with cognitive decline measures
(AddNeuroMed)
100
AD subjects with protein measures
(AddNeuroMed)
282
                  1. Matching subjects
63 AD
 117
Workflow rate of cognitive decline
versus proteins
2. Randomisation of subjects
[random.org/lists]
                  3. Dividing in training/validation
         Training 
           47 subjects, 1016 proteins
Validation 
16 subjects, 1016 proteins                  
4. Feature selection on 
training set 
WEKA feature 
selection classifier Cfs 
subset eval, BestFirst, 
Crossval 25-fold, seed 1
Training set with selected features
47 subjects, 27 proteins
     Independent validation set
16 subjects, 27 proteins







6.a Evaluation on 
training set                   
6.b Re-evaluation 
on validation set 
R2,, Root mean squared error of 
evaluation on training set
R2,, Root mean squared error of 
evaluation on validation set
Table 22: Workflow for rate-of-cognitive decline as dependent variable versus proteins
2.3 Illumina Microarray Analysis
 Lunnon et al. have previously performed the microarray analysis (Lunnon et al. 2013).
This was not in the scope of this PhD thesis. The microarray data were extracted using
Human HT-12 v3 Expression BeadChips (Illumina). The beadchips consisted of 48,803
probes and were optimised to process data from RefSeq (Build 36.2, Rel 22) and  the
UniGene (Build 199) databases. The TotalPrep RNA Ampliﬁcation Kit (Ambion) was
used  to  synthesize  cDNA from  200  ng  total  RNA followed  by  ampliﬁcation  and
biotinylation of cRNA and hybridization. Following hybridization, quality control of the
bead arrays was carried out  using the R Bioconductor package “ComBat”.   The gene
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expression values were variance-stabilization transformed and quantile normalized using
the R Bioconductor package lumi  (Du et al. 2008). The data were adjusted for RNA
integrity  number,  RNA  concentration,  gender  and  age.  Only  probes  showing  an
expression signal across all samples were kept which left 6,282 probes.  A total of 30
chips were excluded from further analysis for reasons including: very low BeadChip
detection  rate,  disparity in  XIST gene expression  gender, inconsistencies  in  subjects
characteristics (Lunnon et al. 2013). 
2.4 SOMAscan protein measures
The protein measurements were previously generated and analysed  by Sattlecker and
colleagues (Sattlecker at  al.  2013). The work describe in this  section was not in the
scope of this  thesis.  Protein levels in  plasma were measured using a Slow Off-Rate
Modified Aptamer (SOMAmer)-based multiplexed proteomic assay (SomaLogic,  Inc,
Boulder,  Colorado).  For  measuring  plasma  proteins  this  array  (SOMAscan)  uses
chemically modified nucleotides: a signature of protein concentration is transformed into
a  DNA  aptamer  concentration,  a  nucleotide  signal  (relative  fluorescence  units)
quantifiable on the DNA microarray using relative florescence. This assay uses unique
nucleotide sequences recognizable by specific hybridization probes (Kiddle et al. 2014).
This assay is capable of simultaneously reading out several thousand proteins even in
small  sample  volumes  (15  µL serum  or  plasma).  The  current  assay  is  capable  of
measuring 813 proteins with low limits of detection (1 pM median), 7 logs of overall
dynamic range (~100 fM–1 µM), and 5% median coefficient of variation. The median
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lower and upper limits of quantification were ~1 pM and ~1.5 nM in buffer, and ~2.95
pM and ~1.5 nM for a subset of the somamers in plasma, full details are given in Gold
et al.  (Gold et al. 2010).  Quality control was performed at the sample and SOMAmer
level,  and involved the use of control SOMAmers on the microarray and calibration
samples.  At the sample level,  hybridization controls on the microarray were used to
monitor sample-by-sample variability in hybridization, while the median signal over all
SOMAmers  was  used  to  monitor  overall  technical  variability.  The  resulting
hybridization scale factor and median scale factor were used to normalize data across
samples. The acceptance criteria for these values were 0.4-2.5, based on historical trends
in  these  values.  SOMAmer-by-SOMAmer  calibration  occurs  through  the  repeated
measurement of calibration samples, these samples were of the same matrix as the study
samples, and were used to monitor repeatability and batch to batch variability. Historical
values  for  these  calibrator  samples  for  each  SOMAmer  were  used  to  generate  a
calibration scale factor. The acceptance criteria for calibrator scale factors is that 95% of
SOMAmers had a calibration scale factor within ±0.4 of the median. The assay required
8μL of plasma from each sample. A single assay was used per plasma sample, and thus
no  technical  replicates  were  performed.  Additionally,  the  samples  were  run  in  two
batches ensuring an even mix of diagnosis groups in each batch. The protein measures
were  normalised.  Principal  component  analysis  showed  that  protein  measures  were
affected by study centre and thus either adjusted for centre using linear regression or
added centre as a covariate in all  downstream analysis  (Sattlecker at  al.  2013).  This
method has enabled to measurements of the concentration level of 1,016 human proteins
representing different molecular pathways and gene families. 
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2.5 MRI
Detailed  information  regarding  data  acquisition,  pre-processing,  and  quality  control
assessment, and WMH extraction have been described in the previous Chapter (pages 82
& 84).
2.6 Multivariate analysis with WEKA software
WEKA  software  was  used  for  performing  feature  selection  and  linear  regression
(Holmes et al. 1994) (Hall et al. 2009) (Witten et al. 2011). 
2.6.1 Feature selection search method
A total  of  6,282 mRNA transcripts  and 1,016 proteins  were  included in  the  feature
selection which was performed, in the training set, with BestFirst Search method and
CFS subset evaluator, with the options 10-fold crossvalidation and seed 1, resulting in a
list  of mRNAs and proteins sorted by the number of folds they appeared in; if they
appeared at least 7 out of 10 times they were included in the analysis.  The Best first
attribute selection method searches the space of attribute subsets by greedy hillclimbing
augmented  with  a  backtracking  facility.  Setting  the  number  of  consecutive  non-
improving nodes allowed controls the level of backtracking done. Best first may start
with the empty set of attributes and search forward, or start with the full set of attributes
and search backward, or start at any point and search in both directions (by considering
all  possible  single  attribute  additions  and  deletions  at  a  given  point).  Here  we  use
forward as direction. The threshold for keeping mRNAs and proteins in the analysis was
if they were found in at least 8 of 10 folds. 
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CFS Subset Evaluator, the standard attribute selection method in WEKA, evaluated the
worth of a subset of attributes by considering the individual predictive ability of each
feature (mRNA, protein) along with the degree of redundancy between them. Subsets of
features that are highly correlated with the dependent variable (here: WMH or CDR-
SOB) while having low intercorrelation are preferred (Witten et al. 2011). The standard
options were used: locallyPredictive=TRUE (identifies locally predictive attributes and
iteratively adds attributes with the highest correlation with the dependent variable as
long as there is not already an attribute in the subset that has a higher correlation with
the attribute  in  question)  and missingSeparate  =False (counts for  missing values  are
distributed across other values in proportion to their frequency).
2.6.2 Linear regression, M5 algorithm, and parameter tuning
A number of options specific to the WEKA classifier function “Linear Regression” were
tested  and  the  most  suitable  applied  using  a  meta  learner  Cross-
ValidatedParameterSelection (CVPS) which gives an unbiased performance estimate for
every step involved in fitting the model while optimising the parameters. The options for
parameter settings included:
-S sets the attribute selection method to use: (0) the default method is M5' (builds trees
whose leaves are associated to multivariate linear models and the nodes of the tree are
chosen over  the  attribute  that  maximizes  the  expected  error  reduction,  given by the
Akaike information criterion (AIC) – a measure of the relative goodness  of  fit  of  a
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statistical model (Akaike, 1973); (1) no selection; (2) greedy, a heuristic method which
finds a solution after a number of steps. 
-C (0)  co-linear attributes are removed; (1) co-linear attributes are not removed.
-R sets the ridge parameter (default = 1.0e-8). The goal is to circumvent the problem of
predictors' co-linearity. The following parameters were tested and applied using CVPS
(Table 23) (Figure 17). 





R -5.99   5.0E-4    5.0
C 0.0 1.0 1.0 
S 0.0 1.0 2.0
 R 4.99
 C 0.0 
 S 0.0
Table 23: Regression and parameter tuning: test- and optimized parameters
Figure 17: Parameter tuning using a 10-fold cross-validation. Using meta learners such as
CVParameterSelection, a nested cross-validation is obtained in which parameters and features
are selected using an inner run of cross-validation on each training fold of the outer evaluation
cross-validation.
2.6.3 Model output and reporting of results
The model output consisted of: (1) run information:  a list of information giving the
learning scheme options, relation name, instances, attributes and test mode that were
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involved in the process; (2) model: a textual representation of the classiﬁcation model
that  was produced on the training data;  (3) summary:  a list  of statistics  (correlation
coefficient and errors), summarizing how accurately the model was able to predict the
true target of the instances under the chosen test mode. 
Reporting of results  included correlation coefficient,  mean absolute  error,  root  mean
squared error, relative absolute error in %, root relative squared error in %, number of
subjects,  number of  features,  type of target  (WMH or cognitive decline slope)  were
reported for the training, 10-fold cross-validated training, and an independent validation
set. The final model (based on the training data), identified with parameter tuning and
regression, was exported to R to extract the test statistics. This was not possible for the
cross-validated  model  and validation  model  because they are directly built  from the
training model and it was not foreseen to export these models from WEKA. 
Power and sample size analysis was performed using G*Power 3.1.7 (Faul et al. 2007 &
2009). A protocol of power analysis was reported with estimated sample sizes for the
validationsets. 
Observations for WEKA
Having a training set and a validation set is regarded as the gold standard. In the current 
study, after generating and analysing training and validation sets, it be became apparent 
that the sample sizes for the validation sets were too low (based on power analysis) 
which is a limitation of the performed analyses (Table 24).  Future work should include 
the collection of more data for larger validation sets. Another possibility would have 
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been to use only larger training sets until further data is collected and apply a cross-
validation. Cross-validation can give an insight how data are expected to generalize in 
an independent validation set but they are no replacement for validation in an 
independent dataset. Cross-validation is a method to predict model fit for a hypothetical 
validation set when an explicit set is not available. 
Study Actual size of validation set Ideal size of validation set
WMH/mRNA (AD, MCI, controls) 46 52
WMH/mRNA (AD) 21 34
WMH/proteins (AD, MCI, controls) 46 51
WMH/proteins (AD) 30 37
Cognitive decline/mRNA (AD) 16 34
Cognitive decline/proteins (AD) 16 31
Table 24: Comparing actual versus ideal sizes of validation sets
A detailed elaboration of how the statistical power and ideal sample sizes were 
calculated can be found in the following sections after a brief introduction to 
conventions and definitions (Table 25).
Power of the models and sample sizes
Effect size (f 2) conventions
f 2  = 0.02 Small effect 
f 2  = 0.15 Medium effect
f 2  = 0.35 Large effect
Table 25: Effect size conventions
Here, the R2 is used as effect size for all posthoc and a priori tests. 
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Statistical measure Description
Effect size f2 Effect size is a simple way of quantifying the difference between two groups that has many 
advantages over the use of tests of statistical significance alone. Effect size emphasises the 
size of the difference rather than confounding this with sample size.
α error probability The rate of the type I error is called the size of the test and denoted by the Greek letter α 
(alpha). It usually equals the significance level of a test, which is the probability of rejecting 
the null hypothesis given that it is true.
F Distribution The F distribution is the distribution of the ratio of two estimates of variance. It is used to 
compute probability values in the analysis of variance. The F distribution has two parameters: 
degrees of freedom (df) numerator and degrees of freedom denominator. 
Numerator df The number of degrees of freedom that the estimate of variance used in the numerator is based
on. 
Denominator df The number of degrees of freedom that the estimate used in the denominator is based on.
Non-centrality 
parameter λ
The noncentrality parameter changes the shape of the F distribution in the analysis of variance,
when there is an actual effect in the populations
Critical F  Critical value of the F-distribution
Power (1- β error 
probability)
 1- β  is the probability of rejecting a null hypothesis correctly when the alternative hypothesis 
is true. Sufficient sample sizes are required to achieve adequate power (sensitivity). Most 
researchers assess the power of their tests using π = 0.80 as a standard for adequacy. 
Table 26: Description of statistical measures
The categorisation based on the correlation coefficient should be seen as a rule of thumb 
because the interpretation also depends on sample size and number of predictors. In 
general, the higher the correlation coefficient the stronger is the relationship between the
variables. 
Correlation threshold (Dancey and Reidy's, 2004)
R Strength of correlation
1 Perfect
0.7 – 0.9 Strong
0.4 – 0.6 Moderate
0.1 – 0.3 Weak
0 Zero
Table 27: Categorisation of correlation strength
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3 Results
3.1 Detection of a panel of mRNA transcripts associated with WMH in AD|MCI|
controls
To detect WMH-associated transcripts, in a mixed group of individuals with AD, MCI,
and controls, a feature selection algorithm was applied which identified  17 significant
mRNA transcripts (from a total of 6,282), in the training set. The detailed workflow is
described in (Table 17). A summary of the significance levels and test statistics can be
found  in  the  appendix  (Table  54).  The  panel  of  transcripts  included  ALAS2
[aminolevulinate,  delta-,  synthase  2],  ARFGAP1 [ADP-ribosylation  factor  GTPase
activating protein 1], CC2D1B [coiled-coil and C2 domain containing 1B], CCDC90A
[mitochondrial  calcium  uniporter  regulator  1],  CREB5 [cAMP  responsive  element
binding  protein  5],  EOMES [eomesodermin],  FAU [Finkel-Biskis-Reilly  murine
sarcoma virus (FBR-MuSV) ubiquitously expressed],  FBXW4 [F-box and WD repeat
domain containing 4], HS.127310 [U2AF homology motif (UHM) kinase 1], LILRA5
[leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 5],
NAG18 [NAG18 mRNA],  NCAPD2 [non-SMC condensin  I  complex,  subunit  D2],
NRBP2 [nuclear  receptor  binding  protein  2],  PNKD [paroxysmal  nonkinesigenic
dyskinesia],  RRAGC [Ras-related  GTP binding  C],  SHARPIN [SHANK-associated
RH domain interactor], and ZNRD1A [zinc ribbon domain containing 1]. 
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To detect the best panel of mRNAs associated with WMH in a mixed group of AD, MCI,
and controls,  a  linear  regression  function,  with the  option  M5 enabled,  was applied
which included  12 transcripts from the 17 previously identified, in the model. In the
training  set,  a  weak  correlation  was  found:  the  panel  of  12  mRNA  transcripts
significantly predicted WMH n= 138, R2= 0.43, F(1,12)= 7.83, P<0.001 (Table 28).  In
the cross-validated training set,  there was little correlation n= 138,  R2= 0.15, and no
correlation  in  an  independent  validation  set  n=  46/  R2=  -0.18;   supplementary
information can be found in the appendix (Table 55). 
Linear regression of WMH-correlated mRNA transcripts n=138 (AD, MCI, and controls) in the 
training set
Variable β Error T - value P - value
Intercept  4896.5 549.2 8.916   4.92e-15 ***
1 ALAS2  8028.5 4911.4 1.635   0.1046
2 ARFGAP1  -8191.1 3792.9 -2.160   0.0327 * 
3 CCDC90A  7635.5 4566.8 1.672   0.097  .
4 CREB5 7693.6 4672.0 1.647   0.10212  
5 EOMES  5374.6 2431.6 2.210   0.0289 *
6 FAU 10756.5 5372.8 2.002   0.0474 *
7 FBXW4 -7732.5 4368.9 -1.770   0.0792 .
8 LILRA5 -1850.7 705.9 -2.622   0.0098 **
9 NCAPD2  6559.4 3119.1 2.103   0.0375 * 
10 PNKD 10037.3 5308.6 1.891   0.061   .
11 RRAGC 7043.1 4012.5 1.755   0.0817 .
12 SHARPIN -5684.4 3969.9 -1.432  0.1547 
Significance codes:  0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05 ‘.’ 0.1 ‘ ’ 1
Residuals:
     Min       1Q   Median       3Q      Max 
-12410.1  -3599.2   -765.4   2152.2  28262.7
Residual standard error: 6233, Multiple R-squared:  0.43, Adjusted R-squared:  0.37
F-statistic: 7.829 on 12,  p-value: 9.92e-11
Table 28: Model specification linear regression mRNA versus WMH in AD, MCI, and controls
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Power and sample sizes WMH/mRNA (AD|MCI|CTL)
Post-hoc
The post-hoc test  on the training  set,  with effect  size  0.43,  α error  probability 0.05,
n=138, 12 predictors, achieved a statistical power of 0.99 (Table 29). The validation set
had zero effect size, thus no posthoc test can be performed. 
A priori
To  detect  an  effect  size  of  0.43  (like  in  the  training),  α error  probability  0.05,
power=0.99, 12 predictors, the required sample size of the validation set would have to
contain 91 subjects (Table 29). 
However, an acceptable power would be already achieved with 0.80. To detect an effect
size of 0.43 (like in the training), α error probability 0.05, power=0.80, 12 predictors, the
required sample size of the validation set would have to contain 52 subjects (Table 29). 
 129
F tests – Linear multiple regression: Fixed model, R2 deviation from zero
Post hoc - achieved 
power of training set
Post hoc - achieved 
power of validation 
set
A priori – required 
sample size of 
validation set for 
power of 0.99
A priori – required 
sample size of 
validation set for 
power of 0.80
Input
Effect size f2 0.43  - - - 0.43 0.43
α error probability 0.05  - - - 0.05 0.05
Power (1- β error 
probability)
 - - -  - - - 0.99 0.80
Total sample size 138  - - -  - - -  - - - 




59.34  - - - 39.13 22.36
Critical F 1.83  - - - 1.8 2.01
Numerator df 12  - - - 12 12
Denominator df 125  - - - 78 39
Total required sample
size
 - - -  - - - 91 52
Achieved Power (1- 
β error probability)
0.99  - - - 0.99 0.80
Table 29: Power and sample sizes WMH/mRNA (AD|MCI|CTL) models
3.2 Detection of a panel of mRNA transcripts associated with WMH in AD
To detect the best panel of mRNAs associated with WMH in a group consisting only of
AD subjects (a subset of the previously used mixed AD, MCI, CTL group),  a linear
regression  function,  with  the  option  M5  enabled,  was  applied  which  included  11
transcripts from previously identified 17 significant WMH-associated mRNA transcripts.
The detailed workflow is described in (Table 18).  In the training set, a strong correlation
was found: the panel of 11 mRNA transcripts significantly predicted WMH n= 53, R2=
0.75,  F(1,11)=  11.25,  P<0.001 (Table  30).  There  was  little  correlation  in  the  cross-
validated training set n=53,  R2= 0.26, and in an independent validation set n= 21/  R2=
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0.11;  supplementary information can be found in the appendix (Table 56). 
Linear regression of WMH-correlated mRNA transcripts n=53 (AD) in the training set
Variable β Error T - value P - value
Intercept  4528.9 700.1           6.469   9.31e-08 ***
1 ALAS2 13927.8 5001.5 2.785   0.0081 **
2 ARFGAP1 -10680.4 4259.7 -2.507   0.0162 *
3 CCDC90A 13316.6 6622.8 2.011   0.051 . 
4 EOMES 6508.9 3966.2 1.641   0.1084 
5 FAU 15046.7 7425.1 2.026   0.0493 * 
6 HS.127310 18507.5 9831.0 1.883   0.0669 . 
7 LILRA5 -1256.4 852.0 -1.475   0.148 
8 NAG18 16711.4 6917.2 2.416   0.0202 * 
9 NCAPD2 11510.8 3811.9 3.020   0.0043 **
10 PNKD 15898.8  6651.5   2.390   0.0215 *
11 SHARPIN -8883.5 4347.1 -2.044   0.0475 *
Significance codes:  0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05 ‘.’ 0.1 ‘ ’ 1
Residuals:
   Min     1Q Median     3Q    Max 
-12237  -2116     13   1732   8699
Residual standard error: 4538, Multiple R-squared:  0.75, Adjusted R-squared:  0.68
F-statistic: 11.25 on 11 DF,  p-value: 3.291e-09
Table 30: Model specification linear regression mRNA versus WMH in AD
3.2.1 Power and sample sizes WMH/mRNA (AD)
Post-hoc
The post-hoc test on the training set, with effect size 0.75, α error probability 0.05, n=53,
11 predictors, achieved a statistical power of  0.98. The post-hoc test on the validation
set,  with  effect  size  0.11,  α error  probability  0.05,  n=  21,  11  predictors,  achieved a
statistical power of 0.08 (Table 31). 
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A priori
To  detect  an  effect  size  of  0.75  (like  in  the  training),  α error  probability  0.05,
power=0.98  (like  in  the  training),  11  predictors,  the  required  sample  size  of  the
validation set would have to contain 51 subjects. 
However, an acceptable power would be already achieved with 0.80. To detect an effect
size of 0.75 (like in the training), α error probability 0.05, power=0.80, 11 predictors, the
required sample size of the validation set would have to contain 34 subjects (Table 31). 
F tests – Linear multiple regression: Fixed model, R2 deviation from zero
Post hoc - achieved 
power of training set
Post hoc - achieved 
power of validation 
set
A priori – required 
sample size of 
validation set for 
power of 0.98
A priori – required 
sample size of 
validation set for 
power of 0.80
Input
Effect size f2 0.75 0.11 0.75 0.75
α error probability 0.05 0.05 0.05 0.05
Power (1- β error 
probability)
 - - - - - - 0.98 0.80
Total sample size 53 21 - - -  - - -




39.75 2.31 38.25 25.5
Critical F 2.03 3.1 2.04 2.26
Numerator df 11 11 11 11
Denominator df 41 9 39 22
Total required sample
size
- - - - - - 51 34
Achieved Power (1- 
β error probability)
0.98 0.08 0.98 0.80
Table 31: Power and sample size in WMH/mRNA (AD) models
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3.3 Detection of a panel of proteins associated with WMH in AD|MCI|controls
To detect WMH-associated proteins, in a mixed group of individuals with AD, MCI, and
controls,  a  feature  selection  algorithm  was  applied  which  identified  27 significant
proteins (out of 1,016), in the training set. A summary of the significance levels and test
statistics  can  be  found in  the  appendix  (Table  58).  The  panel  of  proteins  included:
CXCL16 [chemokine (C-X-C motif) ligand 16], TWEAK [TNFSF12 - tumor necrosis
factor (ligand) superfamily, member 12], HPV E7 Type 16 [Human papillomavirus type
16 E7 Binding Protein/  TRIP13],  Macrophage maanose receptor,  GDF11 [Growth
Differentiation Factor 11/ BMP11], ALPL [Alkaline phosphatase bone], IgM [CD40, -
Tumor necrosis factor ligand],  FCG2B [Fc fragment of IgG, low affinity IIb, receptor
(CD32)], Testican 2, CAMK2B [calcium/calmodulin-dependent protein kinase II beta],
Chk2 [checkpoint kinase 2],  BCL2 [PPP1R20 -B-cell CLL/lymphoma 2],  Kallistatin
[SERPINA4],  STK16 [Serine/Threonine  Kinase  16],  Vasoactive  Intestinal  Peptide,
CNDP1 [carnosine dipeptidase 1 (metallopeptidase M20 family)], Cathepsin H, MBD4
[methyl-CpG binding domain protein 4],  LCMT1 [leucine carboxyl methyltransferase
1], SAA [serum amyloid A1 cluster], MMP12 [matrix metallopeptidase 12 (macrophage
elastase)], PH [Cytohesin 2], FAM107B [  family with sequence similarity 107, member
B], Coagulation Factor V [Factor V Leiden],  C1QBP [Complement Component 1, Q
Subcomponent Binding Protein], Esterase D [ESD], and GPC5 [glypican 5].
To detect the best panel of proteins associated with WMH, in a mixed group of AD,
MCI, and controls, a linear regression function, with the option M5 enabled, was applied
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which included 20 proteins from the 27 previously identified, in the model. The detailed
workflow is described in (Table 19). In the training set, a strong correlation was found:
the panel of 20 proteins significantly predicted WMH n= 136, R2= 0.64, F(1,20)= 10.43,
P<0.001 (Table  32). There was little correlation in the cross-validated training set n=
136,  R2= 0.18, and in an independent validation set n= 46,  R2= 0.09;  supplementary
information can be found in the appendix (Table 59).  
Linear regression of WMH-correlated proteins n= 136 in AD, MCI, and controls in the training set
Variable β Error T - value P - value
Intercept 6111 500.1 12.220   < 2e-16 ***
1 CXCL16soluble 3820.9 2299.4 1.662    0.0993  . 
2 GDF11 -6463.4 1964.9 -3.289    0.0013 **
3 Alkaline phosphatase bone -1644.9 770.9 -2.134    0.035   *
4 IgM -1217.2 828.7 -1.469    0.1446
5 Testican 2  - 4849.7 2698.6 -1.797    0.0749  .
6 Chk 2 6062.0 1096.6 5.528    2.05e-07 ***
7 Bcl 2 5828.8 3029.0 1.924    0.0568 .
8 Kallistatin - 4397.3 2455.5 -1.791    0.076   . 
9 Vasoactive Intestinal Peptide -6794.1 4001.3 -1.698    0.0922 . 
10 CNDP1 -1917.0 1047.6 -1.830    0.0699 .
11 Cathepsin H 3635.1 2430.2  1.496    0.1375
12 MBD4 -4192.8 2589.3 -1.619    0.1081
13 LCMT1  -6090.2 2182.7 -2.790    0.0062 **
14 SAA 761.0 337.7 2.254    0.0261 *
15 PH 1564.7 707.4 2.212    0.029   *
16 FAM107B  3433.2 1591.5 2.157    0.0331 *
17 Coagulation Factor V 6016.2 2090.8  2.878    0.0048 **
18 C1QBP  - 9031.1 4939.2 -1.828    0.0701 . 
19 Esterase D  - 5234.8 1899.7 -2.756    0.0068 ** 
20 GPC5 3479.6 1753.7 1.984    0.0496 *
Significance codes:  0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05 ‘.’ 0.1 ‘ ’ 1
Residuals:
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Linear regression of WMH-correlated proteins n= 136 in AD, MCI, and controls in the training set
Variable β Error T - value P - value
     Min       1Q       Median       3Q      Max 
-11849.2  -3203.0   -701.2   2345.8  16916.6 
Residual standard error: 5621, Multiple R-squared:  0.64, Adjusted R-squared:  0.58
F-statistic: 10.43 on 20 DF,  p-value: < 2.2e-16
Table 32: Model specification of proteins versus WMH in AD, MCI, and controls
3.3.1 Power and sample sizes WMH/proteins (AD|MCI|CTL)
Post-hoc
The post-hoc test  on the training  set,  with effect  size  0.64,  α error  probability 0.05,
n=136,  20 predictors,  achieved a  statistical  power of  0.99.  The post-hoc test  on the
validation  set,  with  effect  size  0.09,  α error  probability  0.05,  n=46,  20  predictors,
achieved a statistical power of 0.11 (Table 33). 
A priori
To  detect  an  effect  size  of  0.64  (like  in  the  training),  α error  probability  0.05,
power=0.99, 20 predictors, the required sample size of the validation set would have to
contain 80 subjects. 
However, an acceptable power would be already achieved with 0.80. To detect an effect
size of 0.64 (like in the training), α error probability 0.05, power=0.80, 20 predictors, the
required sample size of the validation set would have to contain 51 subjects (Table 33). 
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F tests – Linear multiple regression: Fixed model, R2 deviation from zero
Post hoc - achieved 
power of training set
Post hoc - achieved 
power of validation 
set
A priori – required 
sample size of 
validation set for 
power of 0.99
A priori – required 
sample size of 
validation set for 
power of 0.80
Input
Effect size f2 0.64 0.09 0.64 0.64
α error probability 0.05 0.05 0.05 0.05
Power (1- β error 
probability)
- - -  - - - 0.99 0.80
Total sample size 136 46  - - -  - - -




87.04 4.14 51.20 32.64
Critical F 1.66 2.00 1.75 1.93
Numerator df 20 20 20 20
Denominator df 115 25 59 30
Total required sample
size
 - - -  - - - 80 51
Achieved Power (1- 
β error probability)
0.99 0.11 0.99 0.80
Table 33: Power and sample size calculation of WMH/proteins (AD, MCI, controls) models
3.3.2 KEGG pathways
In order to identify functional pathways in which the mRNAs from the mRNA 
expression analysis of cerebral white matter lesions play a role, the detected set 
consisting of  ALAS2, ARFGAP1, CCDC90A, CREB5, EOMES, FAU, FBXW4, 
LILRA5, HS.127310, NAG18, NCAPD2, PNKD, RRAGC, and SHARPIN, was entered
in the pathway analysis (sequence information see appendix).
One significant (p<0.05 Bonferroni corrected) pathway “Ribosome” was found (Table 
35).
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GO_id Term Number of Genes P-value Bonferroni corrected
3010 Ribosome 8 <0.05
Table 34: Significant pathways from mRNA/WMH analysis
3.4 Detection of a panel of proteins associated with WMH in AD
To detect the best panel of proteins associated with WMH, in individuals with AD (a
subset of the group as above, without MCI and controls), a linear regression function,
with  the  option  M5  enabled,  was  applied  which  included 13 proteins  from the  27
previously identified.  The detailed workflow is described in (Table 20).  In the training
set,  a  strong correlation  was  found:  the  panel  of  13  proteins  significantly predicted
WMH  n=  59,  R2=  0.76,  F(1,13)=  10.85,  P<0.001  (Table  35).  There  was  a  weak
correlation in the cross-validated training set n= 59, R2= 0.12, but little correlation in an
independent validation set n= 30, R2=  0.03 (Table 60). 
Linear regression of WMH-correlated proteins n= 59 in AD in the training set 
Variable β Error T - value P - value
Intercept 5666.5 775.1 7.311    3.53e-09 ***
1 GDF 11 -10119.7 2408.1 -4.202    0.0001 ***
2 Testican 2 -7568.9 4255.4 -1.779    0.0821 .  
3 Chk 2 7750.3 1522.3 5.091    6.79e-06 ***
4 Bcl 2 22918.6 3749.7 6.112    2.13e-07 ***
5 Kallistatin -6506.4 4056.0 -1.604    0.1157
6 STK16 15625.7 4912.3 3.181    0.0027 **
7 CNDP1 3598.6 1842.7 1.953    0.0571 .
8 Cathepsin H 11588.9 3486.3 3.324    0.0018 **
9 SAA -950.7 500.9 -1.898    0.0641 .
10 MMP 12 8453.1 3845.0 2.198    0.0331  *
11 FAM107B 3119.8 1960.3 1.591    0.1185
12 C1QBP -14941.8 6924.5 -2.158    0.0363 *
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Linear regression of WMH-correlated proteins n= 59 in AD in the training set 
Variable β Error T - value P - value
13 GPC5 -15051.9 6065.6 -2.482    0.0169 * 
Significance codes:  0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05 ‘.’ 0.1 ‘ ’ 1
Residuals:
     Min       1Q   Median       3Q      Max 
-10873.1  -3710.8    489.6   3037.7   8803.1 
Residual standard error: 5159,  Multiple R-squared:  0.76, Adjusted R-squared:  0.69
F-statistic: 10.85 on 13 DF,  p-value: 6.272e-10
Table 35: Model specification of proteins versus WMH in AD
3.4.1 Power and sample sizes WMH/proteins (AD)
Post-hoc
The post-hoc test on the training set, with effect size 0.76, α error probability 0.05, n=59,
13 predictors, achieved a statistical power of  0.99. The post-hoc test on the validation
set,  with  effect  size  0.03,  α error  probability  0.05,  n=30,  20  predictors,  achieved  a
statistical power of 0.06 (Table 36). 
A priori
To  detect  an  effect  size  of  0.76  (like  in  the  training),  α error  probability  0.05,
power=0.99, 13 predictors, the required sample size of the validation set would have to
contain 59 subjects. 
However, an acceptable power would be already achieved with 0.80. To detect an effect
size of 0.76 (like in the training), α error probability 0.05, power=0.80, 13 predictors, the
required sample size of the validation set would have to contain 37 subjects (Table 36). 
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F tests – Linear multiple regression: Fixed model, R2 deviation from zero
Post hoc - achieved 
power of training set
Post hoc - achieved 
power of validation 
set
A priori – required 
sample size of 
validation set for 
power of 0.99
A priori – required 
sample size of 
validation set for 
power of 0.80
Input
Effect size f2 0.76 0.03 0.76 0.76
α error probability 0.05 0.05 0.05 0.05
Power (1- β error 
probability)
 - - -  - - - 0.99 0.80
Total sample size 59 30  - - -  - - -




44.84 0.90 44.84 28.12
Critical F 1.94 2.40 1.94 2.18
Numerator df 13 13 13 13
Denominator df 45 16 45 23
Total required sample
size
 - - -  - - - 59 37
Achieved Power (1- 
β error probability)
0.99 0.06 0.99 0.81
Table 36: Power and sample sizes WMH/proteins (AD)
3.4.2 KEGG Pathways 
In order to identify functional pathways in which the proteins associated with cerebral 
white matter lesions play a role, the detected set consisting of CXCL16 soluble, GDF11, 
Alkaline phospatase bone, lgM, Testican, CHK2, BCL2, Kallistatin, Vasoactive intestine
Peptide, CNDP1, Cathepsin H, MBD4, LCMT1,SAA, PH, FAM107B, Coagulation 
Factor 5, C1QBP, Esterase D, GPC5, STK16, MMP12, was entered in the pathways 
analysis (sequence information see appendix). Seven significant (p<0.05  Bonferroni 
corrected) pathways were found:  MicroRNAs in cancer, Cell cycle, p53 signaling 
pathway, Apoptosis, Amyotrophic lateral sclerosis (ALS), Colorectal cancer, PI3K-Akt 
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signalling pathway (Table 37). 
GO_id Term Number of Genes P-value Bonferroni corrected
5206 MicroRNAs in cancer 7 <0.05
4110 Cell cycle 6 <0.05
4151 PI3K-Akt signaling pathway 5 <0.05
4115 p53 signaling pathway 4 <0.05
4210 Apoptosis 4 <0.05
5014 Amyotrophic lateral sclerosis 3 <0.05
5210 Colorectal cancer 3 <0.05
Table 37: Significant pathways from proteins/WMH analysis
3.5 Detection of a panel of AD-cognitive decline-associated mRNA transcripts
To detect cognitive decline-associated transcripts, in individuals with AD, the rate of
cognitive decline measures, previously generated (Chapter 1), were analysed together
with mRNA transcripts. To eliminate irrelevant transcripts from the analysis a feature
selection algorithm was applied which identified 27 mRNA transcripts (out of 6,282) in
the training set. The detailed workflow is described in (Table  21). A summary of the
significance levels and test statistics can be found in (Table Error: Reference source not
found). The panel of transcripts included ALS2CR2 [Amyotrophic Lateral Sclerosis 2
Chromosomal Region Candidate Gene 2], BRD2 [bromodomain containing 2], CCR6A
[chemokine  (C-C  motif)  receptor  6],  CD81,  CHMP6 [charged  multivesicular  body
protein 6],  CNOT2 [CCR4-NOT transcription complex, subunit 2],  CTTN [cortactin],
DCTN5 [dynactin  5  (p25)],  DUSP3 [dual  specificity  phosphatase  3],  GNLY
[granulysin],  GPAA1 [glycosylphosphatidylinositol  anchor  attachment  1],  HBA2A
[hemoglobin,  alpha  2],  HLAB [major  histocompatibility  complex,  class  I,  B],
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HS.445414 [chromosome  1  open  reading  frame  132],  KIAA0355 [uncharacterized
protein],  PABPC1A [poly(A) binding protein, cytoplasmic 1], PPHLN1 [periphilin 1],
PRPF40A [PRP40  pre-mRNA  processing  factor  40  homolog  A  (S.  cerevisiae)],
PSCD1A [cytohesin  1],  REPS2 [RALBP1  associated  Eps  domain  containing  2],
RN7SL1 [RNA, 7SL, cytoplasmic 1], RNF7 [ring finger protein 7],  SLC5A6 [solute
carrier  family  5  (sodium/  glucose  cotransporter),  member  6],  TMEM137
[transmembrane protein 137], TMEM59 [transmembrane protein 59], VRK3A [vaccinia
related kinase 3], and YIF1A [Yip1 interacting factor homolog A (S. cerevisiae)].
To detect the best panel of mRNAs associated with the rate of cognitive decline, a linear
regression  function,  with  the  option  M5  enabled,  was  applied  which  included  12
transcripts from the 27 previously identified, in the model. In the training set, a very
strong correlation was found: the panel of 12 mRNA transcripts significantly predicted
the rate of cognitive decline n= 46, R2= 0.86, F(1,12)= 17.01, P<0.001 (Table 38). There
was a strong correlation in the cross-validated training set n= 46, R2= 0.75, but only little
correlation in an independent validation set n=16, R2= 0.13;  supplementary information
can be found in the appendix (Table 60).
Linear regression of cognitive decline-correlated mRNA transcripts n= 46 in the training set
Variable β Error T - value P - value
Intercept 0.0037 0.0004 9.482   6.03e-11 ***
1 CCR6A 0.0071 0.0031  2.315   0.027   *
2 CD81  -0.0027  0.0009 -2.942   0.0059 **
3 CTTN -0.0025 0.0024 -1.019   0.3157
4 GNLY  0.0032 0.0012 2.702   0.0108 *
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Linear regression of cognitive decline-correlated mRNA transcripts n= 46 in the training set
Variable β Error T - value P - value
5 GPAA1 -0.0048  0.0022 -2.214   0.0338 *
6 HBA2A -0.0075  0.0027 -2.749   0.0096 **
7 HLAB  0.0052  0.0028 1.854   0.0727 .
8 PABPC1A 0.0034 0.001   3.330   0.0022 ** 
9 PPHLN1 0.0048 0.0021 2.328   0.0262 * 
10 PSCD1A -0.005  0.0022 -2.233   0.0324 *  
11 REPS2 -0.006  0.002   -2.940   0.006  **
12 RN7SL1 0.0052 0.0018  2.898   0.0066 **
Significance codes:  0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05 ‘.’ 0.1 ‘ ’ 1
Residuals:
       Min         1Q          Median               3Q        Max 
-0.0037994 -0.0010043 -0.0002052  0.0010982  0.0035811 
Residual standard error: 0.002, Multiple R-squared: 0.86, Adjusted R-squared:  0.81
F-statistic: 17.01 on 12 DF,  p-value: 8.492e-11
Table 38: Model specification rate of cognitive decline versus mRNA
3.5.1 Power and sample sizes cognitive decline/mRNA (AD)
Post-hoc
The post-hoc test on the training set, with effect size 0.86,  α error probability 0.05, n=
46,  12  predictors,  achieved  a  statistical  power  of  0.97.  The  post-hoc  test  on  the
validation  set,  with  effect  size  0.13,  α error  probability  0.05,  n=16,  12  predictors,
achieved a statistical power of 0.06 (Table 39). 
A priori
To  detect  an  effect  size  of  0.86  (like  in  the  training),  α error  probability  0.05,
power=0.97  (like  in  the  training),  12  predictors,  the  required  sample  size  of  the
validation set would have to contain 47 subjects. 
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However, an acceptable power would be already achieved with 0.80. To detect an effect
size of 0.86 (like in the training), α error probability 0.05, power=0.80, 12 predictors, the
required sample size of the validation set would have to contain 34 subjects (Table 39). 
F tests – Linear multiple regression: Fixed model, R2 deviation from zero
Post hoc - achieved 
power of training set
Post hoc - achieved 
power of validation 
set
A priori – required 
sample size of 
validation set for 
power of 0.97
A priori – required 
sample size of 
validation set for 
power of 0.80
Input
Effect size f2 0.86 0.13 0.86 0.86
α error probability 0.05 0.05 0.05 0.05
Power (1- β error 
probability)
 - - -  - - - 0.97 0.80
Total sample size 46 16  - - -  - - -




39.56 2.08 40.42 29.24
Critical F 2.06 8.74 2.03 2.25
Numerator df 12 12 13 13
Denominator df 33 3 33 20
Total required sample
size
 - - -  - - - 47 34
Achieved Power (1- 
β error probability)
0.97 0.06 0.97 0.80
Table 39: Power and sample sizes cognitive decline/mRNA (AD)
3.5.2 KEGG Pathways
In order to identify functional pathways in which the mRNAs from the mRNA 
expression analysis of cognitive decline play a role, the detected set consisting of 
CCR6A, CD81, CTTN, GNLY, GPAA1, HBA2A, HLAB, PABPC1A, PPHLN1, 
PSCD1A, REPS2, RN7SL1, was entered in the pathway analysis (sequence information 
see appendix). 
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GO_id Term Number of Genes P-value Bonferroni corrected
563 Glycosylphosphatidylinositol(GPI)-anchor biosynthesis 3 <0.05
5144 Malaria 3 <0.05
3013 RNA transport 3 <0.05
Table 40: Significant pathways from mRNA/cognitive decline analysis
3.6 Detection of a panel of AD-cognitive decline-associated proteins
To detect cognitive decline-associated proteins, in individuals with AD, the previously
generated rate of cognitive decline measures (Chapter 1), were analysed together with
proteins. To eliminate irrelevant proteins from the analysis a feature selection algorithm
was applied which identified 15 proteins (out of 1,016) in the training set. The detailed
workflow is  described in  (Table  22).  A summary of  the  significance  levels  and test
statistics  can  be  found  in  (Table  Error:  Reference  source  not  found).  The  panel  of
proteins  included  IL2sRg [Interleukin  2  receptor],  EPOR [erythropoietin  receptor],
Hemopexin,  OX40 ligand [TNFRSF4/ Tumor Necrosis Factor Receptor Superfamily,
Member 4],  WIF1 [WNT inhibitory factor  1],  ENA78 [CXCL5/ chemokine (C-X-C
motif)  ligand 5],  Siglec9 [sialic acid binding Ig-like lectin 9],  IL19 [interleukin 19],
CRIS3 [HMGCR/  HMG-CoA  reductase],  TFPI [tissue  factor  pathway  inhibitor
(lipoprotein-associated  coagulation  inhibitor)],  CNDP1 [carnosine  dipeptidase  1
(metallopeptidase M20 family)], Thrombin [coagulation factor II (thrombin)],  ENTP3
[ectonucleoside triphosphate diphosphohydrolase 3)],  IL6 [Interleukin 6],  BST1 [bone
marrow stromal cell antigen 1], CBX5 [chromobox homolog 5]. 
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To detect the best panel of proteins associated with the rate of cognitive decline a linear
regression function, with the option M5 enabled, was applied which included 8 proteins
from the 15 previously identified, in the model. In the training set, a strong correlation
was found: the panel of 8 proteins significantly predicted the rate of cognitive decline
n=46,  R2=0.7,  F(1,12)= 11.23,  P<0.001 (Table  41). There was little correlation in the
cross-validated  training  set  n=46/  R2=  0.35,  and  no  correlation  in  an  independent
validation set n=16 /  R2= 0;  supplementary information can be found in the appendix
(Table 61). 
Linear regression of cognitive decline-correlated proteins n= 46 in the training set
Variable β Error T - value P - value
Intercept  0.0031 0.0004 8.697   1.42e-10 ***
1 EPOR 0.0057 0.0022  2.633   0.0122 *
2 OX40 ligand -0.0037 0.0021 -1.809   0.0784 .
3 ENA78 0.0097 0.0024  4.018   0.0003 ***
4 IL19 0.0064 0.0022  2.864   0.0068 ** 
5 CRIS3 -0.0166 0.0062 -2.705   0.0102 *
6 TFPI 0.0033 0.0011  3.116   0.0035 ** 
7 IL6 -0.0098 0.0049 -1.994   0.0534 . 
8 BST1 -0.0031 0.0014 -2.228   0.0319 *
Significance codes:  0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05 ‘.’ 0.1 ‘ ’ 1
Residuals:
          Min              1Q     Median         3Q        Max 
-0.0065048 -0.0007046  0.0002001  0.0008854  0.0045911 
Residual standard error: 0.00206, Multiple R-squared:  0.7,  Adjusted R-squared:  0.64
F-statistic: 11.23 on 8 DF,  p-value: 5.571e-08
Table 41: Model specification cognitive decline versus proteins
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3.6.1 Power and sample sizes cognitive decline/proteins (AD)
Post-hoc
The post-hoc test on the training set, with effect size 0.70,  α error probability 0.05, n=
46, 8 predictors, achieved a statistical power of 0.97. The validation set had zero effect
size, thus no posthoc test can be performed. 
A priori
To detect an effect size of 0.70 (like in the training),  α error probability 0.05, power=
0.97 (like in the training), 8 predictors, the required sample size of the validation set
would have to contain 45 subjects. 
However, an acceptable power would be already achieved with 0.80. To detect an effect
size of 0.70 (like in the training), α error probability 0.05, power=0.80, 8 predictors, the
required sample size of the validation set would have to contain 31 subjects (Table 42). 
 tests – Linear multiple regression: Fixed model, R2 deviation from zero
Post hoc - achieved 
power of training set
Post hoc - achieved 
power of validation 
set
A priori – required 
sample size of 
validation set for 
power of 0.97
A priori – required 
sample size of 
validation set for 
power of 0.80
Input
Effect size f2 0.70 - - - 0.70 0.70
α error probability 0.05 - - - 0.05 0.05
Power (1- β error 
probability)
 - - - - - - 0.97 0.80
Total sample size 46 - - -  - - -  - - -




32.20 - - - 31.50 21.70
Critical F 2.2 - - - 2.21 2.40
Numerator df 8 - - - 8 8




 - - - - - - 45 31
Achieved Power (1- 
β error probability)
0.97 - - - 0.97 0.81
Table 42: Power and sample sizes cognitive decline/proteins (AD)
3.6.2 KEGG pathways
In order to identify functional pathways in which the proteins associated with cognitive 
decline play a role, the detected set consisting of EPOR, OX40 ligand, ENA78, IL19, 
CRIS3, TFPI, IL6, BST1 entered in the pathways analysis (sequence information see 
appendix). 
GO_id Term Number of Genes P-value Bonferroni corrected
4630 JAK-STAT signaling pathway 10 <0.05
4060 Cytokine-cytokine receptor interaction 9 <0.05
4151 PI3K-Akt signaling pathway 6 <0.05
4917 Prolactin signaling pathway 4 <0.05
4640 Hematopoietic cell lineage 4 <0.05
5162 Measles 4 <0.05
5161 Hepatitis B 4 <0.05
5221 Acute myeloid leukemia 3 <0.05
4062 Chemokine signaling pathway 4 <0.05
5203 Viral carcinogenesis 4 <0.05
5220 Chronic myeloid leukemia 3 <0.05
4012 ErbB signaling pathway 3 <0.05
4066 HIF-1 signaling pathway 3 <0.05
5200 Pathways in cancer 4 <0.05
Table 43: Significant pathways from proteins/cognitive decline analysis
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4 Discussion
4.1 Previously identified markers of cognitive decline
A number of blood biomarkers have been suggested such as inflammatory cytokines,
oxidative  stress,  and  thrombocytic/vascular  proteins  (O'Brian  et  al.  2003;  Ho  et  al.,
2005; Whiteley et al. 2009; Skoumalova et al. 2012). These studies investigated certain
categories of proteins whereas the current study includes a large number of proteins
(1,016)  across  various  functional  domains.  Inflammation  and  vascular  factors  were
associated with neurodegeneration and the pathogenesis of dementia  (Schmidt  et  al.,
2002). However, the question arises as to whether these inflammatory blood signatures
indicate  the  presence  of  co-morbidities  which  is  often  likely  in  elderly  individuals
(Engelhart et al. 2004).
Inflammation markers of cognitive decline
Two large studies from the Netherlands, the Rotterdam study (3,874 subjects included in
analyses),  and  the  Leiden  study  (491  subjects  included  in  analyses),  investigated
cognitive decline in old age (Schram et al., 2007). These studies can be of interest for
comparison with the current study. All their analyses were adjusted for age, sex, and
eduction because these factors have an impact on cognitive decline. The current study
also  tested  for  significance  of  these  variates  and  included  them  if  they  returned
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significant in the statistical model of AD disease progression. Schram et al.  investigated
elderly individuals without dementia whereas the current study examined AD patients in
old  age.  Their  study  identified  the  cytokine  IL-6  as  associated  with  worse  global
cognition  and executive  function  (P<0.05)  as  did  the  current  study where  IL-6  was
associated with global cognitive decline (P<0.05). There could be a link to dementia
onset in the elderly subjects under investigation in the Dutch studies: dementia develops
over a long preclinical period so it could be a possible marker in the pre-dementia state
in aged individuals, or it could be an indicator of a co-morbidity shared by the aged
individual from the Dutch studies and the current study. Thus it is imperative to further
investigate  the  function  of  such candidates  before  drawing  any conclusions.  IL-6  is
possibly  worthy  of  further  investigation  because  markers  of  the  earliest  stage  of
cognitive decline are desperately needed before full-blown dementia symptoms occur.
Studies of blood markers which reported associations with cognitive decline exposed a
number  of  limitations  such as  short-follow up time (which  is  also  a  concern  in  the
current  study),  small  subject  pool,  or  the  inclusion  of  only  one  candidate  marker.
Previously,  many  studies  have  shown  minor  associations  between  inflammatory
signatures and cognitive decline but often with small effect size (Weaver et al., 2002;
Teunissen  et  al.,  2003;  Yaffe  et  al.,  2003;  Dik et  al.  2005).  However,  this  does  not
necessarily  mean  that  systemic  inflammation  is  not  a  large  contributor  to  cognitive
decline. On the contrary, it is remarkable that inflammation markers can be identified in
various  populations  with  cognitive  decline,  and  they  are  likely  to  be  involved  in
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cognitive psychophysiology (Schram et al., 2007).  
In  conclusion,  a  number  of  studies,  including  the  current  study,  show  moderate
associations  between inflammatory proteins  and cognitive  decline  but  none of  these
proteins  or  protein  panels  are  yet  fully  validated  to  predict  the  individual  cognitive
disease progression. 
Some studies reported that APOE ε4 is an important factor for cognitive decline, others
did not confirm this (Henderson et al., 1995; Nussbaum et al. 2003). In the current study,
the influence of APOE ε4 on cognitive decline was also tested in the linear mixed model
but  the  variable  did  not  return  significant.  APOE  ε4  is  considered  to  contribute  to
cognitive decline by moderating inflammatory processes. The Rotterdam study found
that IL-6 was associated with cognitive decline only in carriers of the APOE ε4 allele,
whereas, the Leiden study found an association of IL-6 and cognitive decline in both
carriers and non-carries but weaker in non-carriers (Schram et al., 2007).  The proteins
discovered could be due to chance only because they were not statistically controlled for
multiple comparisons. A strength of the current study was a machine learning method
which  takes  into  account  false  positives  in  large  datasets.  Thus,  proteins  identified
during feature selection were not merely found due to chance. However, running a post-
hoc test on IL-6 alone against cognitive decline as the dependent variable, in the current
study, reveals a model power of 0.47. A good model should at least have 0.80. However,
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IL-6 together with the other identified proteins (EPOR, OX40 ligand, ENA78, IL19,
CRIS3, TFPI, BST1) achieved a model power of 0.97 in the training set. The validation
set was too small (consisting of only 16 AD patients) to confirm this model. 
A number  of  studies  demonstrated  that  large  confluent  WMH  are  associated  with
cognitive decline and dementia (Prins, 2015). Smaller lesions might have no or minor
effects  on cognition  brain  plasticity can  compensate  for  these  areas.  WMH baseline
volumes were also associated with more aggressive cognitive decline, 3 or more points
over 6 months or 6 or more points over 12 months (Tosto et al., 2014).
Oxidative stress has an essential impact on the pathogenesis of AD and MCI and can be
detected in the form of e.g. lipid peroxidation products in the blood (Skoumalova, 2011).
These oxidative stress markers could potentially assist in the diagnosis of AD. However,
the fact that they can also be detected in diabetes and cardiovascular diseases makes an
AD specific diagnosis more difficult. 
Oxidative  stress,  the  overproduction  of  free  radicals,  has  been  described  as  a
consequence of Ab misfolding in the presence of activated microglia. In AD patients, an
enzyme  NADPH oxidase  which  facilitates  the  production  of  free  radicals  has  been
detected.  
Another factor is Fe2+ (iron) which can strongly contribute to free radical production,
especially in the most aggressive from of lipid peroxidation.  
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4.2 Novel WMH-associated mRNA transcripts – potential biomarkers?
The following hypothesis was examined in a mixed group of individuals with AD, MCI,
and cognitively normal individuals (AD|MCI|controls), and in a group containing only
individuals with AD: “there would be mRNAs and proteins in blood associated with
WMH”. The aims pursued included to find such blood signatures which could serve as
WMH blood  markers  in  future  when  validated  in  independent  cohorts.  Overall,  the
findings  suggest  that  WMH  pathology  affects  both  the  blood’s  transcriptome  and
proteome. In total,  27 mRNA transcripts and  13 proteins were associated with WMH
severity, in the feature selection which is a process for identifying statistically significant
mRNAs (here from a total of 6,282) and proteins (here from a total of 1,016 proteins).
Here, the feature selection was important to eliminate non-WMH-correlated mRNAs and
proteins  from  the  analysis.  In  addition,  the  identified  features  might  be  potential
candidates for further investigation either individually or in combination. 
4.2.1 A panel of WMH-associated mRNA transcripts in AD|MCI|controls
The key findings  of  this  study is  that  WMH volumes  at  baseline were  significantly
associated with  17 single mRNA transcripts (P<0.05), and with a panel of  12 mRNAs
(n=  138,  R2=  0.43,  P<0.001)  in  individuals  with  AD,  MCI,  or  cognitively  normal
individuals. 
The results suggest that individually the transcripts are highly correlated with WMH,
and that there is a correlation of the panel of mRNA transcripts with WMH volumes, in
 152
the training set,  but was not confirmed in the validation set.  The limitation of these
studies is that the validation sets were slightly underpowered. 
The challenges of multi-center studies are also known in large-scale multi-center trials.
In both cases studies often fail to achieve their recruitment targets, and even if there are
many participants in total they may not undergo the same battery of assessments. This
may result in an underpowered study, which, in turn, may lead to non-significant results
that nevertheless do not rule out the possibility of important insights in the research
question under investigation (Treweek et al., 2013).
Nevertheless,  the  identified  mRNAs  are  worthy  of  further  investigation  because  in
previous studies the members of the panel, ALAS2 (Xu et. al. 2010), ARFGAP1 (Stafa
et  al.  2012),  CCDC90A (Schutzer  2011),  CREB5 (Arezoo  et  al.  2011),  EOMES
(Patsopoulos et al. 2011),  FBXW4 (Soler-López et al. 2011), and  NCAPD2 (Li et al.
2009), have been found to be involved in diseases in which WMH burden is common,
such as ischemic, neurodegenerative and demyelinating disorders. Other members of the
panel  have  not been  previously  linked  to  WMH  such  as  PNKD, FAU, LILRA5,
RRAGC,  SHARPIN. 
Future work could aim to replicate these findings in larger, independent cohorts  with
special focus on the previously discovered and in this study suggested, mRNAs (ALAS
2, ARFGAP 1, CCDC 90A, CREB 5, EOMES, FBXW4, and NCAPD 2) and in addition
the novel WMH-associated mRNAs (PNKD, FAU, LILRA 5, RRAGC, and SHARPIN)
to investigate their potential as a WMH markers.
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Of  note,  5  WMH-associated  mRNA transcripts  were  not  included  this  panel  but
appeared  in  the  feature  selection  were  CC2D1B,  HS.127310,  NAG18,  NRBP2,  and
ZNRD1A.  NRBP2 was previously found by colleagues, in a related study, a blood gene
expression marker of early AD, using the same cohorts (Lunnon et al. 2013). 
4.2.2 A panel of WMH-associated mRNA transcripts in AD
The key findings of this study are that WMH volumes at baseline were significantly
associated with  17 single mRNA transcripts (P<0.05), and with a panel of  11 mRNA
transcripts (n=53, R2=0.75, P<0.001), in individuals with AD. 
The results suggest that individually the mRNA transcripts are highly correlated with
WMH, and that there is  a strong correlation of the panel of mRNA transcripts  with
WMH volumes, in the training set, but could not be confirmed in the validation set. The
limitation of this study is that the validation set consists only of 21 subjects.
Compared  to  the  previous  analysis  which  investigated  WMH-associated  mRNA
transcripts  in  AD|MCI|controls  (n=  138,  R2=  0.43,  P<0.001),  the  current  analysis
performed better by including only individuals with AD, (n= 53, R2= 0.75, P<0.001).  
In this panel of 11, only ALAS2 and NCAPD2 were highly significant (P<0.01). On an
individual  level,  EOMES  and PNKD  (P<0.001),  ARFGAP1,  CCDC90A,  FAU,
HS.127310,  LILRA5,  NAG18,  NCAPD2,  and RRAGC  (P<0.01),  were  highly
significant. 
Future work could aim to replicate these findings in larger, independent cohorts  with
special focus on the previously discovered and in this study suggested, mRNAs (ALAS
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2, ARFGAP 1, CCDC 90A, CREB 5, EOMES, FBXW4, and NCAPD 2) and in addition
the novel WMH-associated mRNAs (PNKD, FAU, HS.127310, LILRA 5, NAG 18, and
RRAGC) to investigate their potential as a WMH marker. 
4.2.3 Individual WMH-associated mRNA transcripts and their implication in biological 
processes or diseases 
The  identified  mRNA transcripts  represent  genes  or  gene  families  which  have  been
reported previously to be associated with (a) oxidative stress, (b) neuronal survival and
differentiation,  (c)  multiple  sclerosis,  (d)  dementia,  and (e)  cancer.  These  biological
processes and diseases can be linked to white matter degeneration and demyelination.
(a) Oxidative stress related mRNA transcripts
A previous study which is of high relevance to the current work, has investigated RNA
in blood of  aged individuals  and patients  diagnosed with Alzheimer's  disease.  They
found that, ALAS2, the rate-limiting enzyme of heme production, was over-expressed in
subjects with high WMH volumes. A contribution of abnormal ALAS 2 expression to
oxidative stress and cardiovascular disease has been suggested (Hall et al. 2009). They
identified  several  other  pathways  related  to  abnormally  high  WMH burden  such  as
inflammation, hormone, metabolic, and central nervous system signalling pathways, and
genes linked to oligodentrocyte proliferation, axonal repair, long term potentiation and
neurotransmission (Xu et. al. 2010). Their aim was to assess if there were significant
differences in expression levels in two groups of patients: with high amount of WMH
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and with small WMH volumes (Xu et. al. 2010). Their results suggest that WMH in
normal ageing and WMH in Alzheimer's disease share a common molecular pathology. 
Their  subjects  were  drawn  from  the  Alzheimer’s  Disease  Center  at  University  of
California Davis an independent cohort compared to the current study. In both studies,
WMH was associated with ALAS 2 expression.  Thus, it can be concluded that there is
most likely an association of WMH with ALAS 2. 
(b) Neuronal survival and differentiation-related mRNA transcripts
CREB5,  a  central  transcription  factor,  implicated  in  neuronal  survival  and
differentiation, has been found within a list of SNPs significantly associated with deep
WMH (Arezoo et al. 2011) (Table 44). 
SNP Chromosome Map position 
(bp)
Gene Location Trait 
associated 
P-value
rs2391665 7 28468319 CREB5 Intron DWMH 6.1 x 10-6
rs77993437 7 28474345 CREB5 Intron DWMH 8.4 x 10-6
rs7790864 7 28478625 CREB5 Intron DWMH 8.3 x 10-6
rs6462085 7 28479848 CREB5 Intron DWMH 9.1 x 10-6
Table 44: Deep WMH (DWMH)-related SNPs were located within genes implicated in neuronal survival 
and differentiation (CREB5) (Arezoo 2011)
(c) Multiple sclerosis-related mRNA transcripts
WMH burden in multiple sclerosis, a chronic inflammatory disease of myelin, is usually
very high  (Arezoo et al. 2011).  A recent study identified new susceptibility alleles for
multiple sclerosis: rs170934(T) at 3p24.1 (odds ratio [OR], 1.17; p = 1.6 × 10(-8)) near
EOMES  (Patsopoulos et al. 2011). Also in the current study, a link of EOMES with
WMH is suggested. 
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CCDC90A has  been  suggested  as  a  diagnostic  biomarker  for  multiple  scelerosis
(Schutzer et al. 2011). Here, the link of CCDC90A with WMH is suggested.
Demyelination,  a  characteristic  for  individuals  with  Parkinson's  a  disease,  has  been
associated with ARFGAP1 (Schutzer 2011).  SLC44A4 may modulate (auto-) immune
responses by TGF-beta (Stafa et al. 2012).  Here, the link of ARFGAP1 and SLC44A4
with WMH is suggested.
In a reconstruction study of the herpes simplex virus immuno-cytochemical evidence
demonstrated that HSV-containing organelles attached to the microtubules implicated
the trans-Golgi network marker  TGN46, a member of the TGN family  (Fujita  et  al.
2012). 
In the current study,  TGOLN2  is  associated with WMH. In several cases of herpex
simplex WMH have been observed (Lee et al. 2006). 
(d) Dementia-related mRNA transcripts
Several  of the identified mRNAs represent  genes or  gene families  which have been
previously linked to AD: NCAPD2 (Li et al. 2009), FBXW4 (Soler-López et al. 2011),
and NRBP2 (Lunnon  et.  al.  2013).  A recent  study  has  associated  NCAPD2  with
Parkinsons disease implicating SNPs in NCAPD2 (rs7311174, p = 0.05; and rs2072374,
p =  0.01)  on  chromosome  12p13  (Zhang  et  al.  2014).  This  locus  contains  genetic
variants predisposed to AD (Lee et al. 2008). UBAP1 is a risk factor for frontotemporal
lobe dementia, and possibly ischemia (Rollinson et al. 2009).
(e) Cancer-related mRNA transcripts
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Four of the WMH-associated mRNAs have been related to brain and other tumours,
NAG18  (Wimmer  et  al.  1999),  FAU  and RRAGC  (Mirrakhimov  et  al.  2013),  and
ZNRD1A which regulates BCL2 (Guo et  al  2008).  Enhanced BCL2 expression was
accompanied by increased apoptosis  in  CD4+ T cells  and natural  killer  cells  of  AD
patients (Humpel et al. 2011). BCL2 was also found in another AD biomarker study who
investigated  the  same  cohort  as  in  the  current  study  (Hye  et  al.  2014).  FAU is
differentially expressed in autism, and glioblastoma, and  RRAGC has been found in
connection with brain neoplasms, and cholangiocarcinoma  (Mirrakhimov et al. 2013).
PNKD – mutations in this gene cause paroxysmal dyskinesia, and alter protein cleavage
and stability (Shen et al. 2011). 
4.2.4 A panel of WMH-associated mRNA transcripts and their implication in biological 
pathways
One  significant  functional  pathway,  'Ribosome',  in  which  the  mRNAs  from  the
expression analysis of WMH play a role, was detected. The ribosomal transport system
can selectively move macromolecules between the nucleoplasm and cytoplasm and may
also respond to differing growth and environmental conditions (Aitchison 2000). 
A number of mutations can affect ribosomal proteins such as translation initiation factors
and  their  regulators.  Translation  factors  support  particular  steps  of  translational
activities, and such factors are necessary for translation initiation in mammalian cells.
For  instance,  eIF2,  transports  the  initiator  methionyl-tRNA (Met-tRNAiMet)  to  the
ribosome to locate the start codon19. eIF2B is the first cytosolic translation initiation
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factor to be identified as being related to human disease. Mutations in any of the genes
for  the eIF2B subunits,  for example,  EIF2B1–5,  cause a  severe autosomal recessive
neurodegenerative disorder called ‘leukoencephalopathy with vanishing white matter’
(Van der Knaap, et al 2002). 
The  fact  that  the  functional  pathway  'Ribosome'  was  identified  could  indicate  that
particular ribosomal activities are associated with increased WMH. 
4.3 Novel WMH-associated proteins – potential biomarkers?
4.3.1 A panel of WMH-associated proteins in AD|MCI|controls
The key findings  of  this  study is  that  WMH volumes  at  baseline were  significantly
associated with 27 single proteins (25 proteins at P<0.05 significance level; 2 proteins at
P<0.1 significance level), and with a panel of 20 proteins (n= 136, R2= 0.64, P<0.001) in
patients with AD, MCI, or cognitively normal individuals. 
The results  suggest  that  individually most  of  the proteins  are  highly correlated with
WMH,  and  that  there  is  a  strong  correlation  of  the  panel  of  proteins  with  WMH
volumes, in the training set, but this could not be confirmed in the validation set. 
The limitation of these studies is that the validation sets were slightly underpowered. 
Nevertheless, the identified proteins are worthy of further investigation because some
members  of  the  panel,  SAA (Chung et  al.  2000),  LCMT1 (Miyamoto  et  al.  2013),
Esterase  D (Hodler  et  al.  2012)  have  been previously associated  with  white  matter
damage. There were also individual proteins, identified by feature selection, which have
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been previously linked to white matter degeneration, such as  CathepsinH  (Han et al.
2003) (Manningen et al 2014).
In this panel of 20, CHK2 (P<0.001), GDF11, LCMT1, F5, and Esterase D (P<0.01),
were  highly  significant.  On  an  individual  level,  GDF11,  CHK2,  and  CathepsinH,
FAM107B, GPC5, and PH were highly significant (P<0.001). 
Future work could aim to replicate these findings in different, independent cohorts with
special focus on the previously discovered and in this study suggested, proteins (SAA,
LCMT1,  Esterase  D,  and Cathepsin  H),  and in  addition  the  novel  WMH-associated
proteins (GDF 11, CHK 2, FAM107B, GPC5, and PH) to investigate their potential as a
WMH/vascular disease marker. 
4.3.2 A panel of WMH-associated proteins in AD
The key findings of this study is that WMH volumes were significantly associated with
27 single  proteins  (25  proteins  at  P<0.05  significance  level;  2  proteins  at  P<0.1
significance  level),  and  with  a  panel  of  13 proteins  (n=  59,  R2= 0.76,  P<0.001)  in
individuals with AD.
The results  suggest  that  individually most  of  the proteins  are  highly correlated with
WMH,  and  that  there  is  a  strong  correlation  of  the  panel  of  proteins  with  WMH
volumes, in the training set, but this could not be confirmed in the validation set.
The limitation of these studies is that the validation sets were slightly underpowered. 
Nevertheless, the identified proteins in the panel are worthy of further investigation:
SAA has been previously associated with white matter damage (Chung et  al.  2000),
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Testican2  with bone metabolism diseases (possible underlying genetic component for
severe WMH) (Hausser et al. 2004), and CathepsinH  (Han et al. 2003). 
In this panel of 13,  GDF11,  CHK2, and  BCL2 (P<0.001),  STK16 and  CathepsinH
(P<0.01)  were  highly  significant.  On  an  individual  level,  GDF11,  CHK2,  and
CathepsinH, FAM107B, GPC5, and PH were highly significant (P<0.001). 
Future work could aim to replicate these findings in different, independent cohorts with
special focus on the previously discovered and in this study suggested, proteins (SAA,
Testican 2, and Cathepsin H), and in addition the novel WMH-associated proteins (GDF
11, CHK 2, BCL 2, STK16, FAM107B, GPC5, and PH), to investigate their potential as
a WMH marker. Such a marker could be important for patient selection in clinical trials,
if MRI images are not available the blood marker could provide the information on the
white matter status of the patients, and on possible vascular co-morbidities. It could be
that AD patients are required in trials who do not have vascular pathology,  signs of
multiple sclerosis or Parkinson's disease. In future, if the proteins could be confirmed in
larger cohorts they could serve as WMH/vascular disease biomarkers.
4.3.3 Individual WMH-associated proteins and their implication in biological processes 
or diseases 
Some of the proteins were reported in previous studies. Many of them were linked to
demylinating  diseases  such  multiple  sclerosis  and  leucoencephalocies,  rare  bone
diseases with WMH, bone and cartilage abnormalities, cancer, neurodegeneration, age,
and AD.
(a) White matter damage, multiple sclerosis,   atherosclerosis, vascularisation
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There is evidence that SAA plays a role in the neuronal loss and white matter damage
occurring  in  AD  and  in  multiple  sclerosis.  Chung  and  colleagues  used  immuno-
histochemical  methods  for  localizing  the  injury specific  apolipoprotein,  acute  phase
serum amyloid A (A-apoSAA), and have demonstrated that affected regions in brains of
individuals with AD and multiple sclerosis appeared intense, staining for A-apoSAA in
comparison to an unaffected region and non-AD/multiple sclerosis brains (Chung et al.
2000).  A  recent  study  linked  SAA  to  ischemic  lesions  in  neonatals  where  SAA
expression is  increased in response to hypoxia leading to a greater risk of mortality
(Hamed et al 2011). Another protein, linked to white matter lesions is C1QBP which is
found in viral diseases caused by mosquitoes, for example Chagas disease. One of the
pathological symptoms that is observed after infection with the virus are WMH. In the
current  study  a  possible  association  of  WMH  and  C1QBP  has  been  suggested.
Regulatory  transcription  factor  binding  sites  in  the  LCMT1 gene  promoter  include
CREB which is identified as an WMH-associated mRNA transcript in the current study.
cAMP  response  element-binding  (CREB)  is  known  to  mediate  oligdentrocyte
differentiation interfering with renewal of white matter (Chung et al. 2000). 
EsteraseD is associated with optic neuritis and can be observed in 87% of individuals
with multiple sclerosis. The disease is affecting the optic nerve and can be accompanied
by ischemic white matter lesions or result from ischemia  (Miyamoto et al. 2013). The
association of WMH and Esterase D is here suggested. Vasoactive intestal polypetide
has emerged as anti-inflammatory candidate to treat multiple sclerosis because of its
abundance in the immune system (Hodler et al. 2012). 
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Progressive brain volume loss and white matter degeneration has been detected in MRI
of  mice  with  Unverricht-Lundborg  type  progressive  myoclonus  epilepsy.  Disease-
causing mutations in CSTB are currently known which lead to reduced expression of the
cystatin B, ubiquitously expressed inhibitor of lysosomal cysteine cathepsins B, H, K, L,
and S. (Manningen et al 2014). CathepsinH has also been detected in connection with
atherosclerotic lesions (Tan & Waschek 2011). A link between cathepsin H and increased
WMH is present in the current study. 
Many of  the  proteins  have  been previously associated  with  cerebro-vascular  events.
GDF11,  a  member  of  the  TGF-β family,  facilitates  neurogenesis  and  can  possibly
improve vascularisation in the brain (Han et al. 2003). GDF11 has been associated with
accelerated rate of cognitive decline (P<0.05) (Sattlecker et al. 2014).
Elevated levels of Alkaline phosphatase can be found in patients with bone -conditions
and -tumors, and are associated with vitamin D and calcium deficiency.  Patients with
bone disease and leucoencephalocies have usually high WMH burden.  IgM plays an
important  role  in  immune responses,  increased activation of inflammatory molecules
correlates with a more demyelination, axonal loss, and WMH (Katsimpardi et al. 2014). 
Coagulation Factor V  is a  gene encoding for “Factor V“ which is a protein of the
coagulation system. Contrary to many other coagulation factors, it is not active as an
enzyme  but  as  a  cofactor.  Factor  V mutations  predispose  for  thrombosis.  Previous
literature and here F5 transcripts suggest that WMH arise in the context of vascular
events.  CYTH1 expression  occurs  in  embryonic  tissues  and stem cells,  myelinating
oligodendrocyte  cells  in  the  forebrain  white  matter.  The  gene  is  linked  to  cascades
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involving the decrease of collagen-induced vascular permeability and arthritis in mice
(Perini et al. 2006).
(b) Oxidized plasma proteins
The modification of proteins by reactive oxygen species plays an important role in AD.
Previously,  specific  oxidized  proteins  in  blood  plasma  of  AD  subjects  have  been
observed with a two- to sixfold greater specific oxidation index compared to controls,
including  isoforms  of  fibrinogen  γ-chain precursor  protein  and  of  α-1-antitrypsin
precursor. It has been postulated that these oxidized proteins could be biomarkers for
AD (Zhu et al. 2000). 
In the current study, a chemokine (C-X-C motif) ligand 16 has been associated with
WMH. Previously,  the chemokine which specifically binds to OxLDL (oxidized low
density  lipoprotein)  has  been  implicated  in  the  pathophysiology  of  atherogenesis,
oxidative damage, WMH, and autoimmune responses in multiple sclerosis  (Choi et al.
2002)  (Fukumoto  et  al.  2004).  Here,  the  association  of  CXCL16  with  WMH  is
suggested. 
In  the  current  study,  serpin  peptidase  inhibitor,  clade  A  (alpha-1  antiproteinase,
antitrypsin),  which  inhibits  human  amidolytic  and  kininogenase  activities  of  tissue
kallikrein, has been associated with WMH. Kallistatin is hypothesised to be linked to
initiation of neuro-degeneration due to the neurotrophic properties of the proteins of the
SERPINA family (Opsahl & Kennedy 2005; Horstman et al. 2010; Haider et al. 2011). 
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Coagulation factor II, which converts fibrinogen to fibrin and activates other factors V,
VII, VIII, XIII, with functions in blood homeostasis, inflammation, and wound healing,
is associated with cognitive decline in the current study.
CXCL16,  Kallistatin,  and BCL2 also appeared in a list of biomarkers suggested for
non-small cell lung-cancer identified in serum and tissue samples  (Opsahl & Kennedy
2005).  
CNDP1 has been associated with paraplegia, a disorder characterized by degeneration of
the corticospinal tracts and posterior column of the spinal cord with more prominent
WMH (Hourani et al. 2009). Sattlecker and colleagues found CNDP1 to be significant in
the classification of AD versus controls subjects (Sattlecker et al 2014). 
(c) Bone metbolism/Bone diseases
Members of the Testican family may participate in the regulation of matrix turnover in
cartilage  (Hausser  et  al.  2004).   Increased  WMH  volumes  have  been  detected  in
individuals with abnormal bone and cartilage metabolism with an underlying genetic
component. Mutations in one of two genes encoding different subunits of a receptor
signalling  complex,  TYROBP and  TREM2,  are  the  suspected  culprits  (Bock  2013).
There is potential to draw an overarching picture to mechanisms in AD involving these
two genes (Hausser et al. 2004).
(d) Cancer-related, age-related, AD-related
Variants  of  CHK2  are associated  with  various  sorts  of  cancer,  and  enhances  tau
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pathology in model organisms  (Jonsson et al. 2013). Members of the CHK family are
implicated in the cell cycle control (Iijima-Ando et al. 2010). In the current study Chk is
somehow associated with elevated WMH burden. CHK2 been associated with entorhinal
volume (P<0.05) in AD (Sattlecker et al. 2014).  CAMK2B has been significant in a
study classifying  AD  versus controls  (P<0.05)  (Sattlecker  et  al.  2014).  STK16 and
C1QBP have been linked to cognitive decline (P<0.05) in AD (Sattlecker et al. 2014).
CNDP 1 and  MMP12 were found to be significant in a classifier AD versus controls
(Sattlecker et al 2014). TWEAK was found to be significant in MCI versus converters
with  MCI to  AD (P<0.05)  (Sattlecker  et  al.  2014).  MBD4  has  not  been previously
related  to  WMH  however,  here  a  correlation  was  found.  FAM107B is  a  locus  on
chromosome 10 showing strong association  with late-onset  AD (Grupe et  al.  2006).
Later studies show that FAM107B expression is observed in tumour development and
proliferation (Nakajima et al. 2012). 
4.3.4 A panel of WMH-associated proteins and their implication in functional pathways
(a)  MicroRNAs in the cancer   pathway
MicroRNAs  are  small  (ca.  18 -  25  nucleotides)  noncoding  single-stranded  RNA
molecules  regulating  gene  expression  and  modulating  the  stability  and  translational
efficiency of mRNAs. Recently, several studies have shown that microRNAs modulate
the  response  to  ischemia  reperfusion  injury and regulate  expression  in  a  number  of
important  molecules  involved in  cell  survival  and apoptosis  (Di  et  al.  2014).  In  the
current  study,  seven  mRNAs were  implicated  in  a  functional  pathway that  includes
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microRNAs in cancer. It could be that some of them also modulate processes in response
to ischemic injuries. 
(b)  Cell cycle   and PI3K-Akt signaling pathway
In  diseases  with  WMH,  such  as  leukodystrophies,  periventricular  leucomalacia,  or
multiple sclerosis, the hypomyelination or the remyelination failure by oligodendrocyte
progenitor cells implicates errors in the sequence of processes that usually occur during
development when progenitors proliferate, migrate through the white matter, contact the
axon,  and differentiate  into  myelin-forming oligodendrocytes  (Nguyen,  2006).  Many
events underlie the progressive deterioration which is specific to demyelination.  Cell
cycle  regulating  factors  that  coordinate  progenitor  cell  division  and  the  onset  of
differentiation, i.e. the initial steps of oligodendrocyte lineage progression, are essential
in  WMH diseases.  In the current  study,  6 proteins were implicated in the cell  cycle
pathway, and 5 proteins in the PI3K-Akt signaling pathway (another important pathway
for  cell  cycle  regulation)  which  could  indicate  that  some  early  cell  developmental
processes in individuals with WMH could be abnormal. 
(c)  Apoptosis and p53   signaling pathway
Four proteins were implicated in the p53 and apoptosis  pathways. Apoptosis plays a
crucial role in cancer (Haupt 2003), and neurodegenerative diseases to eliminate excess,
damaged  or  infected  cells  (Ghavami  et  al.  2014).   Cerebrovascular  WMH  are
accompanied by apoptosis of oligodendroglia and have been suggested to appear as a
consequence of chronic cerebral ischemia (Tomimoto et al. 2003). It could be that the
four identified proteins reflect such apoptotic processes in this patient population.  
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(c) Amyotrophic Lateral Sclerosis and Colorectal cancer pathway
WMH have been found in patients  with  Amyotrophic Lateral  Sclerosis  attributed  to
disease of the gastrointestinal tract (Brown et al. 2009). The the three proteins which
were implicated in the significantly enriched pathway 'Amyotrophic Lateral Sclerosis'
play also a role in Colorectal cancer. It may be that there is an association of intestinal
diseases and WMH. 
4.4 Novel AD cognitive decline-associated mRNA transcripts – potential biomarkers 
for disease progression?
4.4.1 A panel of AD cognitive decline-associated mRNA transcripts
The key findings of this study are that the individual rates of cognitive decline (cognitive
slopes) were significantly associated with  27 single mRNA transcripts (25 mRNAs at
P<0.05; 2 mRNAs at P<0.1 significance level), and with a panel of 11 mRNA transcripts
(n=46,  R2=0.86,  P<0.001),  in  individuals  with AD, in the training set  but  only little
correlation  was  found in  an  independent  validation  set  (n=16,  R2=0.13).  The results
suggest that individually most of the mRNAs are highly correlated with the cognitive
slopes, and that there is a strong correlation of the panel of mRNAs with the slopes, in
the training set, but this could not be confirmed in the validation set. 
The limitation of these studies is that the validation sets were slightly underpowered. 
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Nevertheless, the identified mRNAs in the panel are worthy of further investigation:
TMEM137 (Ehlert et  al.  2007),  SLC5A6 (Shah et  al.  2012),  REPS2 (de Ligt et al.
2012) have been previously associated with cognitive function or decline. 
In  this  panel,  CD81, HBA2A,  PABPC1A,  REPS2,  and RN7SL1 were  highly
significant  (P<0.01).  On  an  individual  level,  ALS2CR  2  and SLC5A6  (P<0.001),
CCR6A, CNOT2, CTTN, GNLY, GPAA1, HBA2A, KIAA0355, PABPC1A, REPS2,
RN7SL1,  and TMEM59 were highly significant (P<0.01). 
Future work could aim to replicate these findings in larger, independent cohorts with
special  focus  on  the  recently  discovered,  and  in  this  study  with  cognitive  decline
associated mRNAs: TMEM 137, SLC 5A 6, REPS 2, and in addition the novel AD-
cognitive decline associated mRNAs, ALS2CR 2, CD 81, HBA 2A, PABPC 1A, RN7SL
1,  CCR 6A,  CNOT 2,  CTTN,  GNLY,  GPAA 1,  HBA 2A,  KIAA0355,  PABPC 1A,
RN7SL 1,  and TMEM 59.
4.4.2  Individual AD  cognitive  decline-associated  mRNA  transcripts  and  their
implications in biological processes or diseases
The mRNA transcripts identified in the current study represent genes or gene families
which  have  been  reported  previously to  be  associated  with  (a)  memory,  (b)  bipolar
disorder, (c) Huntington's disease, (d) Alzheimer's disease, (e) brain metabolism, (f) lipid
metabolism,  (g)  apoptosis,  (h)  sickle  cell  anemia,  and  (i)  cell  signalling.  In  these
diseases  and  conditions  symptoms  such  as  cognitive  impairment  or  rapid  cognitive




Hippocampal  CTTN levels,  phosphorylation,  and  cognitive  processing  have  been
observed to be altered during learning and long-term potentiation (Davis et al 2006). The
transcription of several DUSP genes, including  DUSP3,  is induced by ERK 1/2. The
MAPK/ERK-CREB-Zif268  cascade  contributes  to  the  consolidation  of  long-term
memory (Ekerot et al 2008).
DUSP3 has been suggested by Sattlecker and colleagues to be associated with cognitive
decline in AD (P<0.05) (Sattlecker et al 2014). CREB was associated with WMH in the
current study. VRK3A is a binding partner of DUSP3. They both play a role in the ERK
pathway important for cognitive functions such as learning and memory (Kang & Kim
2008) (Krab et al. 2008).   
(b) Mental disorder / Bipolar disorder
DCTN5 has been investigated in connection with psychiatric cognition disorders such as
bipoloar disorder and is likely to be involved in regulating neural network physiology
(MacLaren  et  al  2011).  YIF1A  has  been  linked  with  bipolar  disorder  in  a  GWAS
analysis (Sklar et al 2012). Patients with bipolar disorder often have symptoms such as
cognitive  impairment  of  memory,  attention  and  executive  functions  (Goodwin  et  al
2008).  PSCD1A interacts with ARF6 which is involved in mental disorders (Myers et
2012). CCR6 is a chemokine receptor that plays a crucial role in number of autoimmune
diseases. It has been identified in human atherosclerotic plaques, but its functional role
in atherogenesis remains unknown.  Wan and colleagues found that genetic deletion of
CCR  6  in  ApoE−/−  mice  significantly  reduced  atherosclerosis  and  macrophages  in
aortas (Wan et al. 2012). A recent study found that CCR 6 exerted effects on cognition in
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mice; higher locomotor activity and lower anxiety has been observed, and they were less
interested in new social contacts (Jaehne et al 2014).  
(c) Huntington's   disease
Another  study  presented  an  interaction  of  a  Huntingtin-associated  protein  with  a
member  of  the  DCTN family.  Huntingtin's  is  characterised  by  vast  cognitive  and
behavioural  changes  (Paulsen  2011).  PPHLN1 is  associated  with  aggregation  and
deposition of pathogenic proteins in Huntington's disease  (Tavanez et al. 2005).  Also
PRPF40A is linked to the development of Huntington's disease with implications for
nuclear toxicity and neurodegeneration (Scappini et al. 2007).  
(d)  Alzheimer's disease
TMEM59  modulates  glycosylation,  cell  surface  expression,  and  secretion  of  the
amyloid precursor protein in AD (Ullrich et al. 2010). p97, a protein found in reactive
microglia and linked to amyloid plaques, has been described as an AD marker (Ujiie et
al. 2002), and is attached to the cell surface by GPAA1 (Eisenhaber et al. 2014). EPOR
was significantly associated with hippocampal volume in AD (Sattlecker et al), and with
cognitive decline in the current study.
(e) Brain metabolism 
Brain  metabolism contributes  to  cognitive  decline in  AD and is  likely influence the
severity of the disease.  Glucose transporters such as  SLC5A  play a  role  in  AD and
diabetes for the maintenance of proper neuronal functioning including cognition (Shah
et al. 2012). 
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(f) Lipid metabolism
TMEM137  linked to Farber lipogranulomatosis,  a rare  inherited condition involving
lipid  metabolism  in  the  body.  In  affected  individuals  intellectual  disability  can  be
observed and severe neurologic deterioration  (Ehlert et al. 2007).  CD81 interacts with
galanin and vasopressin and is affecting behaviour and cognitive ageing, and can be
found in pathways of immune responses and lipid metabolism (Kadish et al. 2009).  
(g) Apoptosis 
 GNLY is involved in mediating processes which can induce apoptosis in brain cells and
play a role in cognitive impairment (de Ligt et al. 2012).  
(h) Sickle cell anaemia 
HBA2A  increased  levels  were found in  sickle  cell  anemia  (Petranovic  et  al.  2014).
Sickle cell anemia has been linked to impaired cognitive function in adults and is likely
to have a large negative effect on the brain (Ballas et al. 2010). 
(i) Cell signalling
REPS2  is  part  of a  protein complex that  regulates  the endocytosis  of  growth factor
receptors and has been related with intellectual disability (de Ligt et al. 2012). 
4.4.3  A  panel  of  AD  cognitive  decline-associated  mRNA  transcripts  and  their
implications in biological processes or diseases
(a) Glycosylphosphatidylinositol (GPI)-anchor biosynthesis pathway
About 100 diseases have recently been identified as being associated with alterations in
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the  glycosylation  pathways.  For  instance,  defects  in  the  GPI-anchor  pathway cause
muscular dystrophies (MD) (Ng & Freeze, 2014). Children with MD show cognitive
impairments, including problems with receptive language, expressive language, visuo-
spatial skills, fine-motor skills, attention, and memory skills. It could be that in the AD
patients of the current sample some glycosylation related changes occur.  
(b) Malaria
Children who had Malaria showed impairments in speech and language tasks (higher
level language functions, vocabulary, pragmatics, phonology) and cognition (non verbal
functioning) (Fernando et al. 2010). In the current study, 3 cognitive decline-associated
mRNAs were implicated in the functional Malaria pathway. 
(c) RNA transport
Differences  in  gene  expression  of  neural  processing  pathways  could  contribute  to
individual differences in maintenance or deterioration of cognitive function. There has
been  evidence  for  up-regulation  of  actin-related  processes  and  down-regulation  of
translation,  RNA  processing  and  localization,  and  vesicle-mediated  transport  in
individuals with cognitive decline (Wilmot et al 2008). Transcriptional differences in AD
patients compared to normal individuals have been reported (Blalock et al. 2004). 
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4.5 Novel AD cognitive decline-associated proteins – potential blood biomarkers for 
AD progression?
4.5.1 A panel of AD cognitive decline-associated proteins
The key findings of this study are that the individual rates of cognitive decline (cognitive
slopes) were significantly associated with  15 single proteins (13 proteins at  P<0.05; 2
proteins  at  P<0.1 significance  level),  and with a  panel  of  8 proteins  (n=46,  R2=0.7,
P<0.001), in individuals with AD, in the training set but this could not be confirmed in
the validation set. In fact, there is overtraining in the training set. Future work should
include testing a number of random training and test splits. The limitation of this study is
that the validation set includes only 16 subjects. It was expected that no validation can
be achieved with this small set. However, the results suggest that individually most of
the identified proteins are highly correlated with the cognitive slopes and that there is a
strong correlation of the panel of proteins with the slopes, in the training set. 
The limitation of these studies is that the validation sets were slightly underpowered. 
Nevertheless,  some  of  the  identified  proteins  in  the  panel  are  worthy  of  further
investigation:  IL6 (Athilingam et al. 2012),  TFPI  (Kim et al 2013) (Sattlecker et al
2014),  IL19 (Sattlecker  et  al  2014)  have  been  previously  associated  with  cognitive
decline  or  cognitive  functioning.  Also  some  of  the  proteins  not  in  the  panel,  but
identified in the feature selection, such as IL2 (Meola et al 2013), ENTPD3 (Sattlecker
et al 2014), have been linked to cognitive deterioration. 
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In  this  panel,  ENA78, IL19,  and TFPI were  highly  significant  (P<0.01).  On  an
individual level, TFPI (P<0.001), IL2sRg, ENA78, Thrombin, and BST1, were highly
significant (P<0.01). 
Future work could aim to replicate these findings in different, independent cohorts with
special  focus  on  the  recently  discovered  and  in  this  study  suggested  proteins  by
Sattlecker and colleagues TFPI, IL19, ENTPD 3, IL2sRg (Sattlecker et al. 2014), and
IL6 (Athilingam et al. 2012), and on the novel proteins ENA78, Thrombin, and BST1
here first associated with cognitive disease progression.
4.5.2  Individual  AD  cognitive  decline-associated  proteins  and  their  implications  in
biological processes or diseases
The identified AD-cognitive decline-associated proteins are implicated in pathways of
(a)  inflammation/the  immune  system,  (b)  Alzheimer's  disease,  and  (c)   Parkinson's
disease.
(a) I  nflammation/the immune system
IL2 enhances transmission of dopamine, has effects on the immune system and has led
to  neuro-degeneration  in  mice  and  worse  cognitive  performance  in  cancer  patients.
Treated with IL 2 patients show cognitive changes in spatial memory and planning. IL 2
can also increase the activity of its precursor enzyme, choline acetyltransferase which
alters  cognitive  performance  in  mice.  IL  2  is  present  in  elevated  levels  in  the
hippocampal  areas  of  post-mortem AD patients  (Meola  et  al.  2013).  Sattlecker  and
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colleagues  have  found  IL2sRg to  be  significant  in  the  classification  of  AD  versus
controls (Sattlecker et al. 2014).
IL19 can  bind  the  IL 20 receptor  complex  and  lead  to  the  activation  of  the  signal
transducer  and activator  of  transcription  3  (STAT3)  which  is  implicated  in  immune
processes and has shown anitinflammatory properties in vascular diseases (England et al
2012).
IL6 has shown an inverse association of plasma IL-6 with attention/working memory
(Athilingam  et  al.  2012).  IL-6  has  also  been  suggested  to  be  a  biomarker  of
inflammation (Fornage et al. 2008). Cytokines such as IL 6 have been implicated in in
neuropsychiatric  disorders,  and elevated levels  of this  cytokine have been associated
with cognitive impairment and heart failure (Fishman 2012).
OX40/OX40L regulates immunity by mediating propagation of T-cell responses and is
linked to  deterioration  of  immune function  with  in  advanced age  (Xia  et  al.  2000).
Sattlecker and colleagues found OX40 and WIF in a classification AD versus controls
and IL19 in MCI versus MCI converting to AD (Sattlecker et al 2014). 
(b) Alzheimer's disease 
Hippocampal EPOR was elevated in individuals with AD and MCI compared to normal
controls.  There  were  heterogenous  patterns  of  EpoR  distributions  in  the  cortex  and
hippocampus. Upregulation of EpoR in these regions could represent neuroprotective
processes  in  the  pathogenesis  of  late  onset  AD  (Assaraf  et  al.  2007).  CRIS3 Rate-
limiting  enzyme  for  cholesterol  synthesis  is  used  in  drugs  for  AD patients  (statins)
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(Assaraf  et  al.  2007).  TFPI  has  recently  been  suggested  as  a  candidate  marker  of
endothelial damage in AD, and is associated with cognitive function in AD (Kim et al
2013).  Chemokines  as  mediators  of  inflammation  have  been  implicated  in  the
pathophysiology of neurodegenerative diseases. The presence of the chemokine receptor
CXCR3 and its ligands could play a role in AD.  Findings of Sattlecker and colleagues
are here suggested:  TFPI and  ENTPD3 were significantly associated with the rate of
cognitive decline in AD (Sattlecker et al 2014).  CBX5 identified to be associated with
cognitive decline in the current study was linked to right hippocampal volume in the
study of  Sattlecker  and  colleagues  (Sattlecker  et  al.  2014).  ENA78 is  a  ligand  for
CXCR3 which is linked to the ERK1/2 pathway that is altered in AD (Xia et al. 2000).  
(c)  Parkinson's disease
BST1 has been related to Parkinson's disease risk variants in the European population
and in Japan: 4p15/BST1 (rs4698412, combined P = 1.8 × 10−6). Mental symptoms of
Parkinson's include cognitive impairment and eventually dementia resulting from a loss
of dopaminergic neurons in the substantia nigra (Myers et al. 2011). 
Two of the proteins (TFPI and  ENTPD3) have been suggested to be associated with
cognitive decline by colleagues using the same cohort (Sattlecker et al. 2014). 
4.5.3  A panel  of  AD cognitive  decline-associated  proteins  and their  implications  in
biological processes or diseases
The panel of proteins was involved in immune pathways such as JAK-STAT, cytokine-
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cytokine  interaction,  and  also  in  cell-cycle  (PI3KAkt),  prolactin,  cancer  and  viral
pathways. The main interest in connection with cognitive-decline associated proteins is
the relation to immune function, cancer and viral pathways. In particular, in the aged
population, cognitive decline can occur subsequent to the presentation of an insult to the
immune  system  which  can  be  a  surgery,  viral  infection,  or  worse,  cancer-related
(Terrando et al 2011). 
5 Model overview
The table gives a brief overview of all results obtained with WEKA software. It shows
that  the  validation  of  the  studies  is  weak to moderate  yet  (based  on the  correlation
coefficient), two of them could not validate (Table 45). In addition, there is insufficient
power of the validation sets (0-9%). Further work needs to be done, including larger
sample  sets,  better  patient  selection  (more  subjects  with  moderate  to  high  WMH
volumes, subjects with stronger decline, for instance more than 2 annual points on the
MMSE.
Strength of correlations for all models
Training – correlation  Validation - correlation




Moderate N= 46, R=0.00, R2=-0.18, 
π = 0.00
Zero
WMH/mRNA (AD) N=53, R=0.87, R2=0.75, 
π = 0.98
Strong N=21, R=0.33, R2=0.11, π
= 0.08
Moderate




Strong N=46, R=0.30, R2=0.09, π
= 0.11
Weak
WMH/proteins (AD) N=59, R=0.87, R2=0.76, 
π = 0.99
Strong N=30, R=0.17, R2=0.03, π
= 0.06
Weak
CogDec/mRNA (AD) N=46, R=0.93, R2=0.86, 
π = 0.97
Strong N=16, R=0.36, R2=0.13, π
= 0.06
Moderate
CogDec/proteins (AD) N=46, R=0.59, R2=0.35, 
π = 0.97
Moderate N=16, R=0.00, R2=0.00, π
= 0.00
Zero
Table 45: Correlation thresholds: R=Strength of correlation; π=power; π = 0.80 standard for power adequacy
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PART III:  FUTURE DIRECTIONS 
1 The potential of blood-based markers for predicting disease progression
There is a pressing lack of blood biomarkers in AD (Saad et al. 2011; Thambisetty et al.
2010;  Humpel 2011; Gupta et al. 2013). This study can contribute to facilitate future
efforts aimed to test new blood biomarkers in larger patient cohorts. In addition, the
findings  suggest  a  panel  of  candidate  mRNA and  proteins  associated  with  brain
pathology of WMH, and clinical cognitive measures of disease decline in AD, which
may  readily  serve  to  facilitate  decision-making  when  measuring  AD  progression.
Clearly, the aim is to find easily obtainable markers and blood-based biomarkers bear an
enormous potential in this respect.  The identified mRNAs and proteins might serve as
potential blood markers for WMH and AD progression which may be useful for patient
selection for clinical trials. However, they require careful validation because peripheral
blood is a complex tissue containing a huge number of proteins. Thus,  it is currently
difficult  to  use protein  biomarkers  in  most  clinical  applications.  However,  in  cancer
treatment several new proteomic technologies have been developed for early detection,
therapeutic  targeting  and,  patient-tailored  therapy  (Bazenet  &  Lovestone  2012).
Hopefully, a similar approach can be used in treatment of AD. It is often cost expensive
to validate the proteins and the techniques have been slow in the past and plasma/serum
mixtures often not uniform (can contain conterminants). Nevertheless, there are several
blood-based biomarkers, potentially important for prediction of conversion to AD and
AD  diagnosis,  recently  identified  (Lunnon  et  al.  2014).  Many  more  blood-based
biomarkers can possibly still be discovered with new, faster, quantitative methods.
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The identified  mRNA and protein  signatures  can  be  used  to  select  experiments  and
facilitate the development and evaluation of therapeutics to treat Alzheimer's disease.
The transcripts and proteins discovered during the course of this study could have the
potential to be included in a novel biomarker panel for predicting AD-specific disease
decline. Identifying how these mechanisms may vary in different patients could lead to a
new horizon in the science of pharmacogenetics. 
There is a non-negligible epigenetic impact on these signatures which can vary from cell
type to cell type. Characterising the individual codes will enable better treatment, but
also better  patient  stratification for clinical  trials  in  the first  place.  Several  vascular,
environmental, psychological and genetic risk factors can have an impact on the AD
disease progression (Lunnon et al. 2013; Kiddle et al. 2014; Hye et al. 2014; Sattlecker
et al. 2014), some of these factors can be reflected in blood signatures. The discovery of
these small molecules is challenging and sometimes described as “finding a needle in a
haystack”, however, with sufficient target selectivity relevant biomarkers such as protein
signatures can be found that correlate with drug activity. 
2 New techniques
It  can be speculated than novel  image sequences,  post-processing techniques,  and/or
imaging  markers  could  unveil  other  factors  contributing  to  (or  associated  with)  AD
disease decline. The discovery of these factors and the analysis of their relationship with
incidence of disease in patients could give new insights into AD. 
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For instance,  multiplex detection platforms using blood from AD patients have been
postulated as an efficient tool aimed to discover new biomarkers of the disease (Imtiaz et
al. 2014). Validation of biomarkers can be performed in independent cohorts and with
different classifier algorithms. These tools are capable of predicting complex signatures
for a disease but clearly more research is needed. In addition, those very sensitive tools
can also be biased, for example, blood signatures can possibly be highly dependent on
environmental factors such as diet or toxic air pollution that have also been proposed as
risk factors for AD (Moulton & Yang 2012). The use of Bayesian algorithms could be
advantageous  in  order  to  combine  empirical  evidence  with  newly  identified  blood
signatures (Liu et al. 2013). 
Moreover, gene expression analyses have recently measured presence and abundance of
RNA species (by means of microarray or RNAseq [also called Whole Transcriptome
Shotgun  Sequencing,  is  a  technology  that  uses  the  capabilities  of  next-generation
sequencing to reveal a snapshot of RNA presence and quantity from a genome at a given
moment  in  time])  in  blood  from  AD  patients.  Expression  profiling  provides  novel
insights  about  gene  behaviour  under  various  conditions.  Microarray  technology can
produce  relatively  reliable  expression  profiles.  This  technology  can  certainly  assist
formulating new biological hypothesis or help explain existing ones. However, careful
interpretation, biological replication- and follow up experiments of expression profiling
are  required,  and  the  experiments  are  time  consuming.  Global  profiling  of  gene
expression by microarray technology, comparing the expression level between normal
and pathological, may not be the best approach. It has been suggested that measures of
 181
interindividual-variation in gene expression may more effectively identify disease/trait-
associated genes  (Gorlov et al. 2014).  Associations of newly identified WMH-related
mRNAs and proteins with known AD related molecules could be investigated in future. 
One of the possible disadvantages of this approach is that it might not necessarily reflect
the blood proteome since many post-translational mechanisms can fine-tune expression
of proteins in blood cells. New emerging techniques should therefore also be considered
such as ribosome profiling which can more precisely quantify the proteins produced in
cells and at the same time provide new insights in the mechanisms of protein synthesis
(Ingolia et al.  2014). These powerful proteomic-based technologies could have many
possible applications in target discovery and validation, drug discovery and response
efficacy, disease mechanisms, patient stratification, or even clinical diagnosis. 
Another aspect to consider when studying AD is that most pioneering studies usually
show  large  disease  effect  sizes  which  are  not  always  confirmed  by  subsequent
experiments.  This  fact  highlights  the  importance  of  biological  validation  in  several
model systems and also probably the need for developing better standardized testing
tools and platforms. For example, publicly available databases of mRNA and protein
biomarker panels are needed for replication and testing the validity of various methods
and biological findings. 
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3 A blood test for Alzheimer's disease
An easily detectable  blood-based biomarker  for  AD-disease  progression has  still  not
been found. Such a biomarker would be extremely useful in clinical trials for predicting
short-term cognitive  decline,  and  thus  to  determine  more  accurately  the  efficacy of
potential treatments for Alzheimer's disease. 
The findings of this thesis can bring this goal one step closer. A number of plausible
biological  associations  have  been  identified.  Following  the  discovery  of  these
associations for assessing AD progression, the implicated panel of candidate proteins
and mRNAs will need to undergo further evaluation with other independent groups of
AD patients and in clinical trials (Figure 18). 
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Figure  18:  Three-step  process  for  biomarker  validation:  The  biological  association  establishes,  by  means  of  a
classifier,  the  link  between  image-based  or  cognitive-based  measure  and  the  underlying  molecular
functions/processes.  Subsequent  validation  can  be  performed  by  classification  of  the  mRNA  and  proteins  in
independent cohorts and in lab experiments determining their detailed function. The validated proteins and mRNA
panel identifiable with a simple blood test could qualify as endpoints in clinical trials.
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Appendices
A. Calculation of the rates of cognitive decline
CDR-SOB model of cognitive decline including WMH, atrophy, gender
Linear mixed-effects model fit by REML
 Data: final_mmse_5_points 
       AIC      BIC    logLik
  1575.671 1622.921 -775.8355
Random effects:
 Formula: ~days | id1
 Structure: General positive-definite, Log-Cholesky parametrization
            StdDev      Corr  
(Intercept) 1.799591820 (Intr)
days        0.003845308 0.121 
 Formula: ~days | site %in% id1
 Structure: General positive-definite, Log-Cholesky parametrization
            StdDev      Corr  
(Intercept) 1.799839460 (Intr)
days        0.003845465 0.121 
Residual    1.114349012       
Fixed effects: cdr ~ days + WMH + atrophy + sex 
                Value Std.Error  DF   t-value p-value
(Intercept)  38.76920  7.385170 299  5.249601  0.0000
days          0.00435  0.000750 299  5.798993  0.0000
WMH           0.00011  0.000044  80  2.490906  0.0148
atrophy     -39.46981  8.918488  80 -4.425617  0.0000
sexMale      -2.11156  0.710057  80 -2.973788  0.0039
 Correlation: 
        (Intr) days   WMH    atrphy
days    -0.004                     
WMH     -0.019 -0.004              
atrophy -0.999  0.002 -0.004       
sexMale -0.394 -0.002 -0.301  0.377
Standardized Within-Group Residuals:
         Min           Q1          Med           Q3          Max 
-3.507413362 -0.400816759 -0.005708781  0.382728121  3.934816288 
Number of Observations: 384
Number of Groups: 
          id1 site %in% id1 
           84            84 
Table 46: Protocol of linear mixed model for the calculation of the rate of cognitive decline using CDR-SOB 
assessment scores and WMH, atrophy, and gender as covariates.
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CDR-SOB model of cognitive decline including WMH, atrophy, gender, 
education, age of onset, apoe, disease duration
Linear mixed-effects model fit by REML
 Data: raw_data_5_points 
       AIC      BIC    logLik
  1598.614 1661.445 -783.3072
Random effects:
 Formula: ~days | id1
 Structure: General positive-definite, Log-Cholesky parametrization
            StdDev      Corr  
(Intercept) 1.808797407 (Intr)
days        0.003846545 0.113 
 Formula: ~days | site %in% id1
 Structure: General positive-definite, Log-Cholesky parametrization
            StdDev      Corr  
(Intercept) 1.809328411 (Intr)
days        0.003846825 0.113 
Residual    1.114204094       
Fixed effects: cdr ~ days + education + apoe + sex + atrophy + WMH + 
onset +      duration_base 
                  Value Std.Error  DF   t-value p-value
(Intercept)    46.56290 10.234640 299  4.549540  0.0000
days            0.00435  0.000750 299  5.797735  0.0000
education      -0.10266  0.072887  76 -1.408492  0.1631
apoe           -0.00964  0.069244  76 -0.139266  0.8896
sexMale        -1.93298  0.730613  76 -2.645700  0.0099
atrophy       -42.60522  9.776859  76 -4.357761  0.0000
WMH             0.00011  0.000047  76  2.293003  0.0246
onset          -0.05920  0.054395  76 -1.088380  0.2799
duration_base   0.00408  0.010710  76  0.380655  0.7045
 Correlation: 
              (Intr) days   eductn apoe   sexMal atrphy WMH    onset 
days          -0.001                                                 
education     -0.243  0.000                                          
apoe          -0.196  0.000  0.009                                   
sexMale       -0.163 -0.001 -0.070 -0.164                            
atrophy       -0.873  0.000  0.167 -0.137  0.319                     
WMH            0.127 -0.003  0.140 -0.151 -0.240 -0.039              
onset         -0.635 -0.003  0.125  0.206 -0.162  0.252 -0.218       
duration_base -0.369 -0.002  0.012 -0.025 -0.015  0.284 -0.166  0.301
Standardized Within-Group Residuals:
        Min          Q1         Med          Q3         Max 
-3.51898401 -0.40229829 -0.01051205  0.37960626  3.92883022 
Number of Observations: 384
Number of Groups: 
          id1 site %in% id1 
           84            84 
Table 47: Protocol of linear mixed model for the calculation of the rate of cognitive decline using CDR-SOB 
assessment scores and WMH, atrophy, gender, education, disease onset, disease duration, and apoe, as covariates.
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MMSE model of cognitive decline including including WMH, atrophy, 
gender
Linear mixed-effects model fit by REML
 Data: final_mmse_5_points 
       AIC      BIC    logLik
  1966.415 2013.697 -971.2073
Random effects:
 Formula: ~days | id1
 Structure: General positive-definite, Log-Cholesky parametrization
            StdDev      Corr  
(Intercept) 2.929846314 (Intr)
days        0.004597678 0.17  
 Formula: ~days | site %in% id1
 Structure: General positive-definite, Log-Cholesky parametrization
            StdDev      Corr  
(Intercept) 2.927742571 (Intr)
days        0.004598807 0.17  
Residual    1.975110168       
Fixed effects: mmse ~ days + WMH + atrophy + sex 
                Value Std.Error  DF   t-value p-value
(Intercept) -3.801763 12.101304 300 -0.314161  0.7536
days        -0.003699  0.001066 300 -3.471109  0.0006
WMH         -0.000173  0.000072  80 -2.396644  0.0189
atrophy     30.987866 14.613679  80  2.120470  0.0371
sexMale      2.432103  1.163068  80  2.091110  0.0397
 Correlation: 
        (Intr) days   WMH    atrphy
days    -0.003                     
WMH     -0.019 -0.003              
atrophy -0.999 -0.001 -0.004       
sexMale -0.395 -0.003 -0.300  0.378
Standardized Within-Group Residuals:
        Min          Q1         Med          Q3         Max 
-2.66162938 -0.50517096  0.03818177  0.55234867  2.60605259 
Number of Observations: 385
Number of Groups: 
          id1 site %in% id1 
           84            84 
Table 48: Protocol of linear mixed model for the calculation of the rate of cognitive decline using MMSE assessment 
scores and WMH, atrophy, and gender as covariates.
 213
MMSE model of cognitive decline including including WMH, atrophy, 
gender, education, age of onset, apoe, disease duration
Linear mixed-effects model fit by REML
 Data: raw_data_5_points 
       AIC     BIC    logLik
  1979.677 2042.55 -973.8383
Random effects:
 Formula: ~days | id1
 Structure: General positive-definite, Log-Cholesky parametrization
            StdDev      Corr  
(Intercept) 2.802085482 (Intr)
days        0.004640754 0.282 
 Formula: ~days | site %in% id1
 Structure: General positive-definite, Log-Cholesky parametrization
            StdDev      Corr  
(Intercept) 2.800850605 (Intr)
days        0.004634611 0.282 
Residual    1.973124029       
Fixed effects: mmse ~ days + education + apoe + sex + atrophy + WMH + 
onset +      duration_base 
                  Value Std.Error  DF   t-value p-value
(Intercept)   -18.32560 16.132594 300 -1.135937  0.2569
days           -0.00374  0.001069 300 -3.496156  0.0005
education       0.34850  0.114868  76  3.033895  0.0033
apoe            0.02728  0.109033  76  0.250158  0.8031
sexMale         2.05394  1.151418  76  1.783837  0.0784
atrophy        39.70781 15.407461  76  2.577181  0.0119
WMH            -0.00014  0.000074  76 -1.954058  0.0544
onset           0.04036  0.085742  76  0.470672  0.6392
duration_base   0.01366  0.016881  76  0.809233  0.4209
 Correlation: 
              (Intr) days   eductn apoe   sexMal atrphy WMH    onset 
days          -0.001                                                 
education     -0.243  0.001                                          
apoe          -0.196  0.002  0.009                                   
sexMale       -0.162 -0.002 -0.070 -0.163                            
atrophy       -0.873  0.002  0.167 -0.136  0.319                     
WMH            0.127 -0.004  0.140 -0.151 -0.240 -0.039              
onset         -0.636 -0.004  0.125  0.207 -0.163  0.253 -0.218       
duration_base -0.368 -0.002  0.012 -0.025 -0.015  0.284 -0.166  0.301
Standardized Within-Group Residuals:
        Min          Q1         Med          Q3         Max 
-2.70305707 -0.50868256  0.03809261  0.55789575  2.58039213 
Number of Observations: 385
Number of Groups: 
          id1 site %in% id1 
           84            84 
Table 49: Protocol of linear mixed model for the calculation of the rate of cognitive decline using MMSE assessment 
scores and WMH, atrophy, gender, education, disease onset, disease duration and APOE genotype as covariates.
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ADAS-cog model of cognitive decline including including WMH, atrophy,
gender
Linear mixed-effects model fit by REML
 Data: final_mmse_5_points 
       AIC      BIC    logLik
  2483.893 -1206.321
Random effects:
 Formula: ~days | id1
 Structure: General positive-definite, Log-Cholesky parametrization
            StdDev    Corr  
(Intercept) 6.4143455 (Intr)
days        0.0109157 0.173 
 Formula: ~days | site %in% id1
 Structure: General positive-definite, Log-Cholesky parametrization
            StdDev     Corr  
(Intercept) 6.41062259 (Intr)
days        0.01091673 0.173 
Residual    3.40142932       
Fixed effects: adas ~ days + sex + atrophy + WMH 
                Value Std.Error  DF   t-value p-value
(Intercept)  60.21001 25.983283 299  2.317260  0.0212
days          0.00529  0.002189 299  2.414890  0.0163
sexMale      -4.85282  2.498470  80 -1.942318  0.0556
atrophy     -45.69813 31.378791  80 -1.456338  0.1492
WMH           0.00033  0.000155  80  2.114972  0.0375
 Correlation: 
        (Intr) days   sexMal atrphy
days    -0.005                     
sexMale -0.394 -0.001              
atrophy -0.999  0.004  0.377       
WMH     -0.019 -0.004 -0.300 -0.004
Standardized Within-Group Residuals:
        Min          Q1         Med          Q3         Max 
-2.55022713 -0.58105258  0.04297236  0.52667560  2.34827157 
Number of Observations: 384
Number of Groups: 
          id1 site %in% id1 
           84            84 
Table 50: Protocol of linear mixed model: rate of cognitive decline based on ADAS-cog assessment with covariates 
WMH, atrophy, and gender
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ADAS-cog model of cognitive decline including including WMH, atrophy,
gender, education, age of onset, apoe, disease duration
Linear mixed-effects model fit by REML
 Data: raw_data_5_points 
       AIC      BIC    logLik
  2443.386 2506.217 -1205.693
Random effects:
 Formula: ~days | id1
 Structure: General positive-definite, Log-Cholesky parametrization
            StdDev     Corr  
(Intercept) 6.16184454 (Intr)
days        0.01093556 0.2   
 Formula: ~days | site %in% id1
 Structure: General positive-definite, Log-Cholesky parametrization
            StdDev     Corr  
(Intercept) 6.16078497 (Intr)
days        0.01093605 0.2   
Residual    3.40043494       
Fixed effects: adas ~ days + education + apoe + sex + atrophy + WMH + 
onset +      duration_base 
                  Value Std.Error  DF    t-value p-value
(Intercept)   100.33152  34.56727 299  2.9025007  0.0040
days            0.00530   0.00219 299  2.4209372  0.0161
education      -0.75087   0.24618  76 -3.0500639  0.0031
apoe           -0.12545   0.23372  76 -0.5367684  0.5930
sexMale        -3.97511   2.46803  76 -1.6106388  0.1114
atrophy       -66.54302  33.01758  76 -2.0153816  0.0474
WMH             0.00029   0.00016  76  1.8631427  0.0663
onset          -0.16012   0.18375  76 -0.8713831  0.3863
duration_base  -0.02474   0.03619  76 -0.6838194  0.4962
 Correlation: 
              (Intr) days   eductn apoe   sexMal atrphy WMH    onset 
days          -0.003                                                 
education     -0.243  0.001                                          
apoe          -0.196  0.001  0.009                                   
sexMale       -0.162 -0.001 -0.070 -0.163                            
atrophy       -0.873  0.004  0.167 -0.136  0.319                     
WMH            0.128 -0.004  0.140 -0.151 -0.240 -0.039              
onset         -0.635 -0.001  0.125  0.207 -0.163  0.252 -0.218       
duration_base -0.369 -0.001  0.012 -0.025 -0.015  0.285 -0.167  0.301
Standardized Within-Group Residuals:
        Min          Q1         Med          Q3         Max 
-2.57664622 -0.58138819  0.04073876  0.52885561  2.38275132 
Number of Observations: 384
Number of Groups: 
          id1 site %in% id1 
           84            84 
Table 51: Protocol of linear mixed model: rate of cognitive decline based on ADAS-cog assessment with covariates 
WMH, atrophy, gender, education, disease onset, duration since disease onset, and APOE genotype as covariates.
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Figure 19: 1st row: rate of cognitive decline baseline model: histogram of the CDR-SOB cognitive decline
slopes (left), Quantile-Quantile- plot of the CDR-SOB cognitive decline slopes (right); 2nd row rate of cognitive
decline baseline model:histogram of the MMSE cognitive decline slopes (left),QQ- plot of the MMSE cognitive
decline slopes (right); 3rd row: rate of cognitive decline baseline model:histogram of the ADAS-cog cognitive
decline slopes (left),QQ- plot of the ADAS-cog cognitive decline slopes (right)
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Power calculation of the CDR-SOB model – rate of cognitive decline 
http://cran.r-project.org/web/packages/longpower/vignettes/longpower.pdf (Donohue et al. 2013)
library(longpower)
liu.liang.linear.power
function (N = NULL, delta = NULL, u = NULL, v = NULL, sigma2 = 1,
          R = NULL, R.list = NULL, sig.level = 0.05, power = NULL,
          Pi = rep(1/length(u), length(u)), alternative = c("two.sided", "one.sided"))
  {
    if (sum(sapply(list(N, delta, sigma2, power, sig.level),
                   is.null)) != 1)
      stop("exactly one of 'N', 'sigma2', 'delta', 'power', and 'sig.level' must be NULL")
    if (!is.null(sig.level) && !is.numeric(sig.level) || any(0 >
                                                               sig.level | sig.level > 1))
      stop("'sig.level' must be numeric in [0, 1]")
    alternative <- match.arg(alternative)
    if (sum(c(!is.null(R), !is.null(R.list))) != 1)
      stop("Exactly one of R or R.list must be specified.")
    if (sum(Pi) != 1)
      stop("Pi must sum to 1.")
    if (!is.null(R)) {
      R.list <- lapply(1:length(u), function(i) R)
    }
    Rinv <- lapply(1:length(R.list), function(i) {
      R <- R.list[[i]]
      if (is.null(dim(R)) & length(R) == 1 & length(u[[i]]) >
            1) {
        R <- matrix(R, length(u[[i]]), length(u[[i]])) +
          diag(1 - R, length(u[[i]]))
      }
      else if (is.null(dim(R)) & length(R) == 1 & length(u[[i]]) ==
                 1) {
        R <- matrix(R, length(u[[i]]), length(u[[i]]))
      }
      return(solve(R))
    })
    n.body <- quote({
      Ipl <- 0
      for (i in 1:length(u)) Ipl <- Ipl + Pi[i] * t(u[[i]]) %*%
        Rinv[[i]] %*% v[[i]]
      Ipl <- Ipl/sigma2
      Ill <- 0
      for (i in 1:length(u)) Ill <- Ill + Pi[i] * t(v[[i]]) %*%
        Rinv[[i]] %*% v[[i]]
      Illinv <- solve(Ill/sigma2)
      Sigma1 <- 0
      for (i in 1:length(u)) Sigma1 <- Sigma1 + Pi[i] * (t(u[[i]]) -
                                                           Ipl %*% Illinv %*% t(v[[i]])) %*% Rinv[[i]] %*% (u[[i]] -
                                                                                                              v[[i]] %*% Illinv %*% t(Ipl))
      Sigma1 <- Sigma1/sigma2
      n1 <- (qnorm(1 - ifelse(alternative == "two.sided", sig.level/2,
                              sig.level)) + qnorm(power))^2/(delta %*% Sigma1 %*%
                                                               delta)[1, 1]
      n <- n1/Pi[1] * Pi
      sum(n)
    })
    if (is.null(sig.level))
      sig.level <- uniroot(function(sig.level) eval(n.body) -
                             N, c(1e-10, 1 - 1e-10))$root
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    else if (is.null(power))
      power <- uniroot(function(power) eval(n.body) - N, c(0.001, 
                                                           31 - 1e-10))$root
    else if (is.null(delta))
      delta <- uniroot(function(delta) eval(n.body) - N, c(1e-10,
                                                           1e+05))$root
    else if (is.null(sigma2))
      sigma2 <- uniroot(function(sigma2) eval(n.body) - N,
                        c(1e-10, 1e+05))$root
    N <- eval(n.body)
    METHOD <- "Longitudinal linear model power calculation (Liu & Liang, 1997)"
    structure(list(N = N, n = N * Pi, delta = delta, sigma2 = sigma2,
                   sig.level = sig.level, power = power, alternative = alternative,
                   R = R, note = "N is total sample size and n is sample size in each group.",
                   method = METHOD), class = "power.longtest")
  }
#<environment: namespace:longpower>
# var of random intercept
sig2.i = 3.23853 
# var of random slope
sig2.s = 0.000014786332 
# residual var
sig2.e = 1.2417736938 
# covariance of slope and intercep
cov.s.i <- 0.8*sqrt(sig2.i)*sqrt(sig2.s)
cov.t <- function(t1, t2, sig2.i, sig2.s, cov.s.i){




R = outer(t, t, function(x,y){cov.t(x,y, sig2.i, sig2.s, cov.s.i)})
R = R + diag(sig2.e, n, n)
u = list(u1 = t, u2 = rep(0,n))
v = list(v1 = cbind(1,1,rep(0,n)),
         v2 = cbind(1,0,t))
> liu.liang.linear.power(d=0.5, u=u, v=v, R=R, sig.level=0.05, 
power=0.80)
     Longitudinal linear model power calculation (Liu & Liang, 1997) 
              N = 89.11301
              n = 44.55651, 44.55651
          delta = 0.5
         sigma2 = 1
      sig.level = 0.05
          power = 0.8
    alternative = two.sided
 NOTE: N is total sample size and n is sample size in each group. 
 R:
         [,1]     [,2]     [,3]     [,4]     [,5]     [,6]     [,7]
[1,] 4.480304 3.239914 3.241298 3.242682 3.244066 3.245450 3.246834
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[2,] 3.239914 4.483073 3.242684 3.244069 3.245454 3.246839 3.248224
[3,] 3.241298 3.242684 4.485843 3.245456 3.246841 3.248227 3.249613
[4,] 3.242682 3.244069 3.245456 4.488616 3.248229 3.249616 3.251003
[5,] 3.244066 3.245454 3.246841 3.248229 4.491390 3.251004 3.252392
[6,] 3.245450 3.246839 3.248227 3.249616 3.251004 4.494167 3.253782
[7,] 3.246834 3.248224 3.249613 3.251003 3.252392 3.253782 4.496945
Table 52: Power calculation of the CDR-SOB model – rate of cognitive decline
B. Listing of identified mRNA, proteins and regression protocol









delta-, synthase 2 
Xp11.21 ALAS2
212
apoptotic nuclear changes, epidermis development, 
keratinization, 
mitochondrion organization, negative regulation of 
inflammatory response, positive regulation of I-kappaB 
kinase/NF-kappaB signaling, protein homooligomerization,
protein linear polyubiquitination, regulation of CD40 
signaling pathway,  







GTPase-activating protein (GAP) for the ADP ribosylation 
factor 1 (ARF1). Involved in membrane trafficking and /or 
vesicle transport. Promotes hydrolysis of the ARF1-bound 
GTP and thus, is required for the dissociation of coat 
proteins from Golgi-derived membranes and vesicles, a 
prerequisite for vesicle's fusion with target compartment. 
Probably regulates ARF1-mediated transport via its 
interaction with the KDELR proteins and RNP24. 
Overexpression induces the redistribution of the entire 







calcium ion import, mitochondrial calcium ion transport, 















binds to the cAMP response element and activates 
transcription
5 eomesodermin 3p24.1 EOMES Functions as a transcriptional activator playing a crucial 
role during development. Functions in trophoblast 
differentiation and later in gastrulation, regulating both 
mesoderm delamination and endoderm specification. Plays 
a role in brain development being required for the 
specification and the proliferation of the intermediate 
progenitor cells and their progeny in the cerebral cortex. 
Also involved in the differentiation of CD8+ T-cells during 










This gene is the cellular homolog of the fox sequence in the
Finkel-Biskis-Reilly murine sarcoma virus (FBR-MuSV). It
encodes a fusion protein consisting of the ubiquitin-like 
protein fubi at the N terminus and ribosomal protein S30 at 
the C terminus. It has been proposed that the fusion protein 
is post-translationally processed to generate free fubi and 
free ribosomal protein S30. Fubi is a member of the 
ubiquitin family, and ribosomal protein S30 belongs to the 
S30E family of ribosomal proteins. Whereas the function of
fubi is currently unknown, ribosomal protein S30 is a 
component of the 40S subunit of the cytoplasmic ribosome.
Pseudogenes derived from this gene are present in the 
genome. Similar to ribosomal protein S30, ribosomal 
proteins S27a and L40 are synthesized as fusion proteins 
with ubiquitin.





Probably recognizes and binds to some phosphorylated 
proteins and promotes their ubiquitination and degradation. 
Likely to be involved in key signaling pathways crucial for 









May plays a role in triggering innate immune responses. 
















egulatory subunit of the condensin complex, a complex 
required for conversion of interphase chromatin into 
mitotic-like condense chromosomes. The condensin 
complex probably introduces positive supercoils into 
relaxed DNA in the presence of type I topoisomerases and 
converts nicked DNA into positive knotted forms in the 
presence of type II topoisomerases. May target the 






Probable hydrolase that plays an aggravative role in the 
development of cardiac hypertrophy via activation of the 
NF-kappa- B signaling pathway












 May have a role in normal immune development and 
control of inflammation






Table 53: Description of WMH-associated mRNAs
(1b) Summary of test statistics from feature selection mRNA versus WMH 
1. ALAS
Residuals:
   Min     1Q Median     3Q    Max 
 -8591  -4560  -2870   2305  41009 
Coefficients:
                    Estimate Std. Error t value Pr(>|t|)    
(Intercept)             5282        664   7.954 6.24e-13 ***
          data$V3    12576       6356   1.979   0.0499 *  
Residual standard error: 7797 on 136 degrees of freedom
Multiple R-squared:  0.02798, Adjusted R-squared:  0.02083 




   Min     1Q Median     3Q    Max 
 -7734  -4898  -2336   2004  38821 
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Coefficients:
                    Estimate Std. Error t value Pr(>|t|)    
(Intercept)           5096.6      652.6   7.810 1.38e-12 ***
         data$V2 -12452.0     4045.6  -3.078  0.00252 ** 
Residual standard error: 7646 on 136 degrees of freedom
Multiple R-squared:  0.06512, Adjusted R-squared:  0.05825 




   Min     1Q Median     3Q    Max 
 -8591  -4560  -2870   2305  41009 
Coefficients:
                    Estimate Std. Error t value Pr(>|t|)    
(Intercept)             5282        664   7.954 6.24e-13 ***
           data$V3    12576       6356   1.979   0.0499 *  
Residual standard error: 7797 on 136 degrees of freedom
Multiple R-squared:  0.02798, Adjusted R-squared:  0.02083 




   Min     1Q Median     3Q    Max 
 -9033  -4540  -2844   2664  41030 
Coefficients:
                    Estimate Std. Error t value Pr(>|t|)    
(Intercept)           5344.9      655.6   8.152 2.09e-13 ***
         data$V4  14586.4     5208.1   2.801  0.00584 ** 
Residual standard error: 7690 on 136 degrees of freedom
Multiple R-squared:  0.05453, Adjusted R-squared:  0.04758 




   Min     1Q Median     3Q    Max 
 -7734  -4642  -2491   2054  40167 
Coefficients:
                    Estimate Std. Error t value Pr(>|t|)    
(Intercept)           5119.7      664.4   7.705 2.45e-12 ***
          data$V5  11850.8     5517.0   2.148   0.0335 *  
Residual standard error: 7777 on 136 degrees of freedom
Multiple R-squared:  0.03281, Adjusted R-squared:  0.0257 




   Min     1Q Median     3Q    Max 
 -9909  -4256  -1985   1970  37236 
Coefficients:
                    Estimate Std. Error t value Pr(>|t|)    
(Intercept)           5398.2      648.3   8.327  7.9e-14 ***
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        data$V6   9162.8     2712.9   3.378 0.000954 ***
Residual standard error: 7596 on 136 degrees of freedom
Multiple R-squared:  0.07739, Adjusted R-squared:  0.07061 




   Min     1Q Median     3Q    Max 
 -9088  -4860  -2578   2297  40098 
Coefficients:
                    Estimate Std. Error t value Pr(>|t|)    
(Intercept)           5326.0      656.2   8.116 2.55e-13 ***
        data$V7  16484.6     6039.8   2.729  0.00719 ** 
Residual standard error: 7700 on 136 degrees of freedom
Multiple R-squared:  0.05193, Adjusted R-squared:  0.04496 




   Min     1Q Median     3Q    Max 
 -9666  -4363  -2052   2297  38849 
Coefficients:
                    Estimate Std. Error t value Pr(>|t|)    
(Intercept)           5223.9      641.9   8.138 2.26e-13 ***
      data$V8 -16574.0     4495.7  -3.687 0.000327 ***
Residual standard error: 7540 on 136 degrees of freedom
Multiple R-squared:  0.09086, Adjusted R-squared:  0.08417 




   Min     1Q Median     3Q    Max 
 -8932  -4581  -2797   2448  39092 
Coefficients:
                    Estimate Std. Error t value Pr(>|t|)    
(Intercept)           5230.9      656.3   7.970 5.72e-13 ***
       data$V9 -22635.1     8500.4  -2.663  0.00868 ** 
Residual standard error: 7710 on 136 degrees of freedom
Multiple R-squared:  0.04955, Adjusted R-squared:  0.04257 




   Min     1Q Median     3Q    Max 
-10897  -4667  -2461   2481  35889 
Coefficients:
                     Estimate Std. Error t value Pr(>|t|)    
(Intercept)            4997.9      653.7   7.646 3.38e-12 ***
         data$V10  -2622.1      820.8  -3.194  0.00174 ** 
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Residual standard error: 7627 on 136 degrees of freedom
Multiple R-squared:  0.0698, Adjusted R-squared:  0.06296 




   Min     1Q Median     3Q    Max 
 -9692  -4514  -2951   1442  40159 
Coefficients:
                     Estimate Std. Error t value Pr(>|t|)    
(Intercept)            5179.9      656.7   7.888 8.98e-13 ***
        data$V11  17742.3     6655.2   2.666  0.00861 ** 
Residual standard error: 7709 on 136 degrees of freedom
Multiple R-squared:  0.04966, Adjusted R-squared:  0.04268 




   Min     1Q Median     3Q    Max 
-10994  -4501  -2370   2022  40078 
Coefficients:
                     Estimate Std. Error t value Pr(>|t|)    
(Intercept)            5098.8      649.1   7.855 1.08e-12 ***
       data$V12  11389.3     3443.8   3.307  0.00121 ** 
Residual standard error: 7608 on 136 degrees of freedom
Multiple R-squared:  0.07444, Adjusted R-squared:  0.06763 




   Min     1Q Median     3Q    Max 
 -9394  -4840  -2316   2190  40441 
Coefficients:
                     Estimate Std. Error t value Pr(>|t|)    
(Intercept)            5122.9      660.9   7.751  1.9e-12 ***
       data$V13  14507.6     5990.7   2.422   0.0168 *  
Residual standard error: 7743 on 136 degrees of freedom
Multiple R-squared:  0.04134, Adjusted R-squared:  0.03429 




   Min     1Q Median     3Q    Max 
-11900  -4185  -2136   1362  42811 
Coefficients:
                     Estimate Std. Error t value Pr(>|t|)    
(Intercept)            5318.2      640.7   8.301 9.13e-14 ***
      data$V14  21596.5     5709.6   3.783 0.000232 ***
Residual standard error: 7523 on 136 degrees of freedom
Multiple R-squared:  0.09519, Adjusted R-squared:  0.08853 





   Min     1Q Median     3Q    Max 
 -9024  -4517  -2209   1759  40666 
Coefficients:
                     Estimate Std. Error t value Pr(>|t|)    
(Intercept)            5256.6      654.1   8.036 3.97e-13 ***
       data$V15  11927.2     4199.3   2.840   0.0052 ** 
Residual standard error: 7684 on 136 degrees of freedom
Multiple R-squared:  0.056, Adjusted R-squared:  0.04905 




   Min     1Q Median     3Q    Max 
 -7668  -4485  -2604   1680  42006 
Coefficients:
                     Estimate Std. Error t value Pr(>|t|)    
(Intercept)              5178        658   7.869 9.97e-13 ***
         data$V16   -11759       4594  -2.560   0.0116 *  
Residual standard error: 7724 on 136 degrees of freedom
Multiple R-squared:  0.04596, Adjusted R-squared:  0.03895 




   Min     1Q Median     3Q    Max 
 -8213  -4811  -2467   2274  39743 
Coefficients:
                     Estimate Std. Error t value Pr(>|t|)    
(Intercept)            5166.4      660.7   7.819 1.31e-12 ***
         data$V17  13270.9     5656.0   2.346   0.0204 *  
Residual standard error: 7753 on 136 degrees of freedom
Multiple R-squared:  0.03891, Adjusted R-squared:  0.03184 
F-statistic: 5.505 on 1 and 136 DF,  p-value: 0.0204
============================================================
Signif. codes:  0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05 ‘.’ 0.1 ‘ ’ 1
Table 54: Test-statistic from selected features: mRNA versus WMH
(1c) Regression - WMH volume versus mRNA expression
In AD MCI & controls
=== Run information ===
Scheme:weka.classifiers.meta.CVParameterSelection -P "C 0.0 1.0 1.0" -P "R -5.99999999 5.0E-4 5.00000001" -X 10 -S 1 -W 
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weka.classifiers.functions.LinearRegression -- -S 0 -R 1.0E-8
Relation:     wml.rna_status-weka.filters.unsupervised.attribute.Reorder-R2,..-6282
Instances:    138
Attributes:   17
              ALAS2
              ARFGAP1
              CC2D1B
              CCDC90A
              CREB5
              EOMES
              FAU
              FBXW4
              HS.127310
              LILRA5
              NAG18
              NCAPD2
              NRBP2
              PNKD
              RRAGC
              SHARPIN
              WMH
Test mode:evaluate on training data
=== Classifier model (full training set) ===
Cross-validated Parameter selection.
Classifier: weka.classifiers.functions.LinearRegression
Cross-validation Parameter: '-C' ranged from 0.0 to 1.0 with 1.0 steps
Cross-validation Parameter: '-R' ranged from -5.99999999 to 5.0E-4 with 5.00000001 steps
Classifier Options: -C 0 -R 4.999849987497029E-4 -S 0
Linear Regression Model
WMH =
   8028.4474 * ALAS2 +
  -8191.0329 * ARFGAP1 +
   7635.5274 * CCDC90A +
   7693.6158 * CREB5 +
   5374.5716 * EOMES +
  10756.512  * FAU +
  -7732.4478 * FBXW4 +
  -1850.664  * LILRA5 +
   6559.3473 * NCAPD2 +
  10037.305  * PNKD +
   7043.0868 * RRAGC +
  -5684.4099 * SHARPIN +
   4896.4628
Time taken to build model: 0.13 seconds
=== Evaluation on training set ===
=== Summary ===
Correlation coefficient                  0.6551
Mean absolute error                   4197.2872
Root mean squared error               5931.9342
Relative absolute error                 77.1988 %
Root relative squared error             75.5584 %
Total Number of Instances              138     
=== Cross-validation ===
=== Summary ===
Correlation coefficient                  0.39  
Mean absolute error                   5436.5803
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Root mean squared error               7535.5722
Relative absolute error                 99.2728 %
Root relative squared error             95.4369 %
Total Number of Instances              138    
=== Re-evaluation on test set ===
User supplied test set
Relation:     wml.rna_status-weka.filters.unsupervised.attribute.Reorder-R2,..,-6282
Instances:     unknown (yet). Reading incrementally
Attributes:   17
=== Summary ===
Correlation coefficient                 -0.1754
Mean absolute error                   8777.6568
Root mean squared error              13373.1989
Total Number of Instances               46     
Table 55: WMH versus mRNA WEKA protocol in AD|MCI|controls
 
In AD
=== Run information ===
Scheme:weka.classifiers.meta.CVParameterSelection -P "C 0.0 1.0 1.0" -P "R -5.99999999 5.0E-4 5.00000001" -X 10 -S 1 -W 
weka.classifiers.functions.LinearRegression -- -S 0 -R 1.0E-8
Relation:     wml.rna_status-weka.filters.unsupervised.attribute.Reorder-R2,...-6282
Instances:    53
Attributes:   17
              ALAS2
              ARFGAP1
              CC2D1B
              CCDC90A
              CREB5
              EOMES
              FAU
              FBXW4
              HS.127310
              LILRA5
              NAG18
              NCAPD2
              NRBP2
              PNKD
              RRAGC
              SHARPIN
              WMH
Test mode:evaluate on training data
=== Classifier model (full training set) ===
Cross-validated Parameter selection.
Classifier: weka.classifiers.functions.LinearRegression
Cross-validation Parameter: '-C' ranged from 0.0 to 1.0 with 1.0 steps
Cross-validation Parameter: '-R' ranged from -5.99999999 to 5.0E-4 with 5.00000001 steps
Classifier Options: -C 0 -R -1.4996250087509377 -S 0
Linear Regression Model
WMH =
  14288.5648 * ALAS2 +
 -11005.0273 * ARFGAP1 +
  13310.0056 * CCDC90A +
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   6658.9233 * EOMES +
  15332.6058 * FAU +
  19844.9624 * HS.127310 +
  -1260.5952 * LILRA5 +
  17393.7616 * NAG18 +
  11779.5723 * NCAPD2 +
  16070.3286 * PNKD +
  -9128.7056 * SHARPIN +
   4500.5989
Time taken to build model: 0.15 seconds
=== Evaluation on training set ===
=== Summary ===
Correlation coefficient                  0.8666
Mean absolute error                   3032.5134
Root mean squared error               3994.3008
Relative absolute error                 57.5639 %
Root relative squared error             49.9262 %
Total Number of Instances               53     
=== Cross-validation ===
=== Summary ===
Correlation coefficient                  0.5062
Mean absolute error                   5696.7188
Root mean squared error               7712.7217
Relative absolute error                107.0533 %
Root relative squared error             95.3073 %
Total Number of Instances               53     
=== Re-evaluation on test set ===
User supplied test set
Relation:     wml.rna_status-weka.filters.unsupervised.attribute.Reorder-R2,..-6282
Instances:     unknown (yet). Reading incrementally
Attributes:   17
=== Summary ===
Correlation coefficient                  0.3366
Mean absolute error                   8607.5686
Root mean squared error              10737.527 
Total Number of Instances               21     
Table 56: WMH versus mRNA WEKA protocol in AD








1 Chemokine (C-X-C 





Chemokine (C-X-C motif) ligand 16; Acts as a scavenger 
receptor on macrophages, which specifically binds to OxLDL 









involved in pathophysiology such as atherogenesis (By 
similarity). Induces a strong chemotactic response. Induces 
calcium mobilization. Binds to CXCR6/Bonzo (273 aa)








Tumor necrosis factor (ligand) superfamily, member 12; Binds 
to FN14 and possibly also to TNRFSF12/APO3. Weak inducer 
of apoptosis in some cell types. Mediates NF-kappa-B 
activation. Promotes angiogenesis and the proliferation of 
endothelial cells. Also involved in induction of inflammatory 
cytokines (330 aa) 
3 Thyroid hormone 
receptor interactor 13 
[Source:HGNC 
Symbol;Acc:12307]  
5p15 HPV E7 Type 16
TRIP13
9319
Thyroid hormone receptor interactor 13 (432 aa)
E7 protein has both transforming and trans-activating activities. 
Disrupts the function of host retinoblastoma protein RB1/pRb, 
which is a key regulator of the cell cycle. Induces the 
disassembly of the E2F1 transcription factors from RB1, with 
subsequent transcriptional activation of E2F1-regulated S-phase 
genes. Inactivation of the ability of RB1 to arrest the cell cycle 
is critical for cellular transformation, uncontrolled cellular 
growth and proliferation induced by viral infection. Stimulation 
of progression from G1 to S phase allows the virus to efficiently
use the cellular DNA replicating machinery to achieve viral 
genome replication. Interferes with histone deacetylation 
mediated by HDAC1 and HDAC2, leading to activation of 
transcription




MRC1 - mannose receptor, C type 1; Mediates the endocytosis 
of glycoproteins by macrophages. Binds both sulfated and non-
sulfated polysaccharide chains. Acts as phagocytic receptor for 
bacteria, fungi and other pathogens
5 Growth differentiation 
factor 11
12q13.13 GDF 11 [BMP11]
10220
Secreted signal that acts globally to specify positional identity 
along the anterior/posterior axis during development. Play 
critical roles in patterning both mesodermal and neural tissues 
and in establishing the skeletal pattern (407 aa) 




Alkaline phosphatase, liver/bone/kidney; This isozyme may play
a role in skeletal mineralization 
7 IgM Xq26 CD40LG
959
CD40LG - CD40 ligand; Mediates B-cell proliferation in the 
absence of co- stimulus as well as IgE production in the 
presence of IL-4. Involved in immunoglobulin class switching
8 Fc fragment of IgG, low 
affinity IIb, receptor 
(CD32) 
1q23 FCG2B [CD32] 
2213
Receptor for the Fc region of complexed or aggregated 
immunoglobulins gamma. Low affinity receptor. Involved in a 
variety of effector and regulatory functions such as phagocytosis
of immune complexes and modulation of antibody production 
by B- cells. Binding to this receptor results in down-modulation 









receptors on B-cells (BCR), T-cells (TCR) or via another Fc 
receptor. Isoform IIB1 fails to mediate endocytosis or 
phagocytosis. Isoform IIB2 does not trigger phagocytosis 
(310 aa) 
9 Testican 2 10q22.1 SPOCK2
9806
SPOCK2 - sparc/osteonectin, cwcv and kazal-like domains 
proteoglycan (testican) 2; May participate in diverse steps of 
neurogenesis. Binds calcium
10 Calcium/calmodulin-






CaM-kinase II (CAMK2) is a prominent kinase in the central 
nervous system that may function in long-term potentiation and 
neurotransmitter release. Member of the NMDAR signalling 
complex in excitatory synapses, it may regulate NMDAR-
dependent potentiation of the AMPAR and synaptic plasticity 
(By similarity) (666 aa) 
11 Checkpoint kinase 2 22q12.1 CHK2
11200
Regulates cell cycle checkpoints and apoptosis in response to 
DNA damage, particularly to DNA double-strand breaks. 
Inhibits CDC25C phosphatase by phosphorylation on 'Ser-216', 
preventing the entry into mitosis. May also play a role in 
meiosis. Regulates the TP53 tumor suppressor through 
phosphorylation at 'Thr-18' and 'Ser-20' (586 aa)
12 B-cell Cell lymphoma 2 18q21.3 BCL2
596
Suppresses apoptosis in a variety of cell systems including 
factor-dependent lymphohematopoietic and neural cells. 
Regulates cell death by controlling the mitochondrial membrane
permeability. Appears to function in a feedback loop system 
with caspases. Inhibits caspase activity either by preventing the 
release of cytochrome c from the mitochondria and/or by 
binding to the apoptosis-activating factor (APAF-1) (239 aa) 
13 Serpin peptidase 






Inhibits human amidolytic and kininogenase activities of tissue 
kallikrein. Inhibition is achieved by formation of an equimolar, 
heat- and SDS-stable complex between the inhibitor and the 
enzyme, and generation of a small C-terminal fragment of the 
inhibitor due to cleavage at the reactive site by tissue kallikrein 
(427 aa)




Protein kinase that act on both serine and threonine residues 
(305 aa) 




VIP causes vasodilation, lowers arterial blood pressure, 
stimulates myocardial contractility, increases glycogenolysis and
relaxes the smooth muscle of trachea, stomach and gall bladder
16 Carnosine dipeptidase 1 18q22.3 CNDP1
84735
Metallopeptidase M20 family (507 aa) 
17 Cathepsin H 15q25.1 CTSH
1512














Mismatch-specific DNA N-glycosylase involved in DNA repair. 
Has thymine glycosylase activity and is specific for G-T 
mismatches within methylated and unmethylated CpG sites. Can
also remove uracil or 5-fluorouracil in G-U mismatches. Has no 
lyase activity. Was first identified as methyl-CpG-binding 
protein (580 aa) 




Methylates the carboxyl group of the C-terminal leucine residue 
of protein phosphatase 2A catalytic subunits (PPP2CA) to form 
alpha-leucine ester residues.
20 Serum amyloid A1 11p15.1 SAA1
6288
 Major acute phase reactant. Apolipoprotein of the HDL 
complex (By similarity) (122 aa) 




May be involved in tissue injury and remodelling. Has 
significant elastolytic activity. Can accept large and small amino
acids at the P1' site, but has a preference for leucine. Aromatic 
or hydrophobic residues are preferred at the P1 site, with small 
hydrophobic residues (preferably alanine) occupying P3 
(470 aa) 
22 Cytohesin 2 19q13.32 PH
9266
Promotes guanine-nucleotide exchange on ARF1, ARF3 and 
ARF6. Promotes the activation of ARF through replacement of 
GDP with GTP (399 aa)
23 FAM107B 10p14 83641 family with sequence similarity 107, member B





Central regulator of hemostasis. It serves as a critical cofactor 
for the prothrombinase activity of factor Xa that results in the 
activation of prothrombin to thrombin.
25 Complement component 




Not known. Binds to the globular "heads" of C1Q thus 
inhibiting C1 activation.







Serine hydrolase involved in the detoxification of formaldehyde 
(282 aa) 
27 Glypican 5 13q32 GPC5
2262
Cell surface proteoglycan that bears heparan sulfate (By 
similarity) (572 aa) 
Table 57: Panel of proteins associated with WMH identified with features selection




   Min     1Q Median     3Q    Max 
-12825  -5150  -2166   2667  45626 
Coefficients:
              Estimate Std. Error t value Pr(>|t|)    
(Intercept)     6478.5      728.6   8.892 3.57e-15 ***
data$V2        8615.8     3012.3   2.860  0.00491 ** 
Residual standard error: 8481 on 134 degrees of freedom
Multiple R-squared:  0.05754, Adjusted R-squared:  0.0505 




   Min     1Q Median     3Q    Max 
-12481  -5572  -2433   2655  46134 
Coefficients:
              Estimate Std. Error t value Pr(>|t|)    
(Intercept)     6261.3      733.7   8.533 2.69e-14 ***
data$V3     -16463.1     6696.5  -2.458   0.0152 *  
Residual standard error: 8546 on 134 degrees of freedom
Multiple R-squared:  0.04316, Adjusted R-squared:  0.03602 
F-statistic: 6.044 on 1 and 134 DF,  p-value: 0.01523
===========================================================
3. HPV E7 Type 16
Residuals:
   Min     1Q Median     3Q    Max 
-13685  -5603  -2403   2631  42735 
Coefficients:
              Estimate Std. Error t value Pr(>|t|)    
(Intercept)     6342.6      729.2   8.699 1.06e-14 ***
data$V4      10210.8     3742.4   2.728  0.00722 ** 
Residual standard error: 8503 on 134 degrees of freedom
Multiple R-squared:  0.05263, Adjusted R-squared:  0.04556 
F-statistic: 7.444 on 1 and 134 DF,  p-value: 0.007218
===========================================================
4. Macrophage mannose receptor
Residuals:
   Min     1Q Median     3Q    Max 
 -9471  -5427  -2697   3209  45612 
Coefficients:
              Estimate Std. Error t value Pr(>|t|)    
(Intercept)     6479.3      729.6   8.880 3.82e-15 ***
data$V5         7505.3     2687.8   2.792    0.006 ** 
Residual standard error: 8493 on 134 degrees of freedom
Multiple R-squared:  0.05499, Adjusted R-squared:  0.04794 




   Min     1Q Median     3Q    Max 
-10404  -5074  -2219   2520  43700 
Coefficients:
            Estimate Std. Error t value Pr(>|t|)    
(Intercept)   6196.4      717.4   8.637  1.5e-14 ***
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data$V6      -9878.5     2775.7  -3.559 0.000516 ***
Residual standard error: 8350 on 134 degrees of freedom
Multiple R-squared:  0.08636, Adjusted R-squared:  0.07954 
F-statistic: 12.67 on 1 and 134 DF,  p-value: 0.0005157
============================================================
6. Alkaline phosphatase bone
Residuals:
   Min     1Q Median     3Q    Max 
 -8172  -5796  -2771   2160  47934 
Coefficients:
            Estimate Std. Error t value Pr(>|t|)    
(Intercept)   6391.4      738.8   8.651 1.39e-14 ***
data$V7      -2211.7     1125.4  -1.965   0.0514 .  
Residual standard error: 8613 on 134 degrees of freedom
Multiple R-squared:  0.02802, Adjusted R-squared:  0.02076 




   Min     1Q Median     3Q    Max 
 -8517  -5610  -2347   2973  47230 
Coefficients:
            Estimate Std. Error t value Pr(>|t|)    
(Intercept)   6160.5      743.8   8.283 1.09e-13 ***
data$V8      -2400.4     1176.9  -2.040   0.0434 *  
Residual standard error: 8604 on 134 degrees of freedom
Multiple R-squared:  0.03011, Adjusted R-squared:  0.02287 




   Min     1Q Median     3Q    Max 
-11034  -5374  -2419   2224  44452 
Coefficients:
              Estimate Std. Error t value Pr(>|t|)    
(Intercept)     6466.8      730.0   8.859  4.3e-15 ***
data$V9        2422.8      879.7   2.754   0.0067 ** 
Residual standard error: 8499 on 134 degrees of freedom
Multiple R-squared:  0.05357, Adjusted R-squared:  0.04651 




   Min     1Q Median     3Q    Max 
 -9849  -5315  -2374   3911  44280 
Coefficients:
            Estimate Std. Error t value Pr(>|t|)    
(Intercept)   6459.6      728.2   8.871 4.03e-15 ***
data$V10     -11043.2     3859.1  -2.862  0.00489 ** 
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Residual standard error: 8481 on 134 degrees of freedom
Multiple R-squared:  0.05759, Adjusted R-squared:  0.05056 




   Min     1Q Median     3Q    Max 
 -8612  -5807  -2526   2379  47167 
Coefficients:
               Estimate Std. Error t value Pr(>|t|)    
(Intercept)      6285.8      734.7   8.555 2.38e-14 ***
data$V11    -12408.4     5284.4  -2.348   0.0203 *  
Residual standard error: 8562 on 134 degrees of freedom
Multiple R-squared:  0.03952, Adjusted R-squared:  0.03235 




   Min     1Q Median     3Q    Max 
 -9407  -5509  -2561   2047  48820 
Coefficients:
            Estimate Std. Error t value Pr(>|t|)    
(Intercept)   6405.1      716.5   8.940 2.73e-15 ***
data$V12    5629.9     1589.4   3.542 0.000547 ***
Residual standard error: 8354 on 134 degrees of freedom
Multiple R-squared:  0.08562, Adjusted R-squared:  0.07879 




   Min     1Q Median     3Q    Max 
 -8647  -5546  -3077   2557  47158 
Coefficients:
            Estimate Std. Error t value Pr(>|t|)    
(Intercept)   6240.1      740.5   8.427 4.88e-14 ***
data$V13    8982.5     4511.4   1.991   0.0485 *  
Residual standard error: 8610 on 134 degrees of freedom
Multiple R-squared:  0.02873, Adjusted R-squared:  0.02149 




   Min     1Q Median     3Q    Max 
-11278  -5367  -2481   2585  41953 
Coefficients:
            Estimate Std. Error t value Pr(>|t|)    
(Intercept)   6318.8      731.1   8.643 1.46e-14 ***
data$V14   -8748.9     3370.3  -2.596   0.0105 *  
Residual standard error: 8525 on 134 degrees of freedom
Multiple R-squared:  0.04788, Adjusted R-squared:  0.04077 





   Min     1Q Median     3Q    Max 
-10717  -5319  -2849   2485  45890 
Coefficients:
               Estimate Std. Error t value Pr(>|t|)    
(Intercept)      6370.5      725.7   8.778 6.79e-15 ***
data$V15      -9476.4     3194.8  -2.966  0.00357 ** 
Residual standard error: 8463 on 134 degrees of freedom
Multiple R-squared:  0.06161, Adjusted R-squared:  0.05461 
F-statistic: 8.798 on 1 and 134 DF,  p-value: 0.003571
============================================================
15. Vasoactive Intestinal Peptide
Residuals:
   Min     1Q Median     3Q    Max 
 -7892  -6004  -2947   3478  46274 
Coefficients:
            Estimate Std. Error t value Pr(>|t|)    
(Intercept)   6411.4      745.3   8.602 1.83e-14 ***
data$V16    -7786.5     5761.5  -1.351    0.179    
Residual standard error: 8677 on 134 degrees of freedom
Multiple R-squared:  0.01345, Adjusted R-squared:  0.006085 




   Min     1Q Median     3Q    Max 
 -9709  -5129  -2745   2800  43986 
Coefficients:
            Estimate Std. Error t value Pr(>|t|)    
(Intercept)   6381.1      729.1   8.751 7.91e-15 ***
data$V17     -4120.4     1507.5  -2.733  0.00712 ** 
Residual standard error: 8502 on 134 degrees of freedom
Multiple R-squared:  0.05281, Adjusted R-squared:  0.04574 




   Min     1Q Median     3Q    Max 
 -9703  -4840  -2701   2647  45699 
Coefficients:
            Estimate Std. Error t value Pr(>|t|)    
(Intercept)   6401.5      707.3   9.050 1.46e-15 ***
data$V18     11962.0     2958.7   4.043 8.86e-05 ***
Residual standard error: 8248 on 134 degrees of freedom
Multiple R-squared:  0.1087, Adjusted R-squared:  0.1021 





   Min     1Q Median     3Q    Max 
 -7237  -5926  -2869   3396  46553 
Coefficients:
            Estimate Std. Error t value Pr(>|t|)    
(Intercept)   6344.3      741.9   8.552 2.43e-14 ***
data$V19     -6175.2     3803.7  -1.623    0.107    
Residual standard error: 8652 on 134 degrees of freedom
Multiple R-squared:  0.01929, Adjusted R-squared:  0.01197 




   Min     1Q Median     3Q    Max 
 -7796  -5843  -2760   2820  47361 
Coefficients:
            Estimate Std. Error t value Pr(>|t|)    
(Intercept)   6365.2      741.1   8.589 1.97e-14 ***
data$V20     -5582.2     3261.0  -1.712   0.0893 .  
Residual standard error: 8642 on 134 degrees of freedom
Multiple R-squared:  0.0214, Adjusted R-squared:  0.0141 




   Min     1Q Median     3Q    Max 
-12727  -5190  -2460   3519  40993 
Coefficients:
            Estimate Std. Error t value Pr(>|t|)    
(Intercept)   6497.6      730.1   8.899 3.43e-15 ***
data$V21      1333.5      478.4   2.788  0.00608 ** 
Residual standard error: 8493 on 134 degrees of freedom
Multiple R-squared:  0.05481, Adjusted R-squared:  0.04776 




   Min     1Q Median     3Q    Max 
-10216  -5129  -2269   2356  46413 
Coefficients:
               Estimate Std. Error t value Pr(>|t|)    
(Intercept)      6352.6      719.7   8.827 5.17e-15 ***
data$V22     11725.0     3506.5   3.344  0.00107 ** 
Residual standard error: 8393 on 134 degrees of freedom
Multiple R-squared:  0.07702, Adjusted R-squared:  0.07013 




   Min     1Q Median     3Q    Max 
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-12876  -4864  -2321   3429  35890 
Coefficients:
            Estimate Std. Error t value Pr(>|t|)    
(Intercept)   6197.2      713.1   8.691 1.11e-14 ***
data$V23    3512.5      926.1   3.793 0.000224 ***
Residual standard error: 8302 on 134 degrees of freedom
Multiple R-squared:  0.09695, Adjusted R-squared:  0.09021 




   Min     1Q Median     3Q    Max 
-11042  -4911  -2605   2559  38846 
Coefficients:
            Estimate Std. Error t value Pr(>|t|)    
(Intercept)   6100.2      721.4   8.456 4.15e-14 ***
data$V24   6766.7     1953.5   3.464 0.000715 ***
Residual standard error: 8370 on 134 degrees of freedom
Multiple R-squared:  0.08218, Adjusted R-squared:  0.07533 
F-statistic:    12 on 1 and 134 DF,  p-value: 0.0007155
============================================================
24. Coagulation Factor V
Residuals:
   Min     1Q Median     3Q    Max 
 -9990  -5226  -2124   2795  45823 
Coefficients:
            Estimate Std. Error t value Pr(>|t|)    
(Intercept)   6129.2      737.7   8.309 9.44e-14 ***
data$V25     7476.6     2990.1   2.500   0.0136 *  
Residual standard error: 8539 on 134 degrees of freedom
Multiple R-squared:  0.04458, Adjusted R-squared:  0.03745 




   Min     1Q Median     3Q    Max 
-11983  -5453  -2046   2127  48230 
Coefficients:
            Estimate Std. Error t value Pr(>|t|)    
(Intercept)   6496.7      726.5   8.943 2.68e-15 ***
data$V26  -20017.4     6635.8  -3.017  0.00306 ** 
Residual standard error: 8454 on 134 degrees of freedom
Multiple R-squared:  0.06359, Adjusted R-squared:  0.0566 




   Min     1Q Median     3Q    Max 
 -7996  -5889  -2371   2444  47168 
Coefficients:
 238
            Estimate Std. Error t value Pr(>|t|)    
(Intercept)   6382.4      739.2   8.634 1.53e-14 ***
data$V27     -5393.6     2811.7  -1.918   0.0572 .  
Residual standard error: 8619 on 134 degrees of freedom
Multiple R-squared:  0.02673, Adjusted R-squared:  0.01946 




   Min     1Q Median     3Q    Max 
-13395  -5196  -2921   2339  40049 
Coefficients:
            Estimate Std. Error t value Pr(>|t|)    
(Intercept)   6297.3      693.6   9.079 1.23e-15 ***
data$V28      9235.1     1952.8   4.729 5.64e-06 ***
Residual standard error: 8087 on 134 degrees of freedom
Multiple R-squared:  0.143, Adjusted R-squared:  0.1366 
F-statistic: 22.37 on 1 and 134 DF,  p-value: 5.636e-06
============================================================
Signif. codes:  0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05 ‘.’ 0.1 ‘ ’ 1
Table 58: Test-statistic from selected features: proteins versus WMH
(2c) Regression -  WMH volume versus protein concentration
In AD, MCI & controls
=== Run information ===
Scheme:weka.classifiers.meta.CVParameterSelection -P "C 0.0 1.0 1.0" -P "R -5.99999999 5.0E-4 5.00000001" -X 10 -S 2 -W 
weka.classifiers.functions.LinearRegression -- -S 0 -R 1.0E-8
Relation:     wml.rna_status-weka.filters.unsupervised.attribute.Reorder-R2,..,1017,1-
weka.filters.supervised.attribute.AttributeSelection-Eweka.attributeSelection.CfsSubsetEval-Sweka.attributeSelection.BestFirst -D 
1 -N 5
Instances:    136
Attributes:   28
              CXCL16__soluble
              TWEAK
              HPV_E7_Type_16
              Macrophage_mannose_receptor
              GDF_11
              Alkaline_phosphatase__bone
              IgM
              FCG2B
              Testican_2
              CAMK2B
              Chk2
              Bcl_2
              Kallistatin
              STK16
              Vasoactive_Intestinal_Peptide
              CNDP1
              Cathepsin_H
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              MBD4
              LCMT1
              SAA
              MMP_12
              PH
              FAM107B
              Coagulation_Factor_V
              C1QBP
              Esterase_D
              GPC5
              WMH
Test mode:evaluate on training data
=== Classifier model (full training set) ===
Cross-validated Parameter selection.
Classifier: weka.classifiers.functions.LinearRegression
Cross-validation Parameter: '-C' ranged from 0.0 to 1.0 with 1.0 steps
Cross-validation Parameter: '-R' ranged from -5.99999999 to 5.0E-4 with 5.00000001 steps
Classifier Options: -C 0 -R 4.999849987497029E-4 -S 0
Linear Regression Model
WMH =
   3820.8925 * CXCL16__soluble +
  -6463.3624 * GDF_11 +
  -1644.9321 * Alkaline_phosphatase__bone +
  -1217.2272 * IgM +
  -4849.6614 * Testican_2 +
   6061.9888 * Chk2 +
   5828.7514 * Bcl_2 +
  -4397.259  * Kallistatin +
  -6794.0243 * Vasoactive_Intestinal_Peptide +
  -1917.0122 * CNDP1 +
   3635.0683 * Cathepsin_H +
  -4192.7536 * MBD4 +
  -6090.1537 * LCMT1 +
    761.025  * SAA +
   1564.6049 * PH +
   3433.2353 * FAM107B +
   6016.1942 * Coagulation_Factor_V +
  -9031.0426 * C1QBP +
  -5234.766  * Esterase_D +
   3479.6264 * GPC5 +
   6110.9159
Time taken to build model: 0.12 seconds
=== Evaluation on training set ===
=== Summary ===
Correlation coefficient                  0.8029
Mean absolute error                   3946.3203
Root mean squared error               5169.2549
Relative absolute error                 65.7989 %
Root relative squared error             59.6101 %
Total Number of Instances              136     
Time taken to build model: 0 seconds
=== Cross-validation  training set ===
Correlation coefficient                  0.4236
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Mean absolute error                   5978.64  
Root mean squared error               8390.7211
Relative absolute error                 99.1771 %
Root relative squared error             96.2715 %
Total Number of Instances              136     
=== Re-evaluation on test set ===
User supplied test set
Relation:     wml.rna_status-weka.filters.unsupervised.attribute.Remove-R2....Reorder-R2,..
Instances:     unknown (yet). Reading incrementally
Attributes:   28
=== Summary ===
Correlation coefficient                  0.2953
Mean absolute error                   7265.2504
Root mean squared error              10126.5349
Total Number of Instances               46     
Table 59: WMH versus protein concentration protocol in AD, MCI, and controls
In AD 
=== Run information ===
Scheme:weka.classifiers.meta.CVParameterSelection -P "C 0.0 1.0 1.0" -P "R -5.99999999 5.0E-4 5.00000001" -X 10 -S 1 -W 
weka.classifiers.functions.LinearRegression -- -S 0 -R 1.0E-8
Relation:     wml.rna_status-weka.filters.unsupervised.attribute.Remove-R2-..-1017
Instances:    59
Attributes:   28
              WMH
              CXCL16__soluble
              TWEAK
              HPV_E7_Type_16
              Macrophage_mannose_receptor
              GDF_11
              Alkaline_phosphatase__bone
              IgM
              FCG2B
              Testican_2
              CAMK2B
              Chk2
              Bcl_2
              Kallistatin
              STK16
              Vasoactive_Intestinal_Peptide
              CNDP1
              Cathepsin_H
              MBD4
              LCMT1
              SAA
              MMP_12
              PH
              FAM107B
              Coagulation_Factor_V
              C1QBP
              Esterase_D
              GPC5
Test mode:evaluate on training data




Cross-validation Parameter: '-C' ranged from 0.0 to 1.0 with 1.0 steps
Cross-validation Parameter: '-R' ranged from -5.99999999 to 5.0E-4 with 5.00000001 steps
Classifier Options: -C 0 -R -2.999750002500625 -S 0
Linear Regression Model
WMH =
 -11324.4264 * GDF_11 +
  -7311.199  * Testican_2 +
   7906.4421 * Chk2 +
  25193.4117 * Bcl_2 +
  -7727.4841 * Kallistatin +
  17206.7093 * STK16 +
   4576.3687 * CNDP1 +
  13432.8211 * Cathepsin_H +
  -1130.5637 * SAA +
   9192.2897 * MMP_12 +
   3772.0682 * FAM107B +
 -14788.0627 * C1QBP +
 -19285.4322 * GPC5 +
   5350.1558
Time taken to build model: 0.04 seconds
=== Evaluation on training set ===
=== Summary ===
Correlation coefficient                  0.8695
Mean absolute error                   3825.124 
Root mean squared error               4565.1257
Relative absolute error                 54.2825 %
Root relative squared error             49.8264 %
Total Number of Instances               59    
=== Cross-validation ===
=== Summary ===
Correlation coefficient                  0.3399
Mean absolute error                   7514.7552
Root mean squared error              12966.1292
Relative absolute error                104.0709 %
Root relative squared error            138.6872 %
Total Number of Instances               59    
=== Re-evaluation on test set ===
User supplied test set
Relation:     wml.rna_status-weka.filters.unsupervised.attribute.Remove-R2-..-1017
Instances:     unknown (yet). Reading incrementally
Attributes:   28
=== Summary ===
Correlation coefficient                  0.1711
Mean absolute error                   7330.0636
Root mean squared error               9574.7467
Total Number of Instances               30  
Table 60: WMH versus protein concentration protocol in AD
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(3a) Panel of mRNA transcripts associated with the rate of cognitive decline 
















STRADB - STE20-related kinase adaptor beta; 
Pseudokinase which, in complex with CAB39, binds to and 
activates STK11. Relocates STK11 from the nucleus to the 






associates with transcription complexes and with acetylated
chromatin during mitosis, and it selectively binds to the 
acetylated lysine-12 residue of histone H4 via its two 
bromodomains. The
gene maps to the major histocompatability complex (MHC)
class II region on chromosome 6p21.3, but sequence 
comparison suggests that the protein is not involved in the 
immune response. This gene has been implicated in 
juvenile myoclonic epilepsy, a common form of epilepsy 
that becomes apparent in adolescence.




Chemokine (C-C motif) receptor 6; Receptor for a C-C type
chemokine. Binds to MIP-3- alpha/LARC and subsequently
transduces a signal by increasing the intracellular calcium 
ions level 
4 CD81 molecule 11p15.5 CD81
[TSPAN28]
975
May play an important role in the regulation of lymphoma 
cell growth. Interacts with a 16-kDa Leu-13 protein to form
a complex possibly involved in signal transduction. May 






chromatin modifying protein 6; Probable core component 
of the endosomal sorting required for transport complex III 
(ESCRT-III) which is involved in multivesicular bodies 
(MVBs) formation and sorting of endosomal cargo proteins 
into MVBs. MVBs contain intraluminal vesicles (ILVs) that
are generated by invagination and scission from the limiting
membrane of the endosome and mostly are delivered to 
lysosomes enabling degradation of membrane proteins, 







The CCR4-NOT complex functions as general transcription
regulation complex









2017 SH3 motif may function as a binding region to 
cytoskeleton. Tyrosine phosphorylation in transformed cells
may contribute to cellular growth regulation and 
transformation
8 Dynactin 5 16p12.2 DCTN5
84516
This gene encodes a subunit of dynactin, a component of 
the cytoplasmic dynein motor machinery involved in 
minus-end-directed transport. The encoded protein is a 
component of the pointed-end subcomplex and is thought to
bind membranous cargo.




activity both toward tyrosine-protein phosphate as well as 
with serine-protein phosphate
10 Granulysin 2p11.2 GNLY
10578
Antimicrobial protein that kills intracellular pathogens. 
Active against a broad range of microbes, including Gram-







Essential for GPI-anchoring of precursor proteins but not 










complex, class I, B
6p21.3 HLAB
3106
B-48 alpha chain Precursor (MHC class I antigen B*48)
(Bw-48); Involved in the presentation of foreign antigens to
the immune system










Diseases associated with KIAA0355 include bipolar 
disorder.







RNA recognition motif-containing protein RRM; Binds the 
poly(A) tail of mRNA. Appears to be an important mediator
of the multiple roles of the poly(A) tail in mRNA 
biogenesis, stability and translation
17 Periphilin 1 12q12 PPHLN1
51535
Involved in epithelial differentiation and contributes to 
epidermal integrity and barrier formation





Binds to WASL/N-WASP and suppresses its translocation 
from the nucleus to the cytoplasm, thereby inhibiting its 
cytoplasmic function. May be involved in pre-mRNA 
splicing
19 Cytohesin 1 2q11.2  PSCD1A
[CYTIP]
The protein encoded by this gene contains 2 leucine zipper 
domains and a putative C-terminal nuclear targeting signal, 
but does not have any hydrophobic regions. This protein is 





Involved in growth factor signaling through its influence on















The signal recognition particle (SRP) is a cytoplasmic 
ribonucleoprotein complex that mediates cotranslational 
insertion of secretory proteins into the lumen of the 
endoplasmic reticulum.




Ring finger protein 7; Probable component of the SCF 
(SKP1-CUL1-F-box protein) E3 ubiquitin ligase complex 
which mediates the ubiquitination and subsequent 
proteasomal degradation of target proteins involved in cell 
cycle progression, signal transduction and transcription. 
Through the RING-type zinc finger, seems to recruit the E2 
ubiquitination enzyme to the complex and brings it into 
close proximity to the substrate. Promotes the neddylation 
of CUL5 via its interaction with UBE2F. May play a role in
protecting cells from apoptosis induced by redox agents
23 Solute carrier 














Isoform 1 may function as a nuclear receptor coactivator, 
enhancing transcription through other coactivators such as 
NCOA6 and CITED1. Isoform 2, functions as a 
transcriptional repressor, modulating transcriptional 






Diseases associated with TMEM59 include liver disease, 
and Alzheimer's disease. Annotations related to this gene 
include endopeptidase activity. 
26 Vaccinia related 
kinase 3
VRK3A required for catalysis




Possible role in transport between endoplasmic reticulum 
and Golgi
Table 61:  Description of cognitive decline-associated mRNAs from feature selection




       Min         1Q     Median         3Q        Max 
-0.0082182 -0.0022373 -0.0005406  0.0019186  0.0121887 
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Coefficients:
             Estimate Std. Error t value Pr(>|t|)    
(Intercept) 0.0038628  0.0005907    6.54 5.42e-08 ***
data$V1     0.0130603  0.0035108    3.72 0.000561 ***
Residual standard error: 0.003908 on 44 degrees of freedom
Multiple R-squared:  0.2393, Adjusted R-squared:  0.222 




       Min         1Q     Median         3Q        Max 
-0.0095582 -0.0027261 -0.0004228  0.0018599  0.0129412 
Coefficients:
              Estimate Std. Error t value Pr(>|t|)    
(Intercept)  0.0029644  0.0006513   4.552 4.17e-05 ***
data$V2     -0.0131997  0.0058109  -2.272   0.0281 *  
Residual standard error: 0.004239 on 44 degrees of freedom
Multiple R-squared:  0.105, Adjusted R-squared:  0.08462 




       Min         1Q     Median         3Q        Max 
-0.0067004 -0.0028614 -0.0003312  0.0018301  0.0140134 
Coefficients:
             Estimate Std. Error t value Pr(>|t|)    
(Intercept) 0.0031473  0.0006098   5.162 5.65e-06 ***
data$V3     0.0156003  0.0053347   2.924  0.00544 ** 
Residual standard error: 0.0041 on 44 degrees of freedom
Multiple R-squared:  0.1627, Adjusted R-squared:  0.1437 




       Min         1Q     Median         3Q        Max 
-0.0110388 -0.0025620 -0.0002307  0.0017755  0.0119764 
Coefficients:
              Estimate Std. Error t value Pr(>|t|)    
(Intercept)  0.0024982  0.0006429   3.886 0.000339 ***
data$V4     -0.0057519  0.0016938  -3.396 0.001460 ** 
Residual standard error: 0.003989 on 44 degrees of freedom
Multiple R-squared:  0.2077, Adjusted R-squared:  0.1897 




       Min         1Q     Median         3Q        Max 
-0.0085210 -0.0030074 -0.0009156  0.0028689  0.0138606 
Coefficients:
              Estimate Std. Error t value Pr(>|t|)    
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(Intercept)  0.0033083  0.0006175   5.357 2.94e-06 ***
data$V5     -0.0111040  0.0043663  -2.543   0.0146 *  
Residual standard error: 0.004184 on 44 degrees of freedom
Multiple R-squared:  0.1281, Adjusted R-squared:  0.1083 




       Min         1Q     Median         3Q        Max 
-0.0074426 -0.0029448  0.0000664  0.0019593  0.0122247 
Coefficients:
              Estimate Std. Error t value Pr(>|t|)    
(Intercept)  0.0036227  0.0006163   5.878  5.1e-07 ***
data$V6     -0.0197117  0.0071450  -2.759  0.00842 ** 
Residual standard error: 0.004137 on 44 degrees of freedom
Multiple R-squared:  0.1475, Adjusted R-squared:  0.1281 




       Min         1Q     Median         3Q        Max 
-0.0097493 -0.0021147 -0.0001392  0.0017233  0.0095500 
Coefficients:
             Estimate Std. Error t value Pr(>|t|)    
(Intercept) 0.0036828  0.0006124   6.014 3.22e-07 ***
data$V7     0.0072192  0.0024491   2.948  0.00511 ** 
Residual standard error: 0.004095 on 44 degrees of freedom
Multiple R-squared:  0.1649, Adjusted R-squared:  0.1459 




       Min         1Q     Median         3Q        Max 
-0.0081032 -0.0024563 -0.0004236  0.0017436  0.0162222 
Coefficients:
              Estimate Std. Error t value Pr(>|t|)    
(Intercept)  0.0032876  0.0006313   5.207 4.85e-06 ***
data$V8     -0.0101979  0.0048498  -2.103   0.0412 *  
Residual standard error: 0.004271 on 44 degrees of freedom
Multiple R-squared:  0.09131, Adjusted R-squared:  0.07066 




       Min         1Q     Median         3Q        Max 
-0.0087018 -0.0025532 -0.0005423  0.0010816  0.0136325 
Coefficients:
              Estimate Std. Error t value Pr(>|t|)    
(Intercept)  0.0033680  0.0006353   5.302 3.54e-06 ***
data$V9     -0.0099663  0.0052562  -1.896   0.0645 .  
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Residual standard error: 0.004308 on 44 degrees of freedom
Multiple R-squared:  0.07554, Adjusted R-squared:  0.05453 




       Min         1Q     Median         3Q        Max 
-0.0082926 -0.0025632 -0.0004306  0.0015250  0.0134168 
Coefficients:
             Estimate Std. Error t value Pr(>|t|)    
(Intercept) 0.0039799  0.0006163   6.457 7.17e-08 ***
data$V10    0.0072559  0.0021663   3.349  0.00167 ** 
Residual standard error: 0.004 on 44 degrees of freedom
Multiple R-squared:  0.2032, Adjusted R-squared:  0.1851 




       Min         1Q     Median         3Q        Max 
-0.0072480 -0.0030077 -0.0004425  0.0017410  0.0118674 
Coefficients:
              Estimate Std. Error t value Pr(>|t|)    
(Intercept)  0.0031190  0.0006073   5.136 6.15e-06 ***
data$V11    -0.0121484  0.0040165  -3.025  0.00415 ** 
Residual standard error: 0.004077 on 44 degrees of freedom
Multiple R-squared:  0.1721, Adjusted R-squared:  0.1533 




       Min         1Q     Median         3Q        Max 
-0.0077682 -0.0023379 -0.0007443  0.0019249  0.0143548 
Coefficients:
             Estimate Std. Error t value Pr(>|t|)    
(Intercept)  0.003342   0.000585   5.713 8.91e-07 ***
data$V12    -0.017587   0.005049  -3.484  0.00113 ** 
Residual standard error: 0.003967 on 44 degrees of freedom
Multiple R-squared:  0.2162, Adjusted R-squared:  0.1984 




       Min         1Q     Median         3Q        Max 
-0.0073274 -0.0030150 -0.0003404  0.0024477  0.0140755 
Coefficients:
             Estimate Std. Error t value Pr(>|t|)    
(Intercept) 0.0033052  0.0006256   5.283 3.77e-06 ***
data$V13    0.0121420  0.0053237   2.281   0.0275 *  
Residual standard error: 0.004237 on 44 degrees of freedom
Multiple R-squared:  0.1057, Adjusted R-squared:  0.0854 
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       Min         1Q     Median         3Q        Max 
-0.0088409 -0.0016793 -0.0006719  0.0019849  0.0136966 
Coefficients:
             Estimate Std. Error t value Pr(>|t|)    
(Intercept) 0.0031836  0.0006199   5.136 6.15e-06 ***
data$V14    0.0094169  0.0036279   2.596   0.0128 *  
Residual standard error: 0.004173 on 44 degrees of freedom
Multiple R-squared:  0.1328, Adjusted R-squared:  0.1131 




       Min         1Q     Median         3Q        Max 
-0.0096253 -0.0025727 -0.0007016  0.0020459  0.0109879 
Coefficients:
              Estimate Std. Error t value Pr(>|t|)    
(Intercept)  0.0034726  0.0006055   5.735 8.27e-07 ***
data$V15    -0.0095739  0.0032793  -2.920  0.00551 ** 
Residual standard error: 0.004101 on 44 degrees of freedom
Multiple R-squared:  0.1623, Adjusted R-squared:  0.1432 




       Min         1Q     Median         3Q        Max 
-0.0087138 -0.0028665 -0.0006023  0.0017318  0.0118942 
Coefficients:
             Estimate Std. Error t value Pr(>|t|)    
(Intercept) 0.0032158  0.0006135   5.242 4.32e-06 ***
data$V16    0.0055342  0.0020179   2.743  0.00878 ** 
Residual standard error: 0.004141 on 44 degrees of freedom
Multiple R-squared:  0.146, Adjusted R-squared:  0.1266 




       Min         1Q     Median         3Q        Max 
-0.0098591 -0.0027344 -0.0004713  0.0023597  0.0130339 
Coefficients:
             Estimate Std. Error t value Pr(>|t|)    
(Intercept) 0.0032582  0.0006141   5.306 3.49e-06 ***
data$V17    0.0101081  0.0037629   2.686   0.0102 *  
Residual standard error: 0.004153 on 44 degrees of freedom
Multiple R-squared:  0.1409, Adjusted R-squared:  0.1214 





      Min        1Q    Median        3Q       Max 
-0.009820 -0.002485 -0.001213  0.002292  0.014889 
Coefficients:
             Estimate Std. Error t value Pr(>|t|)    
(Intercept) 0.0030994  0.0006298   4.921 1.25e-05 ***
data$V18    0.0130702  0.0053070   2.463   0.0178 *  
Residual standard error: 0.004201 on 44 degrees of freedom
Multiple R-squared:  0.1212, Adjusted R-squared:  0.1012 




       Min         1Q     Median         3Q        Max 
-0.0098846 -0.0027833 -0.0002113  0.0012543  0.0137247 
Coefficients:
              Estimate Std. Error t value Pr(>|t|)    
(Intercept)  0.0037248  0.0006781   5.493 1.87e-06 ***
data$V19    -0.0076177  0.0047949  -1.589    0.119    
Residual standard error: 0.004358 on 44 degrees of freedom
Multiple R-squared:  0.05425, Adjusted R-squared:  0.03276 




       Min         1Q     Median         3Q        Max 
-0.0086229 -0.0024903 -0.0001709  0.0015716  0.0113907 
Coefficients:
              Estimate Std. Error t value Pr(>|t|)    
(Intercept)  0.0039773  0.0006465   6.153 2.01e-07 ***
data$V20    -0.0113536  0.0040937  -2.773  0.00811 ** 
Residual standard error: 0.004134 on 44 degrees of freedom
Multiple R-squared:  0.1488, Adjusted R-squared:  0.1295 




       Min         1Q     Median         3Q        Max 
-0.0091788 -0.0022480 -0.0007017  0.0019973  0.0120271 
Coefficients:
             Estimate Std. Error t value Pr(>|t|)    
(Intercept) 0.0041607  0.0006261   6.645  3.8e-08 ***
data$V21    0.0114198  0.0032744   3.488  0.00112 ** 
Residual standard error: 0.003966 on 44 degrees of freedom
Multiple R-squared:  0.2166, Adjusted R-squared:  0.1988 




       Min         1Q     Median         3Q        Max 
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-0.0082629 -0.0024963 -0.0002965  0.0013276  0.0142565 
Coefficients:
              Estimate Std. Error t value Pr(>|t|)    
(Intercept)  0.0030286  0.0006266   4.833 1.67e-05 ***
data$V22    -0.0165915  0.0061985  -2.677   0.0104 *  
Residual standard error: 0.004155 on 44 degrees of freedom
Multiple R-squared:   0.14, Adjusted R-squared:  0.1205 




       Min         1Q     Median         3Q        Max 
-0.0085848 -0.0018501 -0.0001485  0.0018678  0.0117469 
Coefficients:
             Estimate Std. Error t value Pr(>|t|)    
(Intercept) 0.0038243  0.0005839   6.549 5.25e-08 ***
data$V23    0.0092503  0.0024172   3.827 0.000406 ***
Residual standard error: 0.003881 on 44 degrees of freedom
Multiple R-squared:  0.2497, Adjusted R-squared:  0.2327 




       Min         1Q     Median         3Q        Max 
-0.0091566 -0.0020866 -0.0004213  0.0014961  0.0140435 
Coefficients:
              Estimate Std. Error t value Pr(>|t|)    
(Intercept)  0.0033892  0.0006319   5.364 2.88e-06 ***
data$V24    -0.0114025  0.0056282  -2.026   0.0489 *  
Residual standard error: 0.004286 on 44 degrees of freedom
Multiple R-squared:  0.08532, Adjusted R-squared:  0.06454 




       Min         1Q     Median         3Q        Max 
-0.0098304 -0.0021966 -0.0000219  0.0013085  0.0126131 
Coefficients:
              Estimate Std. Error t value Pr(>|t|)    
(Intercept)  0.0033529  0.0005896   5.687 9.72e-07 ***
data$V25    -0.0191828  0.0057158  -3.356  0.00164 ** 
Residual standard error: 0.003998 on 44 degrees of freedom
Multiple R-squared:  0.2038, Adjusted R-squared:  0.1857 




       Min         1Q     Median         3Q        Max 
-0.0109938 -0.0018490 -0.0004393  0.0024643  0.0130403 
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Coefficients:
             Estimate Std. Error t value Pr(>|t|)    
(Intercept) 0.0035761  0.0006332   5.648 1.11e-06 ***
data$V26    0.0117052  0.0053048   2.207   0.0326 *  
Residual standard error: 0.004252 on 44 degrees of freedom
Multiple R-squared:  0.09963, Adjusted R-squared:  0.07917 




       Min         1Q     Median         3Q        Max 
-0.0093942 -0.0024695 -0.0008803  0.0027747  0.0139034 
Coefficients:
             Estimate Std. Error t value Pr(>|t|)    
(Intercept) 0.0033035  0.0006377   5.181  5.3e-06 ***
data$V27    0.0103203  0.0055679   1.854   0.0705 .  
Residual standard error: 0.004316 on 44 degrees of freedom
Multiple R-squared:  0.07243, Adjusted R-squared:  0.05134 
F-statistic: 3.436 on 1 and 44 DF,  p-value: 0.07052
Table 62: Test-statistic from selected features: mRNA versus rate of cognitive decline
(3c) Regression -  rate of decline versus mRNA expression
=== Run information ===
Scheme:weka.classifiers.meta.CVParameterSelection -X 10 -S 1 -W weka.classifiers.functions.LinearRegression -- -S 0 -R 1.0E-8
Relation:     wml.rna_status-weka.filters.unsupervised.attribute.Reorder-..BestFirst -D 1 -N 5-
weka.filters.unsupervised.attribute.Remove-R1-2,8-9,14-15,24,27
Instances:    46
Attributes:   20
              CCR6_A
              CD81
              CHMP6
              CNOT2
              CTTN
              GNLY
              GPAA1
              HBA2_A
              HLAB
              PABPC1_A
              PPHLN1
              PRPF40A
              PSCD1_A
              REPS2
              RN7SL1
              RNF7
              SLC5A6
              TMEM59
              VRK3_A
              CDR-SOB
Test mode:evaluate on training data
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=== Classifier model (full training set) ===
Cross-validated Parameter selection.
Classifier: weka.classifiers.functions.LinearRegression
Classifier Options: -S 0 -R 1.0E-8
Linear Regression Model
CDR-SOB =
      0.008  * CCR6_A +
     -0.0021 * CD81 +
      0.0023 * CTTN +
      0.0039 * GNLY +
     -0.0053 * GPAA1 +
     -0.0078 * HBA2_A +
      0.0041 * HLAB +
      0.0032 * PABPC1_A +
      0.0049 * PPHLN1 +
     -0.004  * PSCD1_A +
     -0.0055 * REPS2 +
      0.0047 * RN7SL1 +
      0.0038
Time taken to build model: 0 seconds
=== Evaluation on training set ===
=== Summary ===
Correlation coefficient                  0.9318
Mean absolute error                      0.0012
Root mean squared error                  0.0016
Relative absolute error                 38.3865 %
Root relative squared error             36.2901 %
Total Number of Instances               46     
 
=== Evaluation on 10f cross-val training set ===
=== Cross-validation ===
=== Summary ===
Correlation coefficient                  0.7519
Mean absolute error                      0.0025
Root mean squared error                  0.0031
Relative absolute error                 74.9358 %
Root relative squared error             69.6695 %
Total Number of Instances               46     
=== Evaluation on test set ===
=== Summary ===
Correlation coefficient                  0.3619
Mean absolute error                      0.0049
Root mean squared error                  0.0055
Relative absolute error                105.2673 %
Root relative squared error             89.7559 %
Total Number of Instances               16     
Table 63: WEKA protocol rate of decline versus mRNA
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1 Interleukin 2 receptor 4q26-q27 IL2sRg
IL2RB
3561
interleukin 2 receptor, beta; Receptor for interleukin-2. This beta 
subunit is involved in receptor mediated endocytosis and 
transduces the mitogenic signals of IL2 
2 Erythropoietin receptor EPOR
2057
Receptor for erythropoietin. Mediates erythropoietin- induced 
erythroblast proliferation and differentiation. Upon EPO 
stimulation, EPOR dimerizes triggering the JAK2/STAT5 signaling
cascade. In some cell types, can also activate STAT1 and STAT3. 





Binds heme and transports it to the liver for breakdown and iron 
recovery, after which the free hemopexin returns to the circulation 






 tumor necrosis factor receptor superfamily, member 4; Receptor 
for TNFSF4/OX40L/GP34 
5 WNT inhibitory factor 1 12q14.2 WIF1
11197
WNT inhibitory factor 1; Binds to WNT proteins and inhibits their 
activities. May be involved in mesoderm segmentation (379 aa) 
6 CXCL5/ chemokine (C-
X-C motif) ligand 5
4q13.3 ENA78
6374
chemokine (C-X-C motif) ligand 5; Involved in neutrophil 
activation. In vitro, ENA-78(8- 78) and ENA-78(9-78) show a 
threefold higher chemotactic activity for neutrophil granulocytes 
(114 aa) 






sialic acid binding Ig-like lectin 9; Putative adhesion molecule that 
mediates sialic-acid dependent binding to cells. Preferentially binds
to alpha-2,3- or alpha-2,6-linked sialic acid. The sialic acid 
recognition site may be masked by cis interactions with sialic acids
on the same cell surface (463 aa) 
8 Interleukin 19 1q32.2 IL19
 29949
May play some important roles in inflammatory responses. Up-
regulates IL-6 and TNF-alpha and induces apoptosis (By 
similarity) (215 aa) 





insulin induced gene 2; Mediates feedback control of cholesterol 
synthesis by controlling SCAP and HMGCR. Functions by 
blocking the processing of sterol regulatory element-binding 
proteins (SREBPs). Capable of retaining the SCAP-SREBF2 
complex in the ER thus preventing it from escorting SREBPs to the
Golgi. Seems to regulate the ubiquitin-mediated proteasomal 
degradation of HMGCR (225 aa) 






Inhibits factor X (X(a)) directly and, in a Xa-dependent way, 
inhibits VIIa/tissue factor activity, presumably by forming a 










antithrombotic action and also the ability to associate with 
lipoproteins in plasma (304 aa) 





carnosine dipeptidase 1 (metallopeptidase M20 family) (507 aa) 
12 Coagulation factor II 11p11.2 Thrombin
14061
coagulation factor II (thrombin); Thrombin, which cleaves bonds 
after Arg and Lys, converts fibrinogen to fibrin and activates 
factors V, VII, VIII, XIII, and, in complex with thrombomodulin, 
protein C. Functions in blood homeostasis, inflammation and 







ectonucleoside triphosphate diphosphohydrolase 3; Has a threefold 
preference for the hydrolysis of ATP over ADP (529 aa) 
14 Interleukin 6 7p21-p15 IL6
 3569
interleukin 6 (interferon, beta 2); Cytokine with a wide variety of 
biological functions. It is a potent inducer of the acute phase 
response. Plays an essential role in the final differentiation of B-
cells into Ig- secreting cells Involved in lymphocyte and monocyte 
differentiation. It induces myeloma and plasmacytoma growth and 
induces nerve cells differentiation Acts on B-cells, T-cells, 
hepatocytes, hematopoeitic progenitor cells and cells of the CNS. 
Also acts as a myokine. It is discharged into the bloodstream after 
muscle contraction and acts to increase the breakdown of fats and 
[...] (212 aa) 




Synthesizes cyclic ADP-ribose, a second messenger that elicits 
calcium release from intracellular stores. May be involved in pre-
B-cell growth (318 aa)
16 Chromobox homolog 5 12q13.13 CBX5
23468
chromobox homolog 5 (HP1 alpha homolog, Drosophila); 
Component of heterochromatin. Recognizes and binds histone H3 
tails methylated at 'Lys-9', leading to epigenetic repression. Can 
interact with lamin B receptor (LBR). This interaction can 
contribute to the association of the heterochromatin with the inner 
nuclear membrane. Involved in the formation of functional 
kinetochore through interaction with MIS12 complex proteins 
(191 aa)
Table 64: Panel of proteins associated with the rate of cognitive decline identified with features selection
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       Min         1Q     Median         3Q        Max 
-0.0057880 -0.0021092 -0.0003732  0.0020204  0.0080228 
Coefficients:
             Estimate Std. Error t value Pr(>|t|)    
(Intercept) 0.0039280  0.0004692   8.372 9.97e-11 ***
data$V1     0.0141571  0.0051915   2.727  0.00908 ** 
Residual standard error: 0.003217 on 45 degrees of freedom
Multiple R-squared:  0.1418, Adjusted R-squared:  0.1227 




       Min         1Q     Median         3Q        Max 
-0.0066778 -0.0022814 -0.0005287  0.0017395  0.0079883 
Coefficients:
             Estimate Std. Error t value Pr(>|t|)    
(Intercept) 0.0039786  0.0004841   8.219 1.66e-10 ***
data$V2     0.0066348  0.0031731   2.091   0.0422 *  
Residual standard error: 0.003315 on 45 degrees of freedom
Multiple R-squared:  0.08855, Adjusted R-squared:  0.0683 




       Min         1Q     Median         3Q        Max 
-0.0053710 -0.0025686 -0.0004959  0.0020547  0.0077094 
Coefficients:
             Estimate Std. Error t value Pr(>|t|)    
(Intercept) 0.0038195  0.0004732   8.071 2.72e-10 ***
data$V3     0.0015471  0.0005867   2.637   0.0114 *  
Residual standard error: 0.003231 on 45 degrees of freedom
Multiple R-squared:  0.1338, Adjusted R-squared:  0.1146 




       Min         1Q     Median         3Q        Max 
-0.0071079 -0.0024594 -0.0007552  0.0027646  0.0097087 
Coefficients:
              Estimate Std. Error t value Pr(>|t|)    
(Intercept)  0.0036875  0.0005174   7.127  6.6e-09 ***
data$V4     -0.0049997  0.0032046  -1.560    0.126    
 256
Residual standard error: 0.003382 on 45 degrees of freedom
Multiple R-squared:  0.05131, Adjusted R-squared:  0.03023 




       Min         1Q     Median         3Q        Max 
-0.0072272 -0.0021012 -0.0001657  0.0022372  0.0088344 
Coefficients:
              Estimate Std. Error t value Pr(>|t|)    
(Intercept)  0.0041333  0.0005053   8.179 1.89e-10 ***
data$V5     -0.0080178  0.0047306  -1.695    0.097 .  
Residual standard error: 0.003366 on 45 degrees of freedom
Multiple R-squared:  0.06001, Adjusted R-squared:  0.03912 




       Min         1Q     Median         3Q        Max 
-0.0065512 -0.0018840 -0.0004982  0.0020962  0.0085624 
Coefficients:
             Estimate Std. Error t value Pr(>|t|)    
(Intercept) 0.0038649  0.0004606   8.392 9.34e-11 ***
data$V6     0.0110981  0.0035942   3.088  0.00345 ** 
Residual standard error: 0.003154 on 45 degrees of freedom
Multiple R-squared:  0.1748, Adjusted R-squared:  0.1565 




       Min         1Q     Median         3Q        Max 
-0.0062476 -0.0022761  0.0002229  0.0018106  0.0066462 
Coefficients:
              Estimate Std. Error t value Pr(>|t|)    
(Intercept)  0.0041322  0.0004787   8.631 4.23e-11 ***
data$V7     -0.0013841  0.0005338  -2.593   0.0128 *  
Residual standard error: 0.003239 on 45 degrees of freedom
Multiple R-squared:   0.13, Adjusted R-squared:  0.1107 




       Min         1Q     Median         3Q        Max 
-0.0066678 -0.0024809 -0.0002979  0.0021453  0.0075960 
Coefficients:
             Estimate Std. Error t value Pr(>|t|)    
(Intercept) 0.0038616  0.0004959   7.786 7.07e-10 ***
data$V8     0.0054714  0.0035872   1.525    0.134    
Residual standard error: 0.003386 on 45 degrees of freedom
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Multiple R-squared:  0.04915, Adjusted R-squared:  0.02802 




       Min         1Q     Median         3Q        Max 
-0.0062711 -0.0024487  0.0003294  0.0018387  0.0082103 
Coefficients:
              Estimate Std. Error t value Pr(>|t|)    
(Intercept)  0.0032784  0.0005452   6.013 2.98e-07 ***
data$V9     -0.0211286  0.0086244  -2.450   0.0182 *  
Residual standard error: 0.003261 on 45 degrees of freedom
Multiple R-squared:  0.1177, Adjusted R-squared:  0.09807 




      Min        1Q    Median        3Q       Max 
-0.006717 -0.001559 -0.000721  0.002033  0.007625 
Coefficients:
             Estimate Std. Error t value Pr(>|t|)    
(Intercept) 0.0039230  0.0004452   8.812 2.34e-11 ***
data$V10    0.0051422  0.0014132   3.639 0.000703 ***
Residual standard error: 0.003052 on 45 degrees of freedom
Multiple R-squared:  0.2273, Adjusted R-squared:  0.2102 




      Min        1Q    Median        3Q       Max 
-0.007250 -0.002364 -0.001181  0.002275  0.008311 
Coefficients:
             Estimate Std. Error t value Pr(>|t|)    
(Intercept) 0.0040304  0.0005006   8.051  2.9e-10 ***
data$V11    0.0016314  0.0011557   1.412    0.165    
Residual standard error: 0.003398 on 45 degrees of freedom
Multiple R-squared:  0.0424, Adjusted R-squared:  0.02112 




       Min         1Q     Median         3Q        Max 
-0.0073623 -0.0018696 -0.0001726  0.0018552  0.0075946 
Coefficients:
             Estimate Std. Error t value Pr(>|t|)    
(Intercept) 0.0041584  0.0004656   8.932 1.58e-11 ***
data$V12    0.0124501  0.0040164   3.100  0.00334 ** 
Residual standard error: 0.003152 on 45 degrees of freedom
Multiple R-squared:  0.176, Adjusted R-squared:  0.1576 





      Min        1Q    Median        3Q       Max 
-0.006799 -0.001748 -0.000639  0.002515  0.007708 
Coefficients:
             Estimate Std. Error t value Pr(>|t|)    
(Intercept) 0.0036672  0.0004963   7.389 2.71e-09 ***
data$V13    0.0100875  0.0046085   2.189   0.0338 *  
Residual standard error: 0.003301 on 45 degrees of freedom
Multiple R-squared:  0.09623, Adjusted R-squared:  0.07614 




       Min         1Q     Median         3Q        Max 
-0.0066311 -0.0020086 -0.0005082  0.0020258  0.0079995 
Coefficients:
              Estimate Std. Error t value Pr(>|t|)    
(Intercept)  0.0038437  0.0004834   7.951 4.06e-10 ***
data$V14    -0.0165336  0.0075982  -2.176   0.0348 *  
Residual standard error: 0.003303 on 45 degrees of freedom
Multiple R-squared:  0.0952, Adjusted R-squared:  0.0751 




       Min         1Q     Median         3Q        Max 
-0.0055037 -0.0022141 -0.0006536  0.0018923  0.0064133 
Coefficients:
              Estimate Std. Error t value Pr(>|t|)    
(Intercept)  0.0040280  0.0004661   8.642 4.09e-11 ***
data$V15    -0.0057518  0.0019836  -2.900  0.00576 ** 
Residual standard error: 0.003187 on 45 degrees of freedom
Multiple R-squared:  0.1574, Adjusted R-squared:  0.1387 




      Min        1Q    Median        3Q       Max 
-0.006373 -0.002206 -0.000886  0.001941  0.008807 
Coefficients:
             Estimate Std. Error t value Pr(>|t|)    
(Intercept) 0.0037612  0.0004951   7.598 1.34e-09 ***
data$V16    0.0078821  0.0041203   1.913   0.0621 .  
Residual standard error: 0.003339 on 45 degrees of freedom
Multiple R-squared:  0.07521, Adjusted R-squared:  0.05466 
F-statistic:  3.66 on 1 and 45 DF,  p-value: 0.06212
Table 65: Test-statistic from selected features: proteins versus rate of cognitive decline
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(4c) Regression - rate of decline versus protein concentration
=== Run information  ===
Scheme:weka.classifiers.meta.CVParameterSelection -P "R -5.99999999 5.0E-4 5.00000001" -P "C 0.0 1.0 1.0" -X 10 -S 1 -W 
weka.classifiers.functions.LinearRegression -- -S 0 -R 1.0E-8
Relation:     wml.rna_status-weka.filters.unsupervised.attribute.Reorder-R2,3,..,1017,1-
weka.filters.supervised.attribute.AttributeSelection-Eweka.attributeSelection.CfsSubsetEval-Sweka.attributeSelection.BestFirst -D 
1 -N 5
Instances:    47
Attributes:   17
              IL_2_sRg
              EPO_R
              Hemopexin
              OX40_Ligand
              WIF_1
              ENA_78
              Siglec_9
              IL_19
              CRIS3
              TFPI
              CNDP1
              Thrombin
              ENTP3
              IL_6
              BST1
              CBX5
              CDR-SOB
Test mode:evaluate on training data
=== Classifier model (full training set) ===
Cross-validated Parameter selection.
Classifier: weka.classifiers.functions.LinearRegression
Cross-validation Parameter: '-R' ranged from -5.99999999 to 5.0E-4 with 5.00000001 steps
Cross-validation Parameter: '-C' ranged from 0.0 to 1.0 with 1.0 steps
Classifier Options: -R 4.999849987497029E-4 -C 0 -S 0
Linear Regression Model
CDR-SOB =
      0.0057 * EPO_R +
     -0.0037 * OX40_Ligand +
      0.0097 * ENA_78 +
      0.0064 * IL_19 +
     -0.0166 * CRIS3 +
      0.0033 * TFPI +
     -0.0098 * IL_6 +
     -0.0031 * BST1 +
      0.0031
Time taken to build model: 0.02 seconds
=== Evaluation on training set ===
=== Summary ===
Correlation coefficient                  0.8383
Mean absolute error                      0.0013
Root mean squared error                  0.0019
Relative absolute error                 48.0469 %
Root relative squared error             54.524  %




Correlation coefficient                  0.5946
Mean absolute error                      0.0021
Root mean squared error                  0.003 
Relative absolute error                 77.4313 %
Root relative squared error             87.1138 %
Total Number of Instances               47     
=== Re-evaluation on test set ===
User supplied test set
Relation:     wml.rna_status-weka.filters.unsupervised.attribute.Reorder-R2...1016
Instances:     unknown (yet). Reading incrementally
Attributes:   17
=== Summary ===
Correlation coefficient                 -0.002 
Mean absolute error                      0.0053
Root mean squared error                  0.0069
Total Number of Instances               16     
Table 66: WEKA protocol - rate of decline versus proteins
C. Protein sequence information
mRNA/WMH


















































































































CXCL16 = CXCL16 soluable, GDF11, ALPL =Alkaline phospatase bone, DOK7 = lgM, SPOK1 = Testican , CHEK2 =CHK2, 
BCL2, SERPINA4 = Kallistatin, VIP =Vasoactive intestine Peptide, CNDP1, CTSH=Cathepsin H, MBD4, LCMT1, SAA1=SAA, 








































































































































































































































































EPOR,  OX40 ligand =TNFRSF4,  ENA78 =CXCL5, IL19,  CRIS3=HMGCR,  TFPI, IL6, BST1
>EPOR
MDHLGASLWPQVGSLCLLLAGAAWAPPPNLPDPKFESKAALLAARGPEELLCFTERLEDLVCFWEEAASAGVGPGNYSFS
YQLEDEPWKLCRLHQAPTARGAVRFWCSLPTADTSSFVPLELRVTAASGAPRYHRVIHINEVVLLDAPVGLVARLADESG
HVVLRWLPPPETPMTSHIRYEVDVSAGNGAGSVQRVEILEGRTECVLSNLRGRTRYTFAVRARMAEPSFGGFWSAWSEPV
SLLTPSDLDPLILTLSLILVVILVLLTVLALLSHRRALKQKIWPGIPSPESEFEGLFTTHKGNFQLWLYQNDGCLWWSPC
TPFTEDPPASLEVLSERCWGTMQAVEPGTDDEGPLLEPVGSEHAQDTYLVLDKWLLPRNPPSEDLPGPGGSVDIVAMDEG
SEASSCSSALASKPSPEGASAASFEYTILDPSSQLLRPWTLCPELPPTPPHLKYLYLVVSDSGISTDYSSGDSQGAQGGL
SDGPYSNPYENSLIPAAEPLPPSYVACS 
>TNFRSF4 
MCVGARRLGRGPCAALLLLGLGLSTVTGLHCVGDTYPSNDRCCHECRPGNGMVSRCSRSQNTVCRPCGPGFYNDVVSSKP
CKPCTWCNLRSGSERKQLCTATQDTVCRCRAGTQPLDSYKPGVDCAPCPPGHFSPGDNQACKPWTNCTLAGKHTLQPASN
SSDAICEDRDPPATQPQETQGPPARPITVQPTEAWPRTSQGPSTRPVEVPGGRAVAAILGLGLVLGLLGPLAILLALYLL
RRDQRLPPDAHKPPGGGSFRTPIQEEQADAHSTLAKI 
>CXCL5 
MSLLSSRAARVPGPSSSLCALLVLLLLLTQPGPIASAGPAAAVLRELRCVCLQTTQGVHPKMISNLQVFAIGPQCSKVEV
VASLKNGKEICLDPEAPFLKKVIQKILDGGNKEN 
>IL19
MCTEGAFPHRSACSLPLTHVHTHIHVCVPVLWGSVPRGMKLQCVSLWLLGTILILCSVDNHGLRRCLISTDMHHIEESFQ
EIKRAIQAKDTFPNVTILSTLETLQIIKPLDVCCVTKNLLAFYVDRVFKDHQEPNPKILRKISSIANSFLYMQKTLRQCQ
EQRQCHCRQEATNATRVIHDNYDQLEVHAAAIKSLGELDVFLAWINKNHEVMFSA 
>HMGCR 
MLSRLFRMHGLFVASHPWEVIVGTVTLTICMMSMNMFTGNNKICGWNYECPKFEEDVLSSDIIILTITRCIAILYIYFQF
QNLRQLGSKYILGIAGLFTIFSSFVFSTVVIHFLDKELTGLNEALPFFLLLIDLSRASTLAKFALSSNSQDEVRENIARG
MAILGPTFTLDALVECLVIGVGTMSGVRQLEIMCCFGCMSVLANYFVFMTFFPACVSLVLELSRESREGRPIWQLSHFAR
VLEEEENKPNPVTQRVKMIMSLGLVLVHAHSRWIADPSPQNSTADTSKVSLGLDENVSKRIEPSVSLWQFYLSKMISMDI
EQVITLSLALLLAVKYIFFEQTETESTLSLKNPITSPVVTQKKVPDNCCRREPMLVRNNQKCDSVEEETGINRERKVEVI
KPLVAETDTPNRATFVVGNSSLLDTSSVLVTQEPEIELPREPRPNEECLQILGNAEKGAKFLSDAEIIQLVNAKHIPAYK
LETLMETHERGVSIRRQLLSKKLSEPSSLQYLPYRDYNYSLVMGACCENVIGYMPIPVGVAGPLCLDEKEFQVPMATTEG
CLVASTNRGCRAIGLGGGASSRVLADGMTRGPVVRLPRACDSAEVKAWLETSEGFAVIKEAFDSTSRFARLQKLHTSIAG
RNLYIRFQSRSGDAMGMNMISKGTEKALSKLHEYFPEMQILAVSGNYCTDKKPAAINWIEGRGKSVVCEAVIPAKVVREV
LKTTTEAMIEVNINKNLVGSAMAGSIGGYNAHAANIVTAIYIACGQDAAQNVGSSNCITLMEASGPTNEDLYISCTMPSI
EIGTVGGGTNLLPQQACLQMLGVQGACKDNPGENARQLARIVCGTVMAGELSLMAALAAGHLVKSHMIHNRSKINLQDL
Q
GACTKKTA 
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>TFPI 
MIYTMKKVHALWASVCLLLNLAPAPLNADSEEDEEHTIITDTELPPLKLMHSFCAFKADDGPCKAIMKRFFFNIFTRQCE
EFIYGGCEGNQNRFESLEECKKMCTRDNANRIIKTTLQQEKPDFCFLEEDPGICRGYITRYFYNNQTKQCERFKYGGCLG
NMNNFETLEECKNICEDGPNGFQVDNYGTQLNAVNNSLTPQSTKVPSLFEFHGPSWCLTPADRGLCRANENRFYYNSVIG
KCRPFKYSGCGGNENNFTSKQECLRACKKGFIQRISKGGLIKTKRKRKKQRVKIAYEEIFVKNM 
>IL6
MNSFSTSAFGPVAFSLGLLLVLPAAFPAPVPPGEDSKDVAAPHRQPLTSSERIDKQIRYILDGISALRKETCNKSNMCES
SKEALAENNLNLPKMAEKDGCFQSGFNEETCLVKIITGLLEFEVYLEYLQNRFESSEEQARAVQMSTKVLIQFLQKKAKN
LDAITTPDPTTNASLLTKLQAQNQWLQDMTTHLILRSFKEFLQSSLRALRQM 
>BST1
MAAQGCAASRLLQLLLQLLLLLLLLAAGGARARWRGEGTSAHLRDIFLGRCAEYRALLSPEQRNKNCTAIWEAFKVALDK
DPCSVLPSDYDLFINLSRHSIPRDKSLFWENSHLLVNSFADNTRRFMPLSDVLYGRVADFLSWCRQKNDSGLDYQSCPTS
EDCENNPVDSFWKRASIQYSKDSSGVIHVMLNGSEPTGAYPIKGFFADYEIPNLQKEKITRIEIWVMHEIGGPNVESCGE
GSMKVLEKRLKDMGFQYSCINDYRPVKLLQCVDHSTHPDCALKSAAAATQRKAPSLYTEQRAGLIIPLFLVLASRTQL 
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